Exploitation of host cellular pathways by Chlamydia trachomatis by Banhart, Sebastian
  
 
 
 
 
Exploitation of host cellular pathways 
by Chlamydia trachomatis 
 
 
D i s s e r t a t i o n 
 
zur Erlangung des akademischen Grades 
d o c t o r   r e r u m   n a t u r a l i u m 
(Dr. rer. nat.) 
im Fach Biologie 
 
 
 
eingereicht an der 
Mathematisch-Naturwissenschaftlichen Fakultät I 
der Humboldt-Universität zu Berlin 
 
von 
Dipl.-Biol. Sebastian Banhart 
 
 
 
 
Präsident der Humboldt-Universität zu Berlin 
Prof. Dr. Jan-Hendrik Olbertz 
 
Dekan der Mathematisch-Naturwissenschaftlichen Fakultät I 
Prof. Dr. Andreas Herrmann 
 
 
 
Gutachter: 1. Prof. Dr. Thomas F. Meyer 
 2. Prof. Dr. Thomas Sommer 
 3. Prof. Dr. Andreas Herrmann 
 
Tag der mündlichen Prüfung: 19.12.2011  
  
 
  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Todo começo é involuntário. 
All beginnings are involuntary. 
 
–  Fernando Pessoa  
  
 
Parts of this work have been or will be published under the following titles: 
 
Banhart S.*, Mehlitz A.*, Mäurer A.P., Kaushansky A., Gordus A.G., Zielecki J., MacBeath G., Meyer 
T.F. 2010. Tarp regulates early Chlamydia-induced host cell survival through interactions with the 
human adaptor protein SHC1. J Cell Biol. 190(1):143-57. (* equal contribution) 
 
Banhart S., Mehlitz A., Fuchs B., Schiller J., Heuer, D., Meyer, T.F. Global lipid analysis reveals 
essential role of cardiolipin synthase 1 for Chlamydia replication. (in preparation) 
  Table of contents 
  
 
  1 
Table of contents 
Table of contents .................................................................................................................................... 1 
Abstract ................................................................................................................................................... 4 
Zusammenfassung .................................................................................................................................. 6 
1 Introduction .................................................................................................................................... 9 
1.1 Chlamydiae ................................................................................................................................. 9 
1.1.1 Taxonomy of Chlamydia ....................................................................................................... 9 
1.1.2 Pathology of Chlamydia ...................................................................................................... 10 
1.1.3 Developmental cycle of Chlamydia ..................................................................................... 11 
1.2 Protein secretion systems ........................................................................................................ 13 
1.2.1 Type III secretion system of Chlamydia .............................................................................. 13 
1.2.2 The effector protein Tarp .................................................................................................... 14 
1.3 Host-pathogen interplay .......................................................................................................... 14 
1.3.1 Chlamydia and the MAPK pathway .................................................................................... 15 
1.3.2 Chlamydia and apoptosis .................................................................................................... 16 
1.3.3 Chlamydia and nutrient acquisition .................................................................................... 18 
1.3.4 Chlamydia and lipids ........................................................................................................... 19 
1.4 Aim of this study ...................................................................................................................... 20 
2 Materials and methods ................................................................................................................. 22 
2.1 Materials and general methods ............................................................................................... 22 
2.1.1 Cell lines and bacteria ......................................................................................................... 22 
2.1.2 Reagents, antibodies and constructs .................................................................................. 22 
2.1.3 Infection time courses ........................................................................................................ 23 
2.1.4 Statistical analysis ............................................................................................................... 23 
2.2 DNA techniques........................................................................................................................ 23 
2.2.1 Transfections ....................................................................................................................... 23 
2.2.2 DNA microarrays and analysis ............................................................................................ 24 
2.2.3 qRT-PCR analysis ................................................................................................................. 24 
2.3 Protein techniques ................................................................................................................... 26 
2.3.1 Peptide synthesis and protein microarrays ........................................................................ 26 
2.3.2 Pull-down assays and immunoblotting ............................................................................... 28 
2.4 Lipid techniques ....................................................................................................................... 28 
2.4.1 Lipid extraction ................................................................................................................... 28 
  Table of contents 
  
 
  2 
2.4.2 MALDI-TOF mass spectrometry .......................................................................................... 29 
2.5 Microscopy ............................................................................................................................... 30 
2.5.1 Immunofluorescence staining and microscopy .................................................................. 30 
2.5.2 Live-cell fluorescence microscopy ...................................................................................... 30 
2.6 Other methods ......................................................................................................................... 30 
2.6.1 Invasion, inclusion formation, and progeny assays ............................................................ 30 
2.6.2 Apoptosis induction and detection, data acquisition and analysis..................................... 31 
2.7 Computational methods .......................................................................................................... 32 
2.7.1 Multiple sequence alignment ............................................................................................. 32 
2.7.2 Prediction of SH3 interactions ............................................................................................ 32 
2.7.3 Modeling of Tarp signaling.................................................................................................. 32 
2.7.4 Docking simulation .............................................................................................................. 33 
3 Results and discussion .................................................................................................................. 35 
3.1 Preface ..................................................................................................................................... 35 
3.2 Part I: Interactions of host cell proteins with the effector protein Tarp ................................. 36 
3.2.1 Peptide design of Tarp interaction sites ............................................................................. 36 
3.2.2 Quantitative SH2/PTB interactome analysis of Tarp N-terminus ....................................... 38 
3.2.3 Quantitative SH3 interactome analysis of Tarp C-terminus ............................................... 42 
3.2.4 Pathway analysis of N-terminal interactome ..................................................................... 45 
3.2.5 Pathway analysis of C-terminal interactome ...................................................................... 46 
3.2.6 Validation of interactions between Tarp’s N-terminus and selected host cell proteins .... 47 
3.2.7 Analysis of the interaction between Tarp’s C-terminus and NCK2 ..................................... 49 
3.2.8 SHC1 activation and influence on MEK/ERK signaling during Chlamydia cell entry ........... 51 
3.2.9 SHC1 activation and its transcriptional regulation during infection ................................... 56 
3.2.10 SHC1 activation and its role as a survival stimulus ............................................................. 62 
3.2.11 Discussion............................................................................................................................ 65 
3.3 Part II: Changes in lipid composition induced by Chlamydia ................................................... 71 
3.3.1 Analysis of lipids using MALDI-TOF mass spectrometry ..................................................... 71 
3.3.2 Temporal changes in lipid composition during the chlamydial infection cycle .................. 75 
3.3.3 Impact of cPLA2 and CRLS1 on chlamydial growth and progeny formation ...................... 83 
3.3.4 Discussion............................................................................................................................ 86 
4 Conclusions and outlook ............................................................................................................... 92 
5 References .................................................................................................................................... 94 
  Table of contents 
  
 
  3 
6 Appendix ..................................................................................................................................... 108 
6.1 Supplemental material ........................................................................................................... 108 
6.2 Abbreviations ......................................................................................................................... 131 
6.3 List of figures .......................................................................................................................... 133 
6.4 List of tables ........................................................................................................................... 135 
6.5 Acknowledgments .................................................................................................................. 136 
6.6 Publications ............................................................................................................................ 137 
6.7 Selbständigkeitserklärung ...................................................................................................... 138 
  Abstract 
 
  4 
Abstract 
The human pathogen Chlamydia trachomatis has evolved to strongly rely on the host due to its 
obligate intracellular replication and the acquisition of essential host cellular nutrients. This intimate 
relationship requires the efficient exploitation of both signaling and trafficking pathways of the host 
cell to ensure the pathogen’s differentiation, replication, and protection from host immune 
responses, e.g., by inhibiting apoptosis. 
Like many bacterial pathogens, C. trachomatis translocates effector proteins into the host cell to 
manipulate host cell functions. The early phase C. trachomatis effector protein Tarp harbors several 
N-terminal SH2 binding sites, which are rapidly tyrosine phosphorylated upon host cell entry, and a 
putative C-terminal SH3 binding site, both for the interaction with host cell proteins. To 
comprehensively and quantitatively assess these interactions, protein microarrays comprising 
virtually all human SH2 and SH3 domains were used. Numerous novel interactions between Tarp and 
human SH2 and SH3 domains were discovered. The adaptor protein SHC1 was among Tarp’s 
strongest SH2-dependent interaction partners. Transcriptome analysis of SHC1-dependent gene 
regulation during infection indicated that SHC1 regulates apoptosis- and growth-related genes. 
SHC1-mediated cell survival and gene regulation was found to be controlled through both MEK/ERK-
dependent and -independent signaling. SHC1 knockdown sensitized infected host cells to TNFα-
induced apoptosis. These findings reveal a critical role for SHC1 in early Chlamydia-induced cell 
survival and suggest that Tarp functions as a multivalent phosphorylation-dependent and 
-independent signaling hub that is important during the early phase of chlamydial infection. 
To acquire host-derived lipids such as cholesterol, sphingomyelin, glycerophospholipids, and neutral 
lipids, C. trachomatis hijacks both vesicular and nonvesicular trafficking pathways and modifies lipids 
during their translocation to the inclusion. To assess infection-dependent changes of the host cell 
lipid composition, infected cells were analyzed by MALDI-TOF mass spectrometry for their lipid 
content, providing a comprehensive list of lipid species existent in both infected and uninfected 
cells, as well as lipids only present in infected cells. Amongst these lipids, phosphatidylinositol and 
cardiolipin species were most prominently influenced by C. trachomatis infection, with infected cells 
harboring increased levels of lipids with comparably short fatty acids. Furthermore, 
phosphatidylinositol, phosphatidylethanolamine, phosphatidylglycerol, and cardiolipin species with a 
characteristic mass difference of 14 Da were detected during the course of infection, indicating the 
presence of Chlamydia-derived branched chain fatty acids and a role of cytosolic phospholipase A2 
in this process. Accordingly, infection of cytosolic phospholipase A2 and cardiolipin synthase 1 
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knockdown cells resulted in a significantly reduced formation of infectious particles in these cells. 
These data demonstrate both the cardiolipin synthase 1 and the cytosolic phospholipase A2 to be 
key enzymes in the chlamydial lipid acquisition and emphasize the importance of cardiolipin and a 
functional nutrient supply for the successful propagation of C. trachomatis. 
Taken together, the results of this work contribute to our knowledge of the pathogen’s repertoire to 
exploit the host cell by actively subverting signaling and trafficking pathways. 
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Zusammenfassung 
Das humanpathogene Bakterium Chlamydia trachomatis ist aufgrund seiner obligat intrazellulären 
Replikationsweise und der Gewinnung essentieller Nährstoffe aus der eukaryotischen Zelle in 
besonderem Maße auf seinen Wirt angewiesen. Diese enge Beziehung erfordert eine effiziente 
Nutzung von Signaltransduktionswegen und intrazellulären Transportrouten der Wirtszelle durch das 
Pathogen, um sowohl die eigene Differenzierung und Replikation sicherzustellen als auch die 
Immunantwort des Wirts zu umgehen, z.B. durch Apoptoseinhibierung. 
Vergleichbar mit vielen bakteriellen Pathogenen überträgt auch C. trachomatis Effektorproteine in 
die Wirtszelle, um zelluläre Funktionen zu manipulieren. Das bereits zu Beginn der Infektion 
sekretierte Effektorprotein Tarp besitzt sowohl mehrere N-terminale SH2-Bindungsstellen, welche 
nach Translokation des Effektors in die Wirtszelle rasch tyrosinphosphoryliert werden, als auch eine 
putative C-terminale SH3-Bindungsstelle. Die Bindungsstellen dienen der Interaktion mit 
Wirtszellproteinen. Zur umfassenden Charakterisierung und Quantifizierung dieser Interaktionen 
wurden Protein-Microarrays verwendet, welche nahezu alle SH2- und SH3-Domänen humaner 
Proteine beinhalten. Dabei wurden zahlreiche neue Interaktionen zwischen Tarp und SH2- bzw. SH3-
Domänen detektiert, wobei das Adaptorprotein SHC1 eine der stärksten SH2-abhängigen 
Interaktionen mit Tarp zeigte. Mittels Transkriptionsanalyse SHC1-abhängiger Genregulation 
während der Infektion konnten Gene identifiziert werden, welche an der Kontrolle von Apoptose- 
und Zellwachstumsprozessen beteiligt sind. Dabei zeigte sich, dass diese Gene sowohl über 
MEK/ERK-abhängige als auch -unabhängige Signaltransduktionswege reguliert werden. Infizierte 
Wirtszellen mit Knockdown von SHC1 wiesen eine erhöhte Apoptoserate nach Stimulation mit TNFα 
auf. Diese Ergebnisse offenbaren eine entscheidende Rolle von SHC1 im Kontext des frühen, 
Chlamydien-induzierten Überlebens der Wirtszelle und deuten darauf hin, dass Tarp als vielseitige, 
phosphorylierungsabhängige und -unabhängige Signaltransduktionsplattform dient, welche in der 
frühen Phase der Chlamydieninfektion von Bedeutung ist. 
Um Wirtszelllipide – u.a. Cholesterol, Sphingomyelin, Glycerophospholipide und Neutrallipide – 
abzufangen und aufzunehmen, nutzt C. trachomatis sowohl vesikuläre als auch nicht vesikuläre 
intrazelluläre Transportrouten der Wirtszelle und modifiziert diese Lipide aktiv, bevor sie zur 
Inklusion transferiert werden. Zur Bestimmung dieser infektionsabhängigen Veränderungen der 
Lipidzusammensetzung der Wirtszelle wurde der Lipidgehalt infizierter Zellen mittels MALDI-TOF-
Massenspektrometrie analysiert. Dies erlaubte eine umfassende Aufstellung der Lipidspezies, welche 
sowohl in infizierten und nichtinfizierten Zellen als auch ausschließlich in infizierten Zellen detektiert 
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wurden. Dabei hatte die Infektion den stärksten Einfluss auf bestimmte Phosphatidylinoslitol- und 
Cardiolipinspezies, wobei infizierte Zellen einen erhöhten Gehalt an Lipiden mit vergleichsweise 
kurzkettigen Fettsäureresten aufwiesen. Des Weiteren konnte im Infektionsverlauf ein Anstieg von 
Phosphatidylinositol-, Phosphatidylethanolamin-, Phosphatidylglycerol und Cardiolipinspezies mit 
einem charakteristischen Massenunterschied von 14 Da verzeichnet werden, was auf 
verzweigtkettige Fettsäurereste chlamydialen Ursprungs und eine Beteiligung der cytosolischen 
Phospholipase A2 hindeutet. Entsprechend zeigten infizierte Wirtszellen mit einem Knockdown der 
cytosolischen Phospholipase A2 oder der Cardiolipinsynthase 1 eine signifikant reduzierte Bildung 
infektiöser Bakterien. Dies zeigt, dass sowohl die Cardiolipinsynthase 1 als auch die cytosolischen 
Phospholipase A2 eine Schlüsselrolle in der chlamydialen Lipidaufnahme einnehmen und 
unterstreicht die Bedeutung von Cardiolipin und einer funktionsfähigen Nährstoffversorgung für die 
erfolgreiche Vermehrung von C. trachomatis. 
Zusammenfassend erweitern die Ergebnisse dieser Arbeit unser Wissen über das Repertoire der 
Chlamydien bei der aktiven Nutzung von Signaltransduktionswegen und intrazellulären 
Transportrouten der Wirtszelle. 
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1 Introduction 
1.1 Chlamydiae 
Chlamydiae are obligate intracellular, gram-negative bacteria, which exhibit a unique biphasic 
developmental cycle (Abdelraham and Belland, 2005). They infect a wide range of host organisms 
and account for a diversity of diseases in humans, such as infections of the urogenital tract, the eye, 
or the lung (Peeling and Brunham, 1996). Due to their intracellular lifestyle, chlamydiae have 
evolved to intimately interact with host cellular signaling and trafficking pathways to both acquire 
nutrients and ensure their own replication (Saka and Valdivia, 2010; Scidmore, 2011). Hence, the 
detailed investigation of chlamydiae and their close relationship to the host is of great biomedical 
relevance. 
1.1.1 Taxonomy of Chlamydia 
According to phylogenetic analyses based on 16S rRNA and 23S rRNA sequencing, the bacterial 
phylum Chlamydiae comprises the only order Chlamydiales consisting of the four families 
Chlamydiaceae, Parachlamydiaceae, Waddliaceae, and Simkaniaceae (Everett et al., 1999; Bush and 
Everett, 2001). The family Chlamydiaceae harbors all human and animal pathogenic species and is 
subdivided into two genera, Chlamydophila and Chlamydia, which include the most important 
human pathogenic species, Chlamydia trachomatis and Chlamydophila pneumoniae (Figure 1-1). 
 
Figure 1-1. Taxonomy of the order Chlamydiales. Graphical representation showing the phylogenetic tree of the order 
Chlamydiales, which consists of four families: Chlamydiaceae, Parachlamydiaceae, Waddliaceae, and Simkaniaceae. The 
family Chlamydiaceae is divided into the two genera Chlamydophila and Chlamydia. Lines do not represent actual 
phylogenetic distances. 
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Recently, there have been efforts to reunite the family Chlamydiaceae into a single genus, 
Chlamydia, stating that this separation is neither widely used by the research community nor is it 
reflecting the natural history of the organism based on genome comparisons (Stephens et al., 2009). 
1.1.2 Pathology of Chlamydia 
The species C. trachomatis is the leading cause of preventable blindness (trachoma) (Wright et al., 
2008) and responsible worldwide for up to 90 million cases per year of sexually transmitted disease 
(STD) (Brunham and Rey-Ladino, 2005). More than 15 serovars (serologically distinct variants) of 
C. trachomatis can be defined, showing different types of pathology, anatomical sites of infection, 
and tissue tropism (Grayston and Wang, 1975; Schachter, 1999; Stephens, 1999). The ocular 
serovars A to C infect mucosal epithelial cells of the conjunctiva, leading to trachoma. Transmission 
may occur by direct contact with eye, nose, and throat secretions from infected individuals, or by 
flies. Symptoms can range from mild inflammation to a strong inflammatory response. If not treated 
with antibiotics, chronic infection can lead to scarring of the eyelid and subsequent blindness 
through scratching of the cornea (Gambhir et al., 2007). The urogenital serovars D to K cause STD by 
infecting mucosal epithelial cells of the urogenital tract. Most acute infections are asymptomatic and 
can lead to chronic inflammation of the urethra (urethritis), the rectum (proctitis), or the cervix 
(cervicitis) if not treated. Severe consequences of untreated ascending Chlamydia infections are 
pelvic inflammatory disease (PID), ectopic pregnancy, and infertility due to tubal scarring and 
occlusion. These complications are a main cause of preventable infertility in industrialized countries 
today (Schachter and Caldwell, 1980; Faro, 1985; Haggerty et al., 2010). The more invasive serovars 
L1 to L3 cause Lymphogranuloma venereum (LGV), a sexually transmitted infection of lymphatics 
and lymph nodes. Comparable to urogenital serovars, the LGV serovars infect mucosal epithelial 
cells of the urogenital tract but additionally spread to regional lymph nodes by infecting 
macrophages, finally causing a systemic infection of lymphoid tissues. Symptoms of LGV are 
lymphadenopathy, including the retro-peritoneal lymph nodes in women or the inguinal lymph 
nodes in men. Chronic inflammation of these tissues can lead to lymphatic obstruction and lymphoid 
tissue destruction (Schachter and Osoba, 1983; Mabey and Peeling, 2002). 
The species C. pneumoniae primarily infects epithelial cells of the upper and lower respiratory tract 
(Wreghitt, 1993). This airborne infection is mainly asymptomatic in the acute phase, though it 
accounts for approximately 10 % of community-acquired pneumonia and 5 % of pharyngitis, 
bronchitis, and sinusitis (Kuo et al., 1995). C. pneumoniae infection has been associated with several 
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chronic diseases, e.g., asthma (Blasi et al., 2009), artherosclerosis (Campbell and Kuo, 2004) or 
Alzheimer’s disease (Shima et al., 2010); however, these associations remain to be further clarified. 
Once detected, Chlamydia infections can be effectively treated with antibiotics including 
tetracyclines, macrolides, and quinolones (Centers for Disease Control and Prevention, 2010). 
However, as infected people are frequently asymptomatic, the infection is often not diagnosed. 
Therefore, additional approaches, such as education on protected sexual intercourse or active 
screening for Chlamydia infections are of great importance (Belland et al., 2004). 
1.1.3 Developmental cycle of Chlamydia 
All Chlamydia species exhibits a unique biphasic developmental cycle initiated by the infectious 
elementary bodies (EBs), which are metabolically inactive and have a diameter of up to 0.3 µm 
(Abdelraham and Belland, 2005). Infection starts with EBs attaching to the host cell (Figure 1-2, (1)). 
So far, attachment is described to be a two step process with a first reversible contact based on 
electrostatic interactions with heparan sulphate-like glycosaminoglycans, followed by a second, 
more specific attachment to a not specified host cell receptor (Dautry-Varsat et al., 2005). 
Attachment is followed by uptake of the infectious particles via endocytosis or phagocytosis 
(Figure 1-2, (2)). Both clathrin-dependent and -independent pathways of bacterial entry are 
described (Dautry-Varsat et al., 2005). Once engulfed by the host cell, EBs reside within a protective 
vacuole called the inclusion. The inclusion membrane is actively modified to prevent fusion with late 
endosomes or lysosomes, thereby avoiding lysosomal degradation (Ojcius et al., 1997; Scidmore 
et al., 2003). Among these modifications is the integration of bacterial Inc proteins into the 
membrane of the inclusion via a type III secretion system (Subtil et al., 2001). The function of these 
proteins is widely unknown. However, IncA is described to be phosphorylated by host cell kinases 
and mediates the homotypic fusion of inclusions (Rockey et al., 1997; Hackstadt et al., 1999). IncG 
has been shown to recruit the protein 14-3-3β to the inclusion membrane (Scidmore and Hackstadt, 
2001). The early inclusion gets translocated to a perinuclear, peri-Golgi site in the vicinity of the 
microtubule-organizing center (MTOC) within 6 h post infectionem (p.i.) (Hackstadt et al., 1996; 
Grieshaber et al., 2003). At 8 to 10 h p.i., EBs differentiate into actively replicating reticulate bodies 
(RBs), the larger (1 µm diameter), metabolically active form of Chlamydia, which is not infectious 
(Mathews et al., 1999) (Figure 1-2, (3)). The inclusion grows and RBs divide by binary fission 
(Abdelraham and Belland, 2005) (Figure 1-2, (5)). Sphingolipids, glycerophospholipids, and 
cholesterol are intercepted from the exocytic pathway between Golgi apparatus and host cell 
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membrane and guided to the inclusion (Hackstadt et al., 1995; Wylie et al., 1997; Carabeo et al., 
2003). The lipid acquisition was shown to be dependent on the activation of the cytosolic 
phospholipase A2 (cPLA2) via the mitogen-activated protein kinase (MAPK) pathway (Su et al., 2004). 
Furthermore, Chlamydia induces fragmentation of the Golgi apparatus, thus leading to the 
formation of ministacks and supporting the efficient lipid acquisition (Heuer et al., 2009). Apart from 
that, other essential nutrients like amino acids, nucleotides, and iron also have to be acquired 
(Karayiannis and Hobson, 1981; McClarty et al., 1993; Al-Younes et al., 2001). 
 
Figure 1-2. Developmental cycle of Chlamydia. The chlamydial developmental cycle starts with the attachment (1) and 
invasion of host cells (2), followed by the differentiation of EBs into RBs within the inclusion (3), intracellular replication of 
RBs (5), redifferentiation of RBs into EBs (6), and the final release of EBs from the host cell (7). An alternative pathway can 
occur during special environmental conditions (e.g., host cell activation by IFNγ), leading to the formation of PBs (4). Figure 
was modified from Byrne and Ojcius, 2004. 
An alternative pathway can occur during special unfavorable environmental conditions (e.g., host 
cell activation by interferon gamma (IFNγ) or treatment with antibiotics), leading to the formation of 
persistent bodies (PBs) with a distinct change in morphology (de la Maza et al., 1987) (Figure 1-2, 
(4)). This allows for a chronic long-term infection of the host cell. However, if the stimulus of 
persistence is omitted, Chlamydia can resume its developmental cycle of acute infection (Beatty 
et al., 1993; Al-Younes et al., 2001). Starting at 16 to 20 h p.i., RBs eventually redifferentiate to form 
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EBs, a not synchronized process resulting in the presence of both bacterial forms in the chlamydial 
inclusion (Figure 1-2, (6)). Release of new infectious particles is achieved by lysis of the host cell 
(Abdelrahman and Belland, 2005) or a form of exocytosis (Beatty, 2007; Hybiske and Stephens, 
2007) at 48 to 72 h p.i., dependent on the chlamydial strain and species, and on growth conditions 
(Figure 1-2, (7)). Released EBs are then ready to infect new cells. 
1.2 Protein secretion systems 
Gram-negative bacteria are known to express and secrete host interactive proteins via type III or 
type IV secretion systems into the host cell cytoplasm to modulate host cell processes (Hueck, 1998; 
Christie et al., 2005). These effector proteins enable the pathogen to undermine host cellular 
functions and pathways. Some of the effectors become phosphorylated upon host cell entry, such as 
the translocated intimin receptor (Tir) of enteropathogenic Escherichia coli (EPEC) (Kenny et al., 
1997) and the cytotoxicity associated gene A (CagA) of Helicobacter pylori (Asahi et al., 2000). 
1.2.1 Type III secretion system of Chlamydia 
C. trachomatis uses a type III system to secrete numerous effector proteins (Valdivia, 2008). This 
needle-like structure enables Chlamydia to secret virulence-associated effector proteins into the 
host cell cytoplasm (Ghosh, 2004; Tampakaki et al., 2004) (Figure 1-3). 
 
Figure 1-3. The type III secretion system. Scheme showing the components of the chlamydial type III secretion system (Tr, 
translocator complex; TC, tip complex; NC, needle complex; basal apparatus; AC, cytoplasmic ancillary proteins). The 
bacterial inner membrane (IM), periplasm (PP), and outer membrane (OM) are bridged by the basal apparatus (blue), while 
the secreted translocon components (gray) are localized at the host membrane (HM). Figure was modifed from Betts-
Hampikian and Fields, 2010. 
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The most well characterized chlamydial effector, the translocated actin-recruiting phosphoprotein 
(Tarp), becomes tyrosine phosphorylated upon entry of Chlamydia into the host cell (Clifton et al., 
2004). To date, several host cell kinases have been implicated in Tarp phosphorylation including SRC, 
ABL, and SYK (Elwell et al., 2008; Jewett et al., 2008; Mehlitz et al., 2008) and the number of Tarp 
phosphorylation sites varies between Chlamydia species and serovars (Jewett et al., 2008). 
1.2.2 The effector protein Tarp 
Despite major difficulties in genetically manipulating Chlamydia species (Heuer et al., 2007; Kari 
et al., 2011), Tarp’s function has been assessed using the heterologous type III secretion system of 
Yersinia pseudotuberculosis (Clifton et al., 2004). This study revealed a critical role of Tarp in the 
actin-driven uptake of bacteria by host epithelial cells. Tyrosine phosphorylation of Tarp, however, 
appears to be uncoupled from actin polymerization because nonphosphorylated C. pneumoniae Tarp 
still induces actin polymerization (Clifton et al., 2005). Furthermore, domain analysis of 
C. trachomatis Tarp based on truncated versions of the protein confirmed that actin recruitment and 
tyrosine phosphorylation involve distinct domains of Tarp (Jewett et al., 2006). Actin polymerization 
is thought to be stimulated through oligomerization of a WAVE2-like actin binding domain in the 
C-terminus of the protein (Jewett et al., 2006) and Tarp phosphorylation takes place at multiple 
N-terminal motifs (Jewett et al., 2008). Phosphotyrosine-containing motifs are known to interact 
with SRC homology 2 (SH2) or phosphotyrosine binding (PTB) domains of signaling proteins 
(Schlessinger and Lemmon, 2003). Phosphorylation of Tyr179 and Tyr189 of Tarp has previously 
been implicated in recruiting the RAC guanine nucleotide exchange factor VAV2 and the regulatory 
subunit of phosphatidylinositol 3-kinase (PI3K) in an SH2-dependent manner (Lane et al., 2008). 
These interactions are thought to participate in a redundant invasion mechanism. Nonetheless, a 
more comprehensive analysis of Tarp’s interactions with host cellular proteins is necessary to 
establish the effector’s functional repertoire and to further clarify the role of Tarp during the early 
phase of Chlamydia infection. 
1.3 Host-pathogen interplay 
Chlamydia has evolved a close relationship to its host, reflected by the efficient exploitation of host 
cellular signaling and trafficking pathways to ensure its intracellular replication and protection from 
host immune responses. This host-pathogen interplay has been investigated for major host cellular 
pathways, such as the MAPK pathway, the regulation of apoptosis, and the trafficking of lipids. 
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1.3.1 Chlamydia and the MAPK pathway 
An important pathway modulating host cell apoptosis and survival is the RAS/RAF/MEK/ERK 
MAPK signaling cascade. This signaling cascade is one of the best studied signal transduction 
pathways and is connected with a variety of cellular functions. An initial extracellular signal is 
transmitted to the cell by the interaction of a ligand with its corresponding receptor tyrosine kinase 
(RTK). Upon this, the receptor’s cytoplasmic domain is autophosphorylated and recruits adaptor 
proteins like the SRC homology-containing protein SHC1 via SH2 interactions (Figure 1-4). 
 
Figure 1-4. The MAPK pathway. Model representing the MAPK pathway, which starts with RTKs being activated by 
extracellular ligands, thus leading to tyrosine autophosphorylation of the receptor’s cytoplasmic domain. Adaptor proteins 
like SHC1 bind to phosphorylated RTKs via SH2 interactions, recruiting other docking proteins such as GRB2. GRB2 activates 
the guanine nucleotide exchange factor SOS, which then drives the switch of inactive, GDP-bound RAS to active, GTP-
bound RAS. Activated RAS promotes recruitment, heterodimerization, and activation of RAF, a kinase that phosphorylates 
and activates MEK. The kinase MEK then activates ERK, which controls gene transcription by regulating several 
transcription factors through phosphorylation. Figure was modified from Cell Signaling Technology, 2010. 
The protein SHC1 represents a molecular adapter, linking extracellular signals to mitogenic 
responses (Pelicci et al., 1992). SHC1 exists as three isoforms, all encoded by a single gene locus (Luzi 
et al., 2000). The isoforms share a common domain composition: a C-terminal SH2 domain, an 
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N-terminal PTB domain, and a central collagen-homology domain (CH1) harboring several 
phosphorylation sites (Ravichandran, 2001). Interaction at these sites with growth factor receptor-
bound protein 2 (GRB2), in conjunction with the RAS exchange factor SOS, activates the 
RAS/RAF/MEK/ERK pathway to induce a mitogenic response (van der Geer et al., 1996). In detail, 
GRB2 activates the guanine nucleotide exchange factor SOS, which then drives the switch of inactive, 
GDP-bound RAS to active, GTP-bound RAS. Activated RAS promotes recruitment, activation, and 
heterodimerization of RAF, a kinase that activates the MAPK/ERK kinase MEK1/2 (Rushworth et al., 
2006; McCubrey et al., 2007). Upon activation, MEK1/2 phosphorylates the extracellular signal-
regulated kinase ERK1/2 at specific tyrosine/threonine residues, which then directly phosphorylates 
a variety of transcription factors including c-JUN, c-MYC, and nuclear factor κB (NF-κB). 
Chlamydia infection was shown to activate ERK, followed by the downstream activation of cPLA2 (Su 
et al., 2004), the induction of interleukin-8 (IL-8) (Buchholz and Stephens, 2008), TNF receptor 1 
(TNFR1) shedding (Paland et al., 2008), and stabilization of MCL-1 (Rajalingam et al., 2008). Recent 
work has revealed that MEK/ERK activation is independent of RAS/RAF during mid and late 
Chlamydia infection (Gurumurthy et al., 2010). 
1.3.2 Chlamydia and apoptosis 
Apoptosis is, among necrosis and autophagy, a type of cell death and fundamentally contributes to 
the balance between proliferation and the maintenance of constant cell numbers, e.g., during 
development and tissue homeostasis of multicellular organisms (Jaattela, 2002). Apoptosis occurs as 
a tightly defined process of irreversible effector caspase activation, resulting in the degradation of a 
series of substrates (Byrne and Ojcius, 2004). It is characterized by changes in cell morphology, such 
as cell shrinkage, pyknosis, plasma membrane blebbing, karyorrhexis, and formation of apoptotic 
bodies (Kerr et al., 1972). During apoptosis, no neighboring cells are damaged and no inflammatory 
response is induced (Fink and Cookson, 2005). Two major pathways of apoptosis induction have 
been described: the extrinsic pathway (death receptor pathway) and the intrinsic pathway 
(mitochondrial pathway) (Figure 1-5). 
In the extrinsic pathway, external death ligands like tumor necrosis factor alpha (TNFα) or FAS ligand 
(FASL) bind to their cognate receptors (members of the TNF receptor family), leading to caspase 8 
activation (Locksley et al., 2001). Type I cells show a high level of active caspase 8, which then 
directly activates effector caspase 3 (Hengartner, 2000). However, in type II cells, levels of active 
caspase 8 a comparably low. Therefore, these cells require the additional activation of the 
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mitochondrial pathway via Bid (Scaffidi et al., 1999). The intrinsic pathway is triggered by 
intracellular stress, e.g., induced by radiation, toxins, hypothermia, or infections. BH3-only proteins 
act as stress sensors and trigger the activation of the BCL-2 family members Bax and Bak (Bouillet 
et al., 2002). Bax and Bak oligomerize in the mitochondrial outer membrane, leading to the release 
of cytochrome c into the cytoplasm (Wei et al., 2001; Willis and Adams, 2005). In type II cells, the 
activation of Bax and Bak is mediated by Bid, which itself gets cleaved by caspase 8 to form 
truncated Bid (tBid). Once cytochrome c is released, it binds to apoptosis activating factor-1 
(APAF-1), forming a complex with caspase 9 (Hill et al., 2004). This complex is called the 
apoptosome. Activated caspase 9 can now activate caspase 3, resulting in cellular apoptosis (Reed, 
2000; Faherty and Maurelli, 2008). Substrates of active caspase 3 are, amongst others, cytokeratin 
18 (CK18) or poly (ADP-ribose) polymerase (PARP). 
 
Figure 1-5. Major pathways of apoptosis induction. Model describing the two major apoptosis induction pathways: the 
extrinsic pathway (left side) and the intrinsic pathway (right side). While the extrinsic pathway (death receptor pathway) is 
triggered by external ligands, the intrinsic pathway (mitochondrial pathway) is caused by intracellular stress. Figure was 
modified from Byrne and Ojcius, 2004. 
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A prerequisite of Chlamydia replication is the pathogen’s ability to prevent apoptosis of its host cell. 
Chlamydia-infected cells become resistant to numerous pro-apoptotic stimuli, including 
staurosporine, etoposide, TNFα, FAS antibody, and granzyme B/perforin (Fan et al., 1998). Anti-
apoptotic activity is thought to be conveyed by the proteolytic degradation of the pro-apoptotic 
BH3-only proteins BIM/BOD and PUMA, and by the mitochondrial sequestration of BAD during 
chlamydial infection (Fischer et al., 2004). Alternatively, recent studies have implicated the anti-
apoptotic BCL-2 family member MCL-1 as a key factor in preventing apoptosis (Rajalingam et al., 
2008). In addition, Chlamydia subverts the function of the pro-apoptotic protein kinase Cδ (PKCδ) by 
increasing diacylglycerol (DAG) levels in the chlamydial inclusion membrane (Tse et al., 2005). 
Together, these observations suggest that Chlamydia prevents host cell apoptosis through a variety 
of mechanisms, likely acting sequentially as infection proceeds (Fan et al., 1998; Perfettini et al., 
2002; Rajalingam et al., 2008). 
1.3.3 Chlamydia and nutrient acquisition 
Due to the obligate intracellular lifestyle and extensive genome condensation of Chlamydia, the 
bacterium has evolved to rely on the host cell in acquiring lipids, amino acids, nucleotides, and other 
nutrients (Trentmann et al., 2007; Saka and Valdivia, 2010) (Figure 1-5). 
 
Figure 1-6. Host cell nutrient acquisition by Chlamydia. Model representing strategies of Chlamydia to exploit host cell 
pathways, including (a) Golgi fragmentation and subsequent association of Golgi ministacks with the inclusion, uptake of 
lipids via exocytic vesicles, (b) recruitment of CD59 to the inner side of the inclusion membrane, (c) cPLA2 activation and 
subsequent processing of host cell phospholipids to assist lipid translocation to the inclusion, (d) uptake of multivesicular 
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bodies via Lda, (e) translocation of lipids droplets, to the inclusion, (f) recruitment of Rab GTPases via Cpn0585 and CT229, 
and (g) recruitment of SNARE proteins (Vamp-3, Vamp-7, Vamp-8) via IncA and CT813. The following abbreviations are 
used: b-FA, Chlamydia-derived branched fatty acid; Lda, lipid droplet-associated protein; MVB, multivesicular body; PL, 
phospholipid. Figure was modified from Saka and Valdivia, 2010. 
Recent findings reveal an intimate interaction between the inclusion and host cell organelles. Both 
Rab GTPases and SNARE proteins get recruited to the bacterial inclusion (Delevoye et al., 2008; 
Paumet et al., 2009; Rejman Lipinski et al., 2009)). Further, lipids such as glycerophospholipids, 
sphingolipids, and cholesterol are acquired by re-routing Golgi-derived exocytic vesicles and 
multivesicular bodies (Wylie et al., 1997; Beatty, 2006; Beatty, 2008; Moore et al., 2008; Robertson 
et al., 2009). This transport is based on the Chlamydia-induced fragmentation of the Golgi apparatus 
(Heuer et al., 2009). Apart from this, Valdivia and colleagues were able to show the uptake of lipid 
droplets (neutral lipid storage vesicles) into the inclusion (Kumar et al., 2006; Cocchiaro et al., 2009). 
1.3.4 Chlamydia and lipids 
The acquisition of host-derived lipids such as cholesterol, sphingomyelin, glycerophospholipids, and 
neutral lipids is of major importance for the successful replication of C. trachomatis. For this 
purpose, the bacterium subverts both vesicular and nonvesicular trafficking pathways (Saka and 
Valdivia, 2010). Membranes of Chlamydia were shown to contain lipid classes that are associated 
with eukaryotic membranes and to reflect the host cell lipid composition (Hatch and McClarty, 
1998a). Among these lipids are phosphatidylcholine (PC) and phosphatidylinositol (PI), which are 
normally derived from the endoplasmic reticulum, and cardiolipin (CL) (Wylie et al., 1997). CL is a 
structural and functional component found exclusively in mitochondrial membranes (Hatch, 1998). It 
is linked with mitochondrial energy production, since several enzymes involved in energy 
metabolism require CL for full enzymatic function and structural stability (Eble et al., 1990; Hatch, 
1998; Gomez and Robinson, 1999). CL has also been associated with targeting tBid to mitochondria, 
thereby contributing to cytochrome c release during apoptosis (Lutter et al., 2000). Formation of CL 
is catalyzed by the cardiolipin synthase 1 (CRLS1) from phosphatidylglycerol and CDP-diacylglycerol 
(Schlame, 2008). The enzyme is localized to the inner membrane of mitochondria and is expressed in 
HeLa cells (Chen et al., 2006; Lu et al., 2006). Interestingly, no homolog of CRLS1 can be found in 
C. trachomatis. 
Furthermore, Chlamydia induces the modification of lipids during their translocation to the inclusion. 
Host-derived glycerophospholipids are deacylated at the sn-2 position of the glycerol backbone and 
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the remaining lysophospholipid gets modified by addition of a Chlamydia-derived branched chain 
fatty acid to the sn-2 position (Wylie et al., 1997). The host enzyme cPLA2 was shown to be 
responsible for the sn-2 deacylation, and pharmacological cPLA2 inhibition reduces 
glycerophospholipid uptake and bacterial replication (Su et al., 2004). Additionally, Chlamydia 
activates cPLA2 via the MAPK pathway (Su et al., 2004; Vignola et al., 2010). 
Taken together, several studies demonstrate the modulation of host cell trafficking and lipid 
metabolism by Chlamydia, indicating that the pathogen is highly dependent on these components. 
However, the central mechanisms and key molecules of these processes remains to be investigated. 
1.4 Aim of this study 
The scope of this thesis was to further dissect the repertoire of C. trachomatis to exploit the host cell 
and actively subvert signaling and trafficking pathways – by identifying novel factors involved in both 
the invasion process and the pathogen’s nutrient acquisition. 
In the first part of this study, a systematic approach was performed to discover and quantify 
phosphorylation-dependent and -independent interactions between the bacterial effector protein 
Tarp and host cell SH2 and SH3 domain-containing proteins. To comprehensively assess these 
interactions, protein microarrays comprising virtually all human SH2 and SH3 domains were used. 
Detected interactions were validated by means of biochemical, microscopic, and computational 
methods and analyzed for their involvement in host cell signaling. Moreover, SH2 and SH3 
interactome data were globally studied for their participation in major cellular processes. Combining 
the knockdown of interaction partners with subsequent transcriptional profiling during infection 
allowed for the identification of specifically regulated genes and their further functional 
characterization. 
In the second part of this study, changes in host cell lipid composition during C. trachomatis infection 
were globally studied by mass spectrometry to gain a better understanding of their significance for 
the pathogen’s survival and replication. Lipid species showing a prominent change during infection 
were selected for further analysis. The knockdown of genes involved in biosynthesis and trafficking 
of these lipids revealed their impact on chlamydial growth and progeny formation. 
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2 Materials and methods 
2.1 Materials and general methods 
2.1.1 Cell lines and bacteria 
HeLa (ATCC no. CCL-2) and End1/E6E7 (ATCC no. CRL-2615), both human cervical epithelial cells, and 
HEp-2 (ATCC no. CCL-23), human laryngeal epithelial cells, were grown in DMEM (Invitrogen, 
Germany) supplemented with 10 % (v/v) fetal calf serum (FCS), 5 mM L-glutamine, and 1 mM sodium 
pyruvate (Invitrogen, Germany). Chlamydia trachomatis LGV biovar strain L2/434/Bu (ATCC no. 
VR-902B, strain collection no. C2), C. trachomatis trachoma type D strain UW-3/Cx (ATCC no. VR-885, 
strain collection no. C4), and Chlamydophila pneumoniae TWAR strain CDC/CWL-029 (ATCC no. 
VR-1310, strain collection no. C1) were purified from confluent HeLa monolayers. In brief, HeLa cells 
were grown to 80 % confluency and were inoculated for 2 h with the respective C. trachomatis 
strain. For infections with C. pneumoniae, inoculated cells were incubated at 22°C for 1 h on a 
shaker, centrifuged (500 rpm at 35°C) for 1 h and then incubated for 2 h at 35°C. The medium was 
replaced by infection medium (DMEM, 5 % (v/v) FCS, 5 mM L-glutamine, 1 mM sodium pyruvate, 
1 µg/ml cycloheximide) and growth was allowed for 48 h. Cells were mechanically detached and 
bacteria were released using 2-5 mm glass beads (Carl Roth, Germany). Low speed supernatant 
(5 min at 4000 g and 4°C) was subjected to high speed centrifugation (25 min at 40000 g and 4°C) to 
pellet the bacteria. Bacteria were washed twice with 10 ml SPG storage buffer (220 mM sucrose, 
50 mM sodium phosphate, 5 mM glutamate, pH 7.4), aliquoted, and stored at -80°C in SPG. 
2.1.2 Reagents, antibodies and constructs 
Chemicals were obtained from Sigma-Aldrich (Germany). Recombinant human TNFα (554618) was 
obtained from BD Biosciences (USA). Antibodies against β-actin (sc-7210), cortactin (3503), ERK1/2 
(9108), p-ERK1/2 (9106), MEK1/2 (9122), p-MEK1/2 (9121), PARP-1/2 (sc-7150), SHC (sc-967 and 
sc-288), p-SHC Tyr239/240 (sc-18074-R), p-Tyr PY99 (sc-7020), NCK1/2 (sc-290), cPLA2 (2832), and 
GST (sc-34072) were acquired from Santa Cruz (USA), or Cell Signaling (USA). Antibodies against the 
M30 epitope of cleaved CK18 (ALX-804-590-T200) and against bacterial Hsp60 (804-071-R100) were 
obtained from Enzo Life Sciences (USA). Secondary Cy2-conjugated antibodies against rabbit IgG 
(111-225-144), mouse IgG (115-225-146), and Cy5-conjugated antibodies against rabbit IgG 
(111-175-144) and mouse IgG (115-175-146) were obtained from Jackson ImmunoResearch 
Laboratories (USA). Alexa Fluor 532 phalloidin for staining of actin was obtained from Invitrogen 
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(Germany). Antiserum against Tarp was raised by immunization of rats with GST-Tarp fusion protein 
(Biogenes, Germany). Monoclonal anti-Chlamydia OMP1 was obtained from University of 
Washington (USA). GST-Tarp was constructed by PCR amplification of nucleotides 6-818 of 
C. trachomatis LGV L2 Tarp or 1-939 of C. trachomatis D Tarp and ligation of the product into 
pGEX4T-3 (GE Healthcare, USA) using dinucleotide sticky-end cloning (strain collection no. H3792 
and H3838). Purification of GST-Tarp was performed according to the manufacturer’s instructions 
using glutathione sepharose (GE Healthcare, USA). pEGFP-C1-RBDRAF-1 (strain collection no. H3972) 
and pmCherry-C1-HRAS (strain collection no. H3974) were obtained from Mark R. Phillips (NYU). 
2.1.3 Infection time courses 
For Western blot analysis, HeLa or End1/E6E7 cells were seeded into 12-well plates at a density of 
60-70 %. Cells were serum starved for 24 h in serum-free growth medium before performing 
infection time course experiments. Infection was performed at indicated multiplicity of infection 
(MOI) with either bacteria or control mock infected cells (i.e., treated with SPG). C. pneumoniae 
infections were synchronized by centrifugation for 1 h at 500 g and 4°C and shifting to 35°C. 
Infection was stopped at the indicated time points by removing the medium, rinsing quickly with 
prewarmed PBS and immediately lysing in SDS loading buffer at 94°C for 5 min. For lipid analysis, 
HeLa or HEp-2 cells were seeded in T75 flasks at a density of 1.5 x 106 cells per flask. Infection was 
carried out with an MOI of 2.5 according to Figure 3-32. Prior to infection and prior to lipid analysis, 
cell numbers were counted manually. 
2.1.4 Statistical analysis 
Statistical significance was determined using Student’s t test. In case of the gene enrichment analysis 
(Figure 3-23), Fisher’s exact test was used to determine statistical significance. P-values below 0.05 
were defined as significant. 
2.2 DNA techniques 
2.2.1 Transfections 
siRNA transfection of HeLa cells was carried out using Lipofectamine 2000 (Invitrogen, Germany) 
according to the manufacturer’s instructions. siRNA against SHC1, CRLS1 (both SMARTpool, Thermo 
Fisher Scientific, Germany), cPLA2 (QIAGEN, Germany), or luciferase (QIAGEN, Germany) were used. 
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Knockdown was confirmed via quantitative real-time PCR (qRT-PCR) or Western blotting 72 h after 
transfection. Plasmid transfection (pEGFP-C1-RBDRAF-1 and pmCherry-C1-HRAS) of HeLa cells was 
performed with Lipofectamine 2000 (Invitrogen, Germany) according to the manufacturer’s 
instructions. Live-cell microscopy experiments were carried out 48 h after transfection. 
2.2.2 DNA microarrays and analysis 
RNA from infected, uninfected, or transfected (and infected) HeLa cells was isolated with the 
RNAeasy Kit (QIAGEN, Germany) according to the manufacturer’s instructions. RNA integrity was 
analyzed using a Bioanalyzer 2100 (Agilent Technologies, USA). DNA microarray experiments were 
performed as two-color dye-reversal ratio hybridizations on arrays containing 44000 human genes 
(AMADID 010646, Agilent Technologies, USA) in biological duplicates. RNA labeling was performed 
with a Fluorescent Linear Amplification kit (Agilent Technologies, USA). Labeling efficiency was 
verified with a Nanodrop photometer (Kisker Biotech, Germany). Before hybridization, cDNA was 
fragmented and mixed with control targets and hybridization buffer according to the manufacturer’s 
instructions (Agilent Technologies, USA). Hybridizations were performed overnight (~17 h) at 60°C. 
Slides were washed according to the manufacturer’s instructions and scanning of microarrays was 
performed at 5 μm resolution using a microarray laser scanner (Agilent Technologies, USA). 
Data analysis was performed on the Rosetta Resolver system 7.2 (Rosetta Biosoftware, USA). Ratio 
profiles were generated from raw scan data by a processing pipeline, which includes preprocessing 
(feature extraction) and postprocessing (Rosetta Resolver) of data and error model adjustments to 
the raw scan data. Ratio profiles were combined in an error-weighted fashion (Rosetta Resolver) to 
create ratio experiments. Expression patterns were identified using stringent analysis criteria of 
1.6-fold expression cutoffs of the ratio experiments and an anti-correlation of the dye reversal ratio 
profiles. Anti-correlation was determined by using the compare function to match two different 
hybridizations pairs and to decide how similar or dissimilar they were. By combining the first and the 
second criteria of analysis, data points with a low p-value (p < 0.01) were filtered out, making the 
analysis robust and reproducible. Additionally, by using this strategy the data selection was 
independent of error models implemented in the Rosetta Resolver system. 
2.2.3 qRT-PCR analysis 
For qRT-PCR, mRNA from HeLa cells was isolated with the RNAeasy Kit (QIAGEN, Germany) according 
to the manufacturer’s instructions. 10 µl mRNA was DNaseI digested with RNase-free DNaseI 
  Materials and methods 
 
  25 
(Fermentas, Germany) according to the manufacturer’s instructions. Digested mRNA was 
phenol/chloroform purified. In brief, 180 µl of RNase free water (Synergy Ultrafiltration System, 
Millipore, USA) and 200 µl of phenol/chloroform (Carl Roth, Germany) were added to the 20 µl 
digestion reaction and vortexed. Samples were phase separated at 12000 g (4°C for 10 min) and the 
supernatant was combined with 200 µl of chloroform followed by vortexing. After repeated phase 
separation mRNA was precipitated using 0.1 vol. of 3 M sodium acetate and 2 vol. of 80 % (v/v) 
ethanol followed by centrifugation at 14000 g (4°C for 15 min). The supernatant was removed and 
the pellet was air dried in a clean bench environment and resuspended in 50 µl of RNase free water. 
mRNA was reverse transcribed using the Revert Aid First Strand Synthesis kit (Fermentas, Germany) 
according to the manufacturer’s instructions and was diluted 1:10 with RNase free water. qRT-PCR 
was set up with Absolute QPCR SYBR Green Mix (Thermo Fisher Scientific, Germany) according to 
the manufacturer’s instructions. qRT-PCR was performed on a Step One Plus device (Applied 
Biosystems, USA) and data were analyzed using the ΔΔCt method, Step One Plus software package 
(Applied Biosystems, USA), and Microsoft Excel. Endogenous controls were GAPDH and L13a. Splice 
variant specific primers were designed using National Center for Biotechnology Information (NCBI) 
Primer Blast or Primer 3 (Rozen and Skaletsky, 2000) (Table 2-1). 
Table 2-1. qRT-PCR primers. List shows the PCR primers used in this study for amplification in qRT-PCR. Primers were 
chosen as described above. 
Primer Sequence (5' to 3') Length (bp) Start (bp) Stop (bp) Tm (°C) GC (%) Product length (bp) 
TEK forward GTGCTGTTCCTTCTTGCCTC 20 300 319 60.0 55.0 
117 
TEK reverse TCCACAAATGTGCATGAGGT 20 416 397 60.0 45.0 
BMF forward AGTCAAACTTTGTGACCGGC 20 58 77 60.2 50.0 
148 
BMF reverse AGTAGGCTCTGGGCAAACAG 20 205 186 59.5 55.0 
EGR1 forward GACCGCAGAGTCTTTTCCTG 20 570 589 60.0 55.0 
110 
EGR1 reverse AGCGGCCAGTATAGGTGATG 20 679 660 60.1 55.0 
FST forward ATCTTGCAACTCCATTTCGG 20 969 988 60.1 45.0 
115 
FST reverse CACTGAACACTTATAGAGAGTTTACCA 27 1083 1057 57.4 37.0 
PHLDA1 forward GGCAAGACAAGGTTTTGAGG 20 176 195 59.7 50.0 
139 
PHLDA1 reverse CGCCAAGTTGTTCAGTAGGG 20 314 295 60.7 55.0 
CXCL1 forward GAAAGCTTGCCTCAATCCTG 20 325 344 60.0 50.0 
107 
CXCL1 reverse CACCAGTGAGCTTCCTCCTC 20 431 412 60.0 60.0 
DKK1 forward ATCATAGCACCTTGGATGGG 20 636 655 59.8 50.0 
112 
DKK1 reverse CCTGAGGCACAGTCTGATGA 20 747 728 60.0 55.0 
  Materials and methods 
 
  26 
SDC4 forward GTCTGGCTCTGGAGATCTGG 20 220 239 60.0 60.0 
139 
SDC4 reverse TAGTTTCTTGGGTTCGGTGG 20 358 339 60.0 50.0 
MAP2K3 forward ATTAGTCAGGCAGGGCAGTG 20 81 100 60.3 55.0 
105 
MAP2K3 reverse GGACTCCAGGGCCTTATCTC 20 185 166 60.0 60.0 
FLI1 forward CGAGAGGAGAGTCATCGTCC 20 701 720 59.9 60.0 
107 
FLI1 reverse TGTCGATCTCCATCAAGCTG 20 807 788 59.9 50.0 
CRLS1 forward CCATGGACAATCCCGAATATG 21 470 490 50.7 47.6 
75 
CRLS1 reverse TTCAATAATCAAATAGCCCAGAACTG 26 544 519 52.0 34.6 
 
2.3 Protein techniques 
2.3.1 Peptide synthesis and protein microarrays 
For SH2/PTB interactome analysis, peptides representing the Tarp phospho-sites were synthesized 
as described (Jones et al., 2006), purified to > 95 % by preparative reverse phase high-performance 
liquid chromatography (HPLC), quality controlled via matrix-assisted laser desorption/ionization 
time-of-flight (MALDI-TOF) mass spectrometry (Thermo Fisher Scientific, Germany), and labeled on 
their N-termini with 5-(and 6)-carboxytetramethylrhodamine (5(6)-TAMRA) from Anaspec (San Jose, 
USA). For SH3 interactome analysis, peptides representing the Tarp SH3 binding site were 
synthesized, purified to > 95 %, and N-terminally biotinylated (Thermo Fisher Scientific, Germany). 
MacBeath and colleagues have previously described cloning, expressing, and purifying virtually every 
human SH2 and PTB domain, as well as preparing microarrays of these domains on chemically-
derivatized glass surfaces (MacBeath and Schreiber, 2000; Jones et al., 2006). In brief, the coding 
regions for each domain were cloned from human cDNA and the corresponding proteins were 
produced recombinantly in E. coli using the T7 expression system. Each domain features an 
N-terminal His6-tag, as well as a thioredoxin-tag to facilitate the high-level production of soluble 
protein. After purifying each domain from large-scale bacterial culture (0.5 l), purity was controlled 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and its aggregation state by size exclusion 
column chromatography. In the current version of the arrays, domains that were impure or did not 
contain soluble, monomeric protein were eliminated. Notably, SH2 domains derived from the signal 
transducers and activator of transcription (STAT) and suppressors of cytokine signaling (SOCS) 
families of proteins did not behave well. By cloning larger portions of STAT1 and STAT2 that included 
their entire SH2 domain-containing cores (Mao and Chen, 2005), soluble, monomeric material for 
these two proteins were obtained. In addition, the N-terminal domain of CBL (Meng et al., 1999), 
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which contains a noncanonical SH2 domain was cloned, expressed, and purified. In total, 133 
domains representing 103 proteins were used in this study. 
To facilitate the rapid and automated processing of the SH2/PTB protein microarrays, a NanoPrint 
microarrayer (TeleChem International, USA) was used to spot the proteins in quadruplicate on 
aldehyde displaying glass substrates, cut to the size of a microtiter plate (112.5 mm x 74.5 mm x 
1 mm) (Erie Scientific, USA). 96 separate arrays were prepared on each glass substrate, and the glass 
was attached to the bottom of a bottomless microtiter plate using an intervening silicone gasket 
(Grace Bio-Labs, USA). Two 16 × 17 microarrays were required to accommodate all 133 domains, as 
well as the appropriate controls (His6-tagged thioredoxin and buffer). Proteins were spotted in 
quadruplicate at a high concentration (40-200 µM), and a low concentration (200 nM) of cyanine 5-
labeled bovine serum albumin (BSA) was included in each sample to facilitate image analysis. Arrays 
were stored at -80°C before use. 
Immediately before use, plates were quenched with buffer A (20 mM HEPES, 100 mM KCl, 
0.1 % (v/v) Tween-20, pH 7.8) containing 1 % (w/v) BSA for 30 min at room temperature, followed by 
several rinses with buffer A. Arrays were probed with eight different concentrations of labeled 
peptides (5 µM, 3 µM, 2 µM, 1 µM, 500 nM, 200 nM, 100 nM, and 10 nM) dissolved in buffer A. 
Peptide solution was removed after a 1 h incubation at room temperature and arrays were washed 
with 150 ml of buffer A for 10 s. Arrays were rinsed briefly with double-distilled H2O (ddH2O) and 
spun upside down in a centrifuge for 1 min to remove residual water. 
SH2/PTB protein microarrays were scanned at 10 µm resolution using an LS400 scanner (Tecan, 
Austria). Spots were defined using the Cy5 image and the mean fluorescence of each spot was 
calculated from the 5(6)-TAMRA image. It has previously been shown that probing a protein 
microarray with a single concentration of a labeled probe can produce very misleading results 
(Gordus and MacBeath, 2006). Therefore, the arrays were probed with eight concentrations of each 
peptide and fit the resulting spot intensities, Fobs, to the following equation: 
 
 
 
(1) 
where F0 is the background fluorescence, Fmax is the maximum fluorescence at saturation, [pep] is 
the total peptide concentration, and KD is the equilibrium dissociation constant. This procedure was 
performed for each peptide/domain interaction. Interactions were considered specific if the data fit 
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well to equation (1) (R2 > 0.9), with KD < 2 µM and Fmax at least twofold higher than the mean 
fluorescence of control spots (His6-tagged thioredoxin). The resulting data were displayed graphically 
using the Cytoscape 2.1 software (Shannon et al., 2003). 
For SH3 interactome analysis, protein microarrays (TranSignal SH3 domain arrays, Panomics, USA) 
consistent of 117 SH3 domains in duplicate were acquired from Panomics (USA) and probed with 
peptides according to the manufacturer’s instructions. In brief, 750 ng of biotin-conjugated peptide 
(wild type or mutated version) were mixed with 15 μg streptavidin-HRP conjugate (Amersham, USA) 
and incubated with the SH3 protein microarrays. Each SH3 domain was spotted in duplicate on the 
membrane. Signal detection was performed using ECL/Hyperfilm (Amersham, USA). Quantification 
was carried out using ImageJ (Girish and Vijayalakshmi, 2004) and Microsoft Excel. Interactions with 
at least 25 % of the signal intensity of the positive control (biotin) and a minimum signal decrease of 
50 % between wild type and mutated peptide were defined as hits. 
2.3.2 Pull-down assays and immunoblotting 
GST-Tarp was phosphorylated while the beads coupled to glutathione sepharose (Pharmacia, USA). 
In brief, GST-Tarp beads were incubated for 30 min at 30°C with recombinant human c-SRC (Cell 
Signaling, USA) in kinase buffer (25 mM HEPES, pH 7.0, 150 mM NaCl, 10 mM MgCl2, 1 % (v/v) 
Nonident P40, 5 mM dithiothreitol, 1 mM Na3VO4, 1x COMPLETE protease inhibitors, 6 mM ATP). 
GST-Tarp beads were washed three times with PBS and incubated with lysate from 107 cells (50 mM 
Tris, pH 7.5, 150 mM NaCl, 1 % (v/v) Nonident P40, 0.5 % (w/v) sodium deoxycholate, 1x COMPLETE 
protease inhibitors) for 2 h at 4°C. Proteins were eluted by incubation with 20 mM of reduced 
glutathione in 50 mM Tris, pH 8.0. Immunoprecipitation and Western blotting were performed 
according to standard procedures (Sambrook and Russel, 2001). Signal detection was performed 
using ECL/Hyperfilm (Amersham, USA). Quantification was carried out using ImageJ (Girish and 
Vijayalakshmi, 2004) and Microsoft Excel. 
2.4 Lipid techniques 
2.4.1 Lipid extraction 
The method of lipid extraction is adopted from Folch et al., 1957. In brief, cells were washed once 
with 10 ml PBS and scraped off in 5 ml PBS per flask. The cell suspension was centrifuged (20 min at 
200 g and 4°C) in glass tubes and pellets were resuspended in 1 vol. chloroform/methanol (2:1). 
  Materials and methods 
 
  29 
After sonicating the cells for 20 min, tube walls were rinsed with 1 vol. chloroform/methanol (2:1) 
and the mixture was shaken vigorously for 4 h at RT. Subsequently to addition of 0.4 vol. ddH2O, the 
mixture was again shaken several times and incubated overnight at 4°C. The lower phase was 
removed and 1 vol. chloroform/methanol (2:1) was added to the remaining upper phase. The 
mixture was shaken and centrifuged (20 min at 200 g and 4°C). Again, the lower phase was removed 
and the combined lower phases were washed with 0.2 vol. ddH2O. After phase separation, the lower 
phase was transferred to a new glass tube and the solvent was evaporated under a stream of 
nitrogen. Extracted lipids were dissolved in 100 µl chloroform, transferred to small glass tubes and 
chloroform was evaporated using a SpeedVac concentrator system. Finally, the extracted lipids were 
dissolved in 15 µl chloroform. 
2.4.2 MALDI-TOF mass spectrometry 
Two approaches were applied: 1. the direct MALDI-TOF measurement of lipids in the crude lipid 
extract, and 2. the separation of lipids by normal phase thin-layer chromatography (TLC) according 
to their head group followed by MALDI-TOF measurement of lipids directly on the TLC plate. In case 
of direct measurement, lipid samples were mixed with an equal volume of matrix solution (0.5 M 
2,3-dihydroxy benzoate, 0.1 % (v/v) trifluoroacetic acid in methanol) and 2 µl aliquots were spotted 
on gold-coated MALDI target plates. In the second approach, lipid samples and a lipid standard 
(containing phosphatidylglycerol (PG), phosphatidylethanolamine (PE), phosphatidic acid (PA), 
phosphatidylinositol (PI), phosphatidylserine (PS), phosphatidylcholine (PC), sphingomyelin (SM), 
and lysophosphatidylcholine (LPC)) were spotted on an aluminum base TLC plate (Merck, Germany). 
Normal phase TLC was performed using a mixture of chloroform/ethanol/ddH2O/triethanolamine 
(30:35:7:35) as running buffer. Subsequently, the TLC plate was dried and stained with primuline. 
Spots were visualized with UV light, marked, and matrix solution (100 mg/ml 2,3-dihydroxy benzoate 
in acetonitril/ddH2O (1:1)) was added. Finally, the TLC plate was fixed on a gold-coated MALDI target 
plate. 
All MALDI-TOF mass spectra were acquired using a Bruker Autoflex workstation (Bruker Daltonics, 
Germany). This system uses a 337 nm pulsed nitrogen laser with an extraction voltage of 20 kV. For 
each mass spectrum, 128 single laser shots were averaged. Spectra were acquired in the reflector 
mode using delayed extraction conditions to improve the spectral resolution. Processing and 
analysis of the acquired spectra was done using the Flex Analysis software (Bruker Daltonics, 
Germany). More details on the methodology are given in Schiller et al., 2004. 
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2.5 Microscopy 
2.5.1 Immunofluorescence staining and microscopy 
For immunofluorescence cells were either seeded in 24- or 12-well plates with or without coverslips 
and were infected in a humidified incubator at 35°C and 5 % (v/v) CO2 with MOI indicated in the 
respective experiments. Cells were fixed at indicated time points with 4 % (w/v) PFA, washed once 
with PBS and stained. In brief, cells were permeabilized with 0.2 % (v/v) Triton X-100 or 0.1 % (v/v) 
saponin in PBS for 30 and 10 min, respectively, and were washed three times with PBS for 5 min at 
RT. Cells were blocked with 2 % (v/v) FCS in PBS for 45 min and were stained with primary antibodies 
diluted in 2 % (v/v) FCS in PBS for 1 h at RT. After three times washing with PBS, samples were 
incubated with secondary antibodies for 1 h in blocking solution at RT in the dark. After one short 
wash with ddH2O, samples were mounted with Mowiol 4-88 (Carl Roth, Germany) and visualized at 
RT on a Leica TCS SPE confocal microscope (photomultiplier equipped) at 63x magnification 
(HCX Plan-Apochromat with a 63x/1.40-0.60 oil objective lens) using the Leica LAS AF TCS SPE 
acquisition software. Data were processed with Adobe Photoshop (adjustment of brightness and 
contrast identical for all images). 
2.5.2 Live-cell fluorescence microscopy 
HeLa cells were seeded in 3.5 cm2 glass-bottom dishes (MatTek, USA) and transfected with 
pEGFP-C1-RBDRAF-1 and pmCherry-C1-HRAS as described above. After 24 h, cells were washed twice 
with PBS and incubated in serum-free medium overnight. The next day, fresh serum-free medium 
was added and cells were monitored in a humidified incubation chamber at 37°C and 5 % (v/v) CO2. 
Image acquisition was done at 60x magnification (Olympus UPlanFL N 60x/1.25 NA lens) with an 
Olympus IX81 microscope equipped with a Hamamatsu C9100-02 CCD camera. Images were 
processed using the Metamorph software (Molecular Devices, USA). 
2.6 Other methods 
2.6.1 Invasion, inclusion formation, and progeny assays 
For measurement of invasion efficiency, inclusion formation, and progeny formation, HeLa cells 
were seeded in 12-well plates and were siRNA transfected as described above. On day 2 cells were 
split into three separate wells and then infected on day 4 at MOI 50 for invasion assays or MOI 1 for 
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inclusion formation and progeny counts. Invasion assays were stopped at 1 and 10 h p.i., cells were 
fixed with ice-cold methanol overnight at -20°C, stained for OMP1 and DNA (Hoechst 33342) and 
analyzed by automated microscopy (Olympus Scan^R system consisting of an Olympus IX81 inverted 
microscope, Hamamatsu charge-coupled device (CCD) camera (model C4742-80-12AG) and the 
Scan^R acquisition software) at 10x magnification (Olympus UPlanS Apo 10x/0.40 NA lens). Data 
were processed using ImageJ (Girish and Vijayalakshmi, 2004) and Microsoft Excel. Inclusion 
formation assays were stopped at 24 h p.i. For SHC1 knockdown, inclusion formation was quantified 
24 h p.i. by manually counting the inclusion forming units (IFU) as inclusions per 40x field on a Leica 
DM-IL cell culture microscope. For cPLA2 or CRLS1 knockdown, cells were fixed with ice-cold 
methanol overnight at -20°C, stained for OMP1 and DNA (Hoechst 33342) and analyzed by 
automated microscopy (Olympus Scan^R system) at 10x magnification. Progeny infections were 
grown for 48 h before glass bead lysis of host cells to release infectious particles and titration of 
infectious particles on fresh HeLa monolayers. After another 24 h of infection, cells were processed 
as described for inclusion formation. Data were processed with Olympus Scan^R Analysis software 
and Microsoft Excel. 
2.6.2 Apoptosis induction and detection, data acquisition and analysis 
HeLa cells were seeded in 12-well plates and infected with C. trachomatis L2 at MOI 50 for 6 h, then 
apoptosis was induced by the addition of TNFα (25 ng/ml) and cycloheximide (10 µg/ml) for an 
additional 4 h (Figure 3-19). Infection with C. pneumoniae (MOI 50) was assisted by centrifugation 
(1 h at 500 g and 35°C), followed by 5 h of incubation before apoptosis induction as described for 
C. trachomatis. For the PARP cleavage assay, cells were directly lysed in 2x sample buffer (Laemmli) 
and heated at 95°C for 10 min. For quantification, Western blots were imaged using a LAS-3000 
bioluminescence reader (Fujifilm, USA) and the Image Reader LAS-3000 software (Fujifilm, USA). 
Respective bands and their lane backgrounds were measured using the Advanced Image Data 
Analyzer (AIDA) software and the ratio of cleaved PARP to the total PARP amount was calculated. 
For the CK18 cleavage and the terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) 
assays cells were spun down before staining. CK18 staining was done as described in the 
immunofluorescence section, and TUNEL staining was performed according to manufacturer’s 
instructions (DeadEnd Fluorometric TUNEL System, Promega, USA) with green fluorescence of 
apoptotic cells due to fluorescein-12-dUTP labeling. Nuclei were stained blue with Hoechst 33342. 
Images of stained PBS stored cells were acquired at RT using an automated microscope (Olympus 
Scan^R system consisting of an Olympus IX81 inverted microscope, Hamamatsu charge-coupled 
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device (CCD) camera (model C4742-80-12AG) and the Scan^R acquisition software) at 10x 
magnification (Olympus UPlanS Apo 10x/0.40 NA lens). Cells positive for cleaved CK18, TUNEL, and 
nuclei were counted using ImageJ (Girish and Vijayalakshmi, 2004) and the ratio (cells with cleaved 
CK18 / total nuclei or TUNEL positive cells / total nuclei) was calculated. An average of 10000 cells 
per condition was analyzed. Apoptosis inhibition was depicted as ratios from uninfected TNFα-
stimulated and infected TNFα-stimulated cells. 
2.7 Computational methods 
2.7.1 Multiple sequence alignment 
Alignment analysis of multiple protein sequences was performed using the ClustalW2 software 
(Larkin et al., 2007) provided by the European Bioinformatics Institute (EMBL-EBI). Tarp protein 
sequences of C. trachomatis L2 and C. trachomatis D were retrieved from NCBI, uploaded to the 
ClustalW2 software, and analysis was performed with default settings. 
2.7.2 Prediction of SH3 interactions 
Online prediction software (SH3-Hunter) (Ferraro et al., 2007) was used to recognize putative SH3 
interaction sites within the Tarp protein sequence and predict putative SH3 domain-containing 
proteins as interaction partners. An interaction score between 0 and 1 is calculated to rank the 
probability of the predicted interaction. 
2.7.3 Modeling of Tarp signaling 
Interaction partners identified using the SH2/PTB protein arrays were analyzed for their participation 
in signaling pathways using Ingenuity Pathway Analysis (IPA) software (Ingenuity Systems, USA) and 
the Kyoto Encyclopedia of Genes and Genomes (KEGG) (Kanehisa et al., 2010). Only signaling 
pathways associated with at least two Tarp interaction partners were considered in the model. 
Pathways involved in SHC1-dependent regulation of the 21 apoptosis and cell growth related genes 
were obtained by using IPA. In brief, all known transcriptional regulators upstream of the SHC1-
dependently regulated genes were introduced into the model and then linked to SHC1 using the 
“Path Explorer” tool of IPA. Pathways were grouped for MEK/ERK dependency. Interaction partners 
identified with the SH3 protein arrays were grouped according their participation in major molecular 
and cellular functions based on IPA. The top five functional categories and annotations are given in 
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Table 3-2. Functional categories were further described by their detailed functional annotations, 
giving more information on the specific involvement of the interacting molecules. 
2.7.4 Docking simulation 
Docking simulations were performed using the AutoDock 4 software package and the AutoDockTools 
(ADT) interface (Sanner, 1999). This software runs an automated procedure to predict the 
interaction of ligands (I) with biomacromolecular targets (E) (equation 2). 
 
 
(2) 
For the computational docking experiment, structural data of the second SH3 domain of NCK2 were 
used (2FRW). The structure of the Tarp SH3 binding site was modeled by using the known structure 
of the paxillin SH3 binding site (2O9V). Several docking simulations were performed with varying 
degrees of freedom regarding the movement of residues of NCK2 facing the interaction interface. 
Each docking simulation led to a set of secondary structures of the Tarp SH3 binding site 
characterized by their individual equilibrium dissociation constant KD and free energy of binding ∆G 
(equation 3). 
  
(3) 
Among these, one structure had both a minimal dissociation constant KD and a minimal free energy 
of binding ∆G, thus representing the most likely secondary structure of the Tarp SH3 binding site 
interacting with NCK2. 
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3 Results and discussion 
3.1 Preface 
The human pathogen Chlamydia trachomatis has developed versatile strategies of subverting host 
cell signaling and trafficking pathways to ensure its intracellular replication and efficiently acquire 
nutrients. To broaden the current knowledge of the pathogen’s repertoire in manipulating the host 
cell, two approaches were followed. One project, presented in the first part of this thesis, 
concentrates on the invasion phase of C. trachomatis and the interactions of the type III secreted 
effector protein Tarp with host cellular SH2 and SH3 domain-containing proteins. Another project, 
illustrated in the second part of this thesis, investigates changes in lipid composition of infected host 
cells and thereby explores lipid trafficking pathways affected by C. trachomatis. Taken together, 
both parts administer to a better understanding of Chlamydia infection from two different 
perspectives.
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3.2 Part I: Interactions of host cell proteins with the effector protein Tarp 
3.2.1 Peptide design of Tarp interaction sites 
The C. trachomatis effector protein Tarp shows high homology among different serovars. 
Comparison of the Tarp amino acid sequences from serovar L2 and D identifies differences mainly in 
the number and sequence of N-terminal tyrosine phosphorylation sites (Figure 3-1 and Figure 3-2). 
 
Figure 3-1. Graphical representation of Tarp. Tarp amino acid sequences from C. trachomatis L2 and D differ in the 
number and motif of N-terminal tyrosine phosphorylation sites (gray region). Both serovars have the identical sequence for 
a putative C-terminal SH3 binding site (black region). Tarp from Chlamydophila pneumoniae is devoid of both types of 
interaction sites. 
C. trachomatis D Tarp features three identical ENIYE motifs at tyrosine residues Tyr171, Tyr221, and 
Tyr271 (Figure 3-2 and Figure 3-3 A), whereas C. trachomatis L2 Tarp has nine sites of tyrosine 
phosphorylation at residues Tyr136, Tyr140, Tyr189, Tyr239, Tyr242, Tyr291, Tyr341, Tyr390, and 
Tyr394 (Figure 3-2 and Figure 3-3 B). Six of these nine C. trachomatis L2 phosphorylation sites – 
Tyr136/140, Tyr238/242 and Tyr390/394 – are double-phosphorylation sites of the primary 
sequence ENIYENIYESI (Figure 3-2 and Figure 3-3 B). The C-terminal region of Tarp harbors a putative 
SH3 binding site with the primary sequence SVQTLLPSPPPTPSTTTLRT consisting of two overlapping 
core motifs (consensus sequence PxxP (Mayer, 2001)) (Figure 3-2). The sequence of this SH3 binding 
site is identical for Tarp from C. trachomatis L2 and D, and is also shared by other serovars, e.g., 
serovars A, B, C, and G. In contrast, Chlamydophila pneumoniae Tarp neither shows N-terminal 
tyrosine phosphorylation sites nor a C-terminal SH3 binding site (Clifton et al., 2005) (Figure 3-1). 
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Figure 3-2. Multiple alignment of Tarp sequences. Multiple sequence alignment of the Tarp protein sequences of 
C. trachomatis L2 and D. Alignment was calculated using the ClustalW2 software (Larkin et al., 2007) provided by the 
EMBL-EBI. Tyrosine phosphorylation sites are highlighted in black. Tarp from C. trachomatis D and L2 share three single-
phosphorylation sites, whereas Tarp from C. trachomatis L2 additionally harbors three double-phosphorylation sites. The 
putative SH3 binding site is marked in gray. 
To identify cellular interaction partners of the Tarp N-terminus, fluorescently labeled peptides 
representing the N-terminal sites of tyrosine phosphorylation on Tarp were synthesized. Eight 
peptides, each comprising 18 amino acids surrounding the respective phosphorylation sites, were 
synthesized in their non-, singly, or doubly phosphorylated states (Table 6-1). A fluorescent dye was 
coupled to the N-terminus of each peptide for detection purposes. These peptides were then used 
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to investigate interactions with human SH2 and PTB domains. For analysis of interactions between 
cellular SH3 domains and the Tarp C-terminus, wild type (SVQTLLPSPPPTPSTTTLRT) and mutated 
(SVQTLLDSPDPTDSTTTLRT) versions representing the putative SH3 binding site and the surrounding 
amino acids were synthesized and, for further detection, N-terminally biotinylated. Mutation was 
achieved by replacing respective proline residues with aspartic acid, rendering the binding site 
nonfunctional (Saksela et al., 1995; Collette et al., 2000; Antoku et al., 2008). 
3.2.2 Quantitative SH2/PTB interactome analysis of Tarp N-terminus 
To identify and quantify interactions between Tarp-derived peptides representing the N-terminal 
tyrosine phosphorylation sites and human signaling proteins, protein microarrays comprising 133 
SH2 and PTB domains were probed in duplicate with eight concentrations of each Tarp-derived 
peptide and the observed fluorescence data, Fobs, was fit to an equation that describes saturation 
binding, as described previously (Jones et al., 2006). By this, binding affinities between every peptide 
and every recombinant domain were measured. From the resulting quantitative dataset, a graphical 
representation of biophysical interactions with phospho-sites of the D and L2 serovariants of Tarp 
was constructed (Figure 3-3). Three Tarp phosphorylation states were defined: nonphosphorylated 
(Figure 3-3, A and B), singly phosphorylated (Figure 3-3, C and D), and doubly phosphorylated 
(Figure 3-3 E). Because not all SH2/PTB domain-containing proteins are expressed at appreciable 
levels in every cell type or at every subcellular location, these diagrams should be viewed as 
quantitative maps of potential Tarp interactions in the context of particular cell expression patterns. 
Nonphosphorylated peptides derived from both Tarp D and Tarp L2 exhibited very few interactions 
with human SH2 and PTB domains, as anticipated. Most notably, the tyrosine kinase ABL2 (ARG) and 
the GTPase activating protein RASA1 interacted with Tarp peptides (Figure 3-3, A and B, and 
Table 6-1). By probing the arrays with the singly phosphorylated version of the Tarp D peptide, the 
affinity of its interaction with ABL2 increased and several new interactions appeared, including a 
high affinity interaction with the SH2 domain of SHC1 (KD < 200 nM) and interactions with the SH2 
domains of CRKL, ABL1, SHC3, and RASA1. Even more prominent changes were observed with 
phosphorylated Tarp L2 peptides. Numerous high affinity interactions occurred, most notably with 
the SH2 domains of ABL1, ABL2, FGR, SYK, HCK, YES1, GRB2, CRKL, NCK2, SHB, TENC1, RASA1, VAV2, 
and SHC1; and with all three isoforms of the regulatory subunit of PI3K (Figure 3-3 D). Interestingly, 
the incremental effect of introducing the doubly phosphorylated peptide was minimal: only minor 
changes in affinities for some interaction partners (e.g., VAV2, PI3KR2, SYK, and HCK) were observed 
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(Figure 3-3 E and Table 6-1). This result is consistent with previous findings that doubly 
phosphorylated peptides derived from a variety of human RTKs behave similarly as compared to 
their singly phosphorylated counterparts (Jones et al., 2006). 
 
Figure 3-3. Quantitative protein interaction mapping. Quantitative data were obtained by probing SH2/PTB domain 
microarrays with fluorescently labeled Tarp peptides (performed by MacBeath and colleagues). The resulting data were 
used to construct quantitative protein interaction maps. White circles within the square represent peptides derived from 
C. trachomatis. Peptide allocation can be derived from Table 6-1 and the peptide legend, which shows phosphorylation 
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status and position within the full length protein. For example, peptide 2 in Figure 3-1 A mimics the three identical ENIYE 
repeats of serovar D Tarp in the nonphosphorylated state. Green and blue circles around the square represent individual 
SH2 and PTB domains, respectively. Circles outside the square indicate tandem domains (corresponding spot on the 
protein array contains both domains), which are connected to their individual domains (i.e., full length SYK is in possession 
of two SH2 domains located either N- or C-terminally). A color coded line is used to reflect the measured interaction 
strength between each domain-peptide pair (n = 2). Exact values are provided in Table 6-1. Interactions with KD ≥ 2 µM are 
omitted. (A and B) Interaction maps of nonphosphorylated Tarp D and L2. (C and D) Interaction maps of singly 
phosphorylated Tarp D and L2. (E) Interaction map of doubly phosphorylated Tarp from C. trachomatis serovar L2. 
Notably, no PTB domains recognized any of the Tarp-derived peptides, except the PTB domain of 
IRS1, which recognized the doubly phosphorylated peptide derived from Tarp L2 (Figure 3-3 E). 
These data suggest that Tarp proteins may have been evolutionarily optimized to recognize SH2 
domains that preferentially bind sequences C-terminally of phosphotyrosines (Sudol, 1998). 
To highlight differences in binding affinities, the interaction maps for Tarp D, Tarp L21 (singly 
phosphorylated), and Tarp L22 (doubly phosphorylated) were prepared using three different affinity 
thresholds (Figure 3-4, A-C). 
 
Figure 3-4. Quantitative analysis of the phospho-interactome. Interaction networks of the phospho-states from Figure 3-3 
were binned using three different affinity thresholds (KD < 500 nM, KD < 1000 nM, and KD < 1500 nM). In A-C, only 
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peptide/domain interactions below the stated threshold are shown (red lines). p-Tarp D refers to phosphorylated Tarp 
from C. trachomatis serovar D; p-Tarp L21 and L22 refer to singly and doubly phosphorylated Tarp from serovar L2, 
respectively. (A) Tarp D is less promiscuous than Tarp L2 and has few interaction partners at all affinity thresholds. (B) Tarp 
L21 exhibits highly promiscuous binding even at the highest affinity threshold (KD < 500 nM). (C) Tarp L22 has fewer high-
affinity interaction partners (KD < 500 nM) than Tarp L21, but the number of interactors increases sharply as the affinity 
threshold is relaxed. To the right, the number of Tarp interaction partners at each affinity threshold is depicted in bar 
diagrams. Multiple domains from proteins interacting with more than one phospho-site are only counted once. 
Tarp D exhibited high affinity interactions (KD < 500 nM) with only two proteins, increasing to six as 
the threshold was relaxed to 1500 nM (Figure 3-4 A). In contrast, Tarp L21 (singly phosphorylated) 
exhibited promiscuous binding even at the highest affinity threshold (Figure 3-4 B). Surprisingly, 
hyperphosphorylation of Tarp L2 decreased the number of high affinity interactions, but the overall 
number of interaction partners for Tarp L22 sharply increased as the affinity threshold was relaxed 
(Figure 3-4 C). 
Comparison of the different sets of interaction partners for both Tarp serovariants (Tarp D and L2) 
revealed two common interaction partners in the nonphosphorylated state (Figure 3-5 A) and a core 
set of six proteins in the phosphorylated state (Figure 3-5, B and C). This set included the adaptor 
protein SHC1, which bound both serovariants with high affinity. Tarp L21 and L22 were both found to 
interact with all of the phospho-Tarp D binding partners (Figure 3-5, B and C), which suggests that 
signaling initiated by the Tarp D serovariant constitutes a subset of the signaling initiated by Tarp L2. 
Tarp L21 and L22 were very similar, with 17 interaction partners in common (Figure 3-5 D). 
 
Figure 3-5. Comparison analysis of the phospho-interactome. Venn diagrams showing the number of overlapping 
interactions (white) between nonphosphorylated Tarp D (red) and L2 (green) (A), singly phosphorylated Tarp D (red) and 
L21 (green) (B), singly phosphorylated Tarp D (red) and doubly phosphorylated L22 (blue) (C), and singly phosphorylated 
Tarp L21 (green) and doubly phosphorylated L22 (blue) (D). 
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Overall, these results show that phosphorylation of Tarp enables multiple high affinity interactions 
with human SH2 domains; that a core set of proteins involved in MAPK signaling is able to interact 
with both serovariants of Tarp; and that signaling initiated by Tarp D likely constitutes a subset of the 
signaling initiated by Tarp L2. 
3.2.3 Quantitative SH3 interactome analysis of Tarp C-terminus 
To validate the functionality of the putative C-terminal SH3 binding site and to further investigate 
interactions of Tarp with cellular SH3 domain-containing proteins, protein arrays (TranSignal SH3 
domain arrays, Panomics, USA) consistent of 117 SH3 domains in duplicate were used. The arrays 
were incubated with both wild type and mutated version of the peptide representing the C-terminal 
SH3 binding site (Figure 3-6). 
 
Figure 3-6. Workflow scheme of quantitative SH3 interactome analysis. Peptides representing the C-terminal SH3 binding 
site of C. trachomatis Tarp were synthesized and incubated with protein arrays comprising 117 SH3 domains. A mutated 
peptide version serving as negative control was processed in parallel. 
Interaction intensities of the biotinylated peptides were quantified using HRP labeled streptavidin 
and normalized to biotin (positive control) and GST (negative control). Interactions with at least 25 % 
of the positive control signal intensity and a minimum signal decrease of 50 % between wild type 
and mutated peptide were defined as hits. These selection criteria lead to a set of 34 interactions 
(Figure 3-7 and Table 3-1). Among these interactions were high affinity interactions with a 
dissociation constant comparable to the biotin/streptavidin interaction (KD ≈ 100 nM) (Chivers et al., 
2010), most notably with the SH3 domains of CRK, CSK, VAV3, SRC, FYB, ABL2, NCK2, HCK, and YES1 
(Figure 3-7 and Table 3-1). 
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Figure 3-7. Quantitative SH3 interactome analysis. Bar diagram showing relative signal intensities of selected interactions 
between the respective SH3 domain and the peptide representing the Tarp SH3 binding site. Signals are sorted by intensity 
and normalized to positive and negative controls (orange). Interactions with wild type and mutated peptide are given in 
dark blue and light blue, respectively. 
Interestingly, several of the measured interactions with Tarp’s C-terminus were also detected to 
interact with the N-terminus of Tarp. These molecules, namely ABL2, CRK, HCK, NCK2, VAV1, VAV2, 
and YES1 all harbor both SH2 and SH3 domains, making them capable of interacting with both Tarp 
interaction sites (Figure 3-3, Figure 3-7, and Table 3-1). Amongst these, NCK2 and VAV2 showed the 
strongest interaction with both SH2 and SH3 binding sites of Tarp. 
Table 3-1. Interaction partners of the Tarp SH3 binding site. Interaction strength is given relative to the positive control 
(biotin (+)) and the negative control (GST (-)). Peptides were synthesized representing the primary sequence of the putative 
SH3 binding site. Amino acid sequence of peptides is given in the footnotes. Additionally, interaction scores based on 
computational prediction (Ferraro et al., 2007) and measured interaction with the Tarp N-terminus are listed. 
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CRK-D2 203.7 1.4 82.7 11.0 59.4 6.2 0.977 Tarp L2 
VINE-D3 164.5 16.5 41.6 5.5 74.7 11.0   
CSK 147.5 2.9 45.1 2.2 69.4 2.6   
VAV3-D1 138.6 16.9 62.9 10.7 54.6 13.8   
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C-SRC 137.7 8.5 65.5 12.4 52.4 10.4 0.990  
FYB-D1 125.9 20.5 51.4 0.4 59.2 10.5   
LASP1 124.5 0.1 16.3 3.6 86.9 1.8   
NEBL 109.2 8.6 25.2 13.2 76.9 10.9   
RHG4 93.6 11.2 35.2 4.6 62.4 7.9   
UAS3 87.6 19.0 22.1 9.3 74.8 14.1   
ARGBP2-D2 76.7 15.6 1.8 11.3 97.6 13.5   
ABL2 72.6 14.4 17.2 8.5 76.3 11.4 0.990 Tarp L2, D 
NCK2-D3 72.0 3.4 28.2 2.0 60.8 2.7 0.968 Tarp L2 
KIAA0418-D3 69.6 6.7 26.0 5.7 62.7 6.2   
HCK 69.0 7.3 17.4 6.9 74.7 7.1 0.990 Tarp L2 
YES1 64.4 0.7 28.6 5.7 55.5 3.2 0.991 Tarp L2 
ARGBP2-D1 59.4 12.1 9.9 2.0 83.3 7.1   
MY7A 58.6 7.1 6.3 4.3 89.3 5.7   
SJHUA 57.0 8.3 6.8 1.2 88.1 4.7   
SPCN 56.6 0.2 8.4 4.3 85.3 2.3   
NCK2-D2 55.1 6.8 11.9 6.9 78.3 6.8 0.982 Tarp L2 
NEBULIN 49.2 9.2 19.8 1.3 59.6 5.2 0.773  
ITK 48.0 5.1 5.1 3.4 89.4 4.2 0.986  
KIAA1139 46.6 11.6 -7.8 8.4 116.8 10.0   
VAV2-D1 45.2 9.6 8.4 12.3 81.5 10.9 0.984 Tarp L2 
EPS8 44.8 2.2 4.3 1.1 90.5 1.7 0.988  
CORTACTIN 41.1 2.3 7.8 3.3 81.0 2.8 0.965  
CLASS IB SH3 DOMAIN 37.3 0.7 9.0 8.8 75.9 4.8   
VAV1-D2 34.4 0.0 -27.1 5.6 178.7 2.8 0.975 Tarp L2 
GRAF 33.9 11.8 -23.5 3.1 169.3 7.5   
NCK1-D1 33.8 1.9 -43.5 2.9 228.5 2.4 0.973  
CXORF9-D1 32.9 9.2 -24.7 3.3 175.1 6.2   
C-SRC 32.5 15.7 14.2 2.8 56.3 9.3 0.990  
SLK 30.2 0.7 7.3 6.0 75.9 3.4   
ARGBP2-D3 28.6 5.2 -19.3 6.9 167.2 6.0   
Biotin (+) 100.0 32.1 100.0 25.2 0.0 28.7   
GST (–) 0.0 7.4 0.0 7.3 0.0 7.4   
 
a D1, D2, D3 specifies the respective SH3 domain of the protein 
b wild type peptide, amino acid sequence SVQTLLPSPPPTPSTTTLRT 
c mutated peptide, amino acid sequence SVQTLLDSPDPTDSTTTLRT 
d according to SH3 prediction software (SH3-Hunter) (Ferraro et al., 2007) 
e detected interactions based on SH2/PTB protein microarrays (Figure 3-2 and Table 6-1) 
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3.2.4 Pathway analysis of N-terminal interactome 
To identify signaling pathways that are potentially activated by the N-terminal interactome of Tarp, 
IPA software and KEGG (Kanehisa et al., 2010) were used. Signaling pathways associated with at 
least two Tarp interaction partners were used to construct a qualitative model of Tarp-mediated 
signaling (Figure 3-8). 
 
Figure 3-8. Tarp phospho-interactome and putative signaling. Model showing interaction partners and possible 
downstream signaling pathways of a single-phosphorylation site of Tarp D (A), a single-phosphorylation site of Tarp L2 (B), 
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or a double-phosphorylation site of Tarp L2 (C). Interacting proteins are listed in columns corresponding to the different 
phosphorylation states of the respective site (highlighted by dashed colored lines). Interaction partners were analyzed for 
their participation in signaling pathways (marked by continuous colored lines) using IPA software and KEGG (Kanehisa 
et al., 2010). Only signaling pathways with involvement of at least two Tarp interactions identified on the SH2/PTB protein 
microarrays were included in the model. 
Both serovariants of Tarp were found to interact with proteins commonly associated with EGF 
receptor (EGFR) signaling and MAPK signaling (Figure 3-8, A-C). Interestingly, Tarp L2 also interacted 
with proteins associated with immune signaling pathways of B and T cells, as well as with innate 
immune responses of natural killer (NK) cells, macrophages, and neutrophils (Figure 3-8, B and C). 
Connection of Tarp L2 with these additional signaling pathways involved in modulation of the 
immune response derives mainly from interactions mediated by its doubly phosphorylated state 
(Figure 3-8, B and C). 
3.2.5 Pathway analysis of C-terminal interactome 
To further functionally analyze the C-terminal interaction partners of Tarp, the measured 
interactions were grouped according to their involvement in major molecular and cellular functions 
based on IPA software. The major categories are ranked based on the number of interaction 
partners involved and are further specified by their detailed functional annotations, while only the 
top five annotations are given for each category (Table 3-2). 
Table 3-2. Functional categories of Tarp SH3 interactions. Table lists top five functional categories of the 34 interaction 
partners of Tarp’s C-terminal SH3 binding site and the respective number of molecules involved. Each functional category is 
subdivided by the top five functional annotations, giving information on the specific involvement of the interacting 
molecules. Interaction partners were analyzed for their participation in major functional categories using IPA software. 
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Cellular assembly and 
organization 
22 Formation of lamellipodia 8 1.61E-11 CRK, LASP1, NCK1, NCK2, C-SRC, VAV1, VAV2, VAV3 
Formation of cellular protrusions 10 2.51E-10 CRK, CORTACTIN, HCK, LASP1, NCK1, NCK2, C-SRC, VAV1, VAV2, 
VAV3 
Organization of cytoskeleton 9 1.18E-09 ABL2, RHG4, CRK, EPS8, ITK, NCK1, NCK2, SPCN, VAV1 
Organization of actin filaments 6 2.45E-09 ABL2, RHG4, CSK, NCK1, NCK2, SJHUA 
Organization of actin cytoskeleton 7 1.31E-08 ABL2, CRK, EPS8, NCK1, NCK2, SPCN, VAV1 
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Cellular function and 
maintenance 
18 Organization of cytoskeleton 9 1.18E-09 ABL2, RHG4, CRK, EPS8, ITK, NCK1, NCK2, SPCN, VAV1 
Organization of actin filaments 6 2.45E-09 ABL2, RHG4, CSK, NCK1, NCK2, SJHUA 
Organization of actin cytoskeleton 7 1.31E-08 ABL2, CRK, EPS8, NCK1, NCK2, SPCN, VAV1 
Phagocytosis of cells 6 2.45E-07 CRK, CSK, HCK, MY7A, VAV1, VAV2 
Phagocytosis of eukaryotic cells 5 2.89E-06 CSK, HCK, MY7A, VAV1, VAV2 
Cellular development 13 Development of transitional B lymphocytes 3 1.47E-08 VAV1, VAV2, VAV3 
Maturation of lymphocytes 4 2.01E-05 CSK, ITK, VAV1, VAV2 
Cell spreading of eukaryotic cells 5 2.10E-05 CRK, HCK, C-SRC, VAV2, VAV3 
Development of cells 11 2.33E-05 ABL2, CRK, CSK, HCK, ITK, NCK2, SJHUA, C-SRC, VAV1, VAV2, 
VAV3 
Shape change of eukaryotic cells 6 3.05E-05 CRK, HCK, NCK2, C-SRC, VAV2, VAV3 
Cellular growth and 
proliferation 
17 Proliferation of eukaryotic cells 16 4.33E-08 CRK, CSK, EPS8, FYB, HCK, ITK, NCK1, NCK2, CXORF9, SLK, SPCN, 
C-SRC, UAS3, VAV1, VAV2, VAV3 
Proliferation of lymphocytes 10 5.05E-08 FYB, HCK, ITK, NCK1, NCK2, CXORF9, UAS3, VAV1, VAV2, VAV3 
Proliferation of cells 17 1.27E-07 CRK, CSK, EPS8, FYB, HCK, ITK, LASP1, NCK1, NCK2, CXORF9, SLK, 
SPCN, C-SRC, UAS3, VAV1, VAV2, VAV3 
Proliferation of normal cells 13 4.50E-07 CSK, FYB, HCK, ITK, NCK1, NCK2, CXORF9, SLK, C-SRC, UAS3, 
VAV1, VAV2, VAV3 
Proliferation of T lymphocytes 7 1.68E-05 FYB, ITK, NCK1, NCK2, CXORF9, UAS3, VAV1 
Cell-to-cell signaling and 
interaction 
19 Turnover of focal adhesions 3 7.35E-08 ABL2, CSK, NCK2 
Phagocytosis of cells 6 2.45E-07 CRK, CSK, HCK, MY7A, VAV1, VAV2 
Activation of leukocytes 9 5.05E-07 CSK, HCK, ITK, NCK1, CXORF9, C-SRC, VAV1, VAV2, VAV3 
Phagocytosis of eukaryotic cells 5 2.89E-06 CSK, HCK, MY7A, VAV1, VAV2 
Activation of lymphocytes 7 3.94E-06 CSK, ITK, NCK1, CXORF9, C-SRC, VAV1, VAV2 
 
a functional sorting according to IPA software 
As stated above, the molecules interacting with the C-terminal SH3 binding site of Tarp are mainly 
involved in cellular assembly and organization, cellular function and maintenance, cellular 
development, cellular growth and proliferation, and cell-to-cell signaling and interaction. 
Interestingly, a major proportion of putative interaction partners is involved in processes of 
phagocytosis, cytoskeletal rearrangement, and proliferation. 
3.2.6 Validation of interactions between Tarp’s N-terminus and selected host cell proteins 
To test whether the identified protein interactions have relevance for chlamydial infection, the 
strongest interaction partner of both serovariants of Tarp, SHC1, and a serovariant L2-specific 
interaction partner, NCK2, were selected for further experimental validation. Heterologously 
expressed GST fused to Tarp from C. trachomatis serovars D and L2 (Figure 3-9 A) was coupled to 
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beads, phosphorylated in vitro by SRC kinase, and incubated with host cell lysate. Truncated versions 
of N-terminal Tarp were used to avoid the actin nucleating activity of the C-terminal region (Jewett 
et al., 2006) and additional interaction of cellular proteins with any noncharacterized Tarp motifs 
such as the C-terminal SH3 binding site. 
 
Figure 3-9. Validation of Tarp/SHC1 interaction. (A) Graphical representation of Tarp D, Tarp L2, and the respective GST-
Tarp fusion proteins including all phospho-sites. Truncated versions of Tarp were used to avoid the actin nucleating activity 
of the C-terminus (Jewett et al., 2006) and any unknown binding regions. (B) Western blot showing pull-down of SHC1 and 
NCK2 from HeLa cell lysate using bead coupled phospho-GST-Tarp. The fusion protein was phosphorylated in vitro with 
recombinant human SRC. Input shows Tarp loading (bead coupled, black arrowheads) and SHC1 and NCK2 loading in HeLa 
cell lysate (black arrowheads). Pulled down SHC1 and NCK2 are indicated by open arrowheads. SHC1 was only pulled down 
in lanes where Tarp was phosphorylated (indicated as p-Tarp). NCK2 was only pulled down with p-Tarp L2. As a control, 
beads were phosphorylated in the absence of GST-Tarp and did not pull down SHC1. (C) Western blot showing 
coimmunoprecipitation of SHC1 (white arrowheads) and Tarp (black arrowhead) after infection of HeLa or End1/E6E7 cells 
(C. trachomatis L2, MOI 500) for 60 min (performed by A. Mehlitz). 
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Both phosphorylated Tarp D and Tarp L2 bound SHC1 and showed a strong preference for the 
SHC1p52 isoform (Figure 3-9 B). In contrast, only phosphorylated Tarp L2 was capable of precipitating 
NCK2 (Figure 3-9 B). This is consistent with the array data because peptides derived from phospho-
sites on Tarp L2, but not Tarp D, were recognized by the SH2 domain of NCK2. Focussing on SHC1, 
the common interaction partner of both serovariants, a coimmunoprecipitation experiment 
revealed, that endogenous SHC1 and Tarp L2 coprecipitated from two separate C. trachomatis-
infected cell types (Figure 3-9 C). These experiments show that the interactions with SHC1 and NCK2 
highlighted by the SH2/PTB protein microarrays are also observed with full-length proteins.  
3.2.7 Analysis of the interaction between Tarp’s C-terminus and NCK2 
The interactions of the C-terminal SH3 binding site of Tarp were further investigated focussing on 
NCK2, an interaction partner with both a high interaction signal and predication score. To assess the 
ability of NCK2 to bind the Tarp SH3 motif, a computational docking experiment was performed. This 
automated procedure uses the Protein Data Bank (PDB) file format describing the three-dimensional 
structures of molecules to predict interactions of ligands with macromolecular targets (Figure 3-10). 
 
Figure 3-10. Workflow scheme of docking experiments. The C-terminal SH3 binding site of C. trachomatis Tarp shows high 
homology to the paxillin SH3 binding site. Docking experiments of NCK2 and the Tarp SH3 binding site were carried out 
using structural data of paxillin (2O9V) and the second SH3 domain of NCK2 (2FRW). 
While structural data of the second SH3 domain of NCK2 (PDB ID number 2FRW) were available, the 
three-dimensional structure of Tarp is not described so far. Therefore, the structure of the Tarp SH3 
binding site was modeled by using the known structure of the paxillin SH3 binding site, which shows 
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high homology to the Tarp SH3 sequence. The structural data file 2O9V (PDB ID number) describes 
the left-handed polyproline II helix of the paxillin SH3 binding site bound to the SH3 domain of its 
interaction partner ponsin. The structure file also contains information about the general orientation 
of binding site and binding domain. Subsequently, all structural data were uploaded to the AutoDock 
4 software package using the ADT interface. Several docking simulations were performed with 
varying degrees of freedom regarding the movement of NCK2 residues facing the interaction 
interface. Each docking simulation led to a set of secondary structures of the Tarp SH3 binding site 
with one structure having both a minimal dissociation constant KD and a minimal free energy of 
binding ∆G, representing the most likely secondary structure of the Tarp SH3 binding site interacting 
with NCK2 (Figure 3-11). 
 
Figure 3-11. Model of Tarp/NCK2 interaction. The C-terminal Tarp SH3 binding site is highlighted in green, the second SH3 
domain of NCK2 is colored blue. In this docking simulation, two residues of NCK2 facing the binding pocket (Phe7, Tyr51) 
were allowed to move freely during the automated docking procedure, resulting in an estimated free energy of binding ∆G 
of -6.90 kcal/mol, equivalent to a dissociation constant KD of 8.80 µM. Different angles of view are given in (A), (B), and (C) 
with a 90 degree horizontal rotation from (A) to (B) and a 90 degree vertical rotation from (A) to (C). 
In this docking simulation, two residues of NCK2 facing the binding pocket (Phe7, Tyr51) were 
allowed to move freely during the computational procedure, resulting in a secondary structure 
model with a minimal estimated free energy of binding ∆G of -6.90 kcal/mol, equivalent to a 
dissociation constant KD of 8.80 µM. This is in the lower range of expected values for SH3 
interactions in general (1-200 µM) (Li, 2005). A second docking simulation with six freely moving 
residues of NCK2 (Phe7, Tyr9, Asp15, Trp35, Asn50, Tyr51) resulted in a secondary structure with a 
minimal estimated free energy of binding of -10.46 kcal/mol, equivalent to a dissociation constant KD 
of 21.69 nM. Interestingly, both secondary structure models of the Tarp SH3 binding site were nearly 
identical (data not shown). This fact additionally supports the validity of the observed Tarp/NCK2 
interaction via Tarp’s C-terminal SH3 binding site. 
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3.2.8 SHC1 activation and influence on MEK/ERK signaling during Chlamydia cell entry 
Next, the influence of Tarp/SHC1 interaction on major downstream signaling pathways was assessed 
by investigating the activation of the MEK/ERK cascade upon phosphorylation of SHC1. As previously 
shown, recruitment of SHC1 to endogenous human receptors leads to its phosphorylation on 
Tyr239/240 and Tyr317 (van der Geer et al., 1996). To test SHC1 activation during C. trachomatis 
infection, time course experiments were performed in HeLa cells. All three SHC1 isoforms were 
phosphorylated on Tyr239/240 during invasion of C. trachomatis (Figure 3-12 A) and for up to 5 h p.i. 
(Figure 3-12 B). In contrast, during infection with C. pneumoniae, which translocates a Tarp homolog 
(Cpn0572) lacking the phosphorylation sites (Clifton et al., 2005), SHC1 phosphorylation was only 
marginally increased (Figure 3-12 C). Quantification of Western blotting data revealed that SHC1 
phosphorylation was significantly increased during infections with C. trachomatis, but not 
C. pneumoniae (Figure 3-12 D). 
 
Figure 3-12. SHC1 activation during early chlamydial infection. Western blots showing SHC1 phosphorylation on tyrosine 
residues Tyr239/240 (p-SHC1Y239/240, white arrowheads) and Tarp phosphorylation (p-Tarp, black arrowheads) during a time 
course infection experiment (C. trachomatis L2, MOI 200; HeLa cells) for 120 min p.i. (A) and up to 5 h p.i. (B) (performed 
by A. Mehlitz). Control experiment using C. pneumoniae (MOI 200, HeLa cells) showed only marginal SHC1 phosphorylation 
on tyrosine residues Tyr239/240 (p-SHC1Y239/240, white arrowheads) (C). Tarp phosphorylation was determined with a 
tyrosine phosphorylation specific antibody. Hsp60 was used as an infection control (gray arrowhead). Controls (N) were 
mock infected with SPG for 60 min. (D) Densitometric quantification of SHC1 p52 Tyr239/240 phosphorylation. Values were 
calculated from Figure 3-12, A and C, and normalized to total SHC1 p52 (n = 2, error bars indicate standard error (SE)). 
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Interestingly, the SHC1p52 isoform was most rapidly and most strongly phosphorylated by 
C. trachomatis infection (Figure 3-12 A), which is consistent with the observed binding preference of 
Tarp L2 and D (Figure 3-9 B). Furthermore, immunofluorescence staining experiments showed that 
SHC1 activation was accompanied by recruitment of the protein to bacteria during host cell entry 
(Figure 3-13, A and B). 
 
Figure 3-13. SHC1 phosphorylation and subcellular localization upon infection. Immunofluorescence staining of SHC1 
(red, white arrowheads) (A) and p-SHC1 (red, white arrowheads) (B) after infection of HeLa cells for 60 min (C. trachomatis 
L2, green, MOI 200) (performed by A. Mehlitz). Vesicular structures of SHC1 and p-SHC1 were located in close proximity to 
Chlamydia EBs. These structures were not observed in control cells. 
Both SHC1 phosphorylation (van der Geer et al., 1996) and Chlamydia infection (Su et al., 2004) have 
been shown to activate the MEK/ERK cascade via RAS and RAF; however, Chlamydia-induced 
MEK/ERK activation has mainly been demonstrated at later infection time points, e.g., from 12 h p.i. 
(Paland et al., 2008). Because Tarp is secreted within minutes after attachment, RAS, MEK, and ERK 
activation was investigated during this early phase of infection. 
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To examine RAS activation, HeLa cells were transfected with a reporter construct for activated RAS. 
This construct, GFP-RBDRAF-1, consists of GFP fused to the RAS binding domain (RBD) of RAF-1 and 
selectively binds to the active, GTP-bound form of RAS (Bivona et al., 2006). It has previously been 
shown that endogenous levels of RAS are not sufficient to recruit detectable amounts of the GFP 
reporter (Bivona et al., 2006). Therefore, cells were cotransfected with mCherry-tagged H-RAS for 
the overexpression of RAS. HeLa cells were infected with C. trachomatis L2 (phase contrast, 
MOI 100). RAS activation at the plasma membrane could be detected from 2 min after addition of 
infectious particles to the cells, decreasing to basal levels after 12 min (Figure 3-14). 
 
Figure 3-14. RAS activation during early chlamydial infection. Live-cell imaging of HeLa cells transfected with GFP-RBDRAF-1 
(green), a reporter for RAS activation, and mCherry-tagged H-RAS (red) after infection with C. trachomatis L2 (phase 
contrast, MOI 100). Cells show recruitment of the GFP construct to the plasma membrane starting at 2 min after addition 
of C. trachomatis EBs. White arrowheads mark activated cells. White bar equals 10 µm. 
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Further downstream RAS activation, both MEK and ERK phosphorylation increased sharply 5-10 min 
p.i. in HeLa (Figure 3-15) and End1/E6E7 cells (primary immortalized endocervical cells; data not 
shown), then decreased to ~20 % and ~10 % above basal levels for MEK and ERK, respectively, after 
1 h. MEK/ERK activation was dependent on MOI (data not shown). 
 
Figure 3-15. MEK/ERK activation during early chlamydial infection. (A) Western blots showing MEK (white arrowheads) 
and ERK (black arrowheads) phosphorylation during a time course infection experiment (C. trachomatis L2, MOI 200; HeLa 
cells), peaking at ~5 min (performed by A. Mehlitz). Densitometric quantification of MEK (B) and ERK phosphorylation (C). 
Values were calculated from Figure 3-15 A and normalized to total MEK or ERK (n = 2, error bars indicate SE). All values are 
normalized to the “5 min” infection time point. Controls (N) were mock infected with SPG for 60 min. 
The role of SHC1 in infection and Chlamydia-induced early MEK/ERK activation was further examined 
by siRNA-mediated knockdown of SHC1. Upon Chlamydia infection, SHC1 knockdown reduced MEK 
and ERK phosphorylation (Figure 3-16, A and B). 
 
Figure 3-16. MEK/ERK activation and SHC1 dependency. Western blots showing MEK (A) and ERK (B) phosphorylation 
during an infection time course (C. trachomatis L2, MOI 200; HeLa cells) of a representative experiment (performed by A. 
Mehlitz). Cells were either treated with siRNA against luciferase (control) or SHC1. MEK and ERK activation were reduced 
upon infection. Controls (N) were mock infected with SPG for 60 min. 
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A similar degree of reduction occurred after stimulation of uninfected SHC1 knockdown cells with 
inducers of MEK/ERK phosphorylation such as TNFα and EGF (Figure 3-17, A and B). 
 
Figure 3-17. MEK/ERK activation in SHC1 knockdown cells. Western blots showing MEK (A) and ERK (B) phosphorylation 
during a time course after stimulation of cells with 25 ng/ml TNFα or 50 ng/ml EGF (performed by A. Mehlitz). HeLa cells 
were either treated with siRNA against luciferase (control) or SHC1. Controls (N) were mock infected with SPG for 60 min. 
SHC1 knockdown resulted in a 90-95 % reduction at the protein level (Figure 3-18 A) and did not 
affect adhesion, invasion, inclusion formation, or numbers of progeny (Figure 3-18 B). 
 
Figure 3-18. Chlamydial invasion, inclusion formation, and progeny after SHC1 knockdown. (A) Western blot showing 
nearly complete knockdown of all three SHC1 isoforms after siRNA-mediated gene silencing. (B) Bar diagrams showing 
adhesion/invasion efficiency, inclusion formation, and progeny formation after knockdown with luciferase (siLuci) or SHC1 
(siSHC) siRNA or transfection reagent only (no KD). Adhesion/invasion efficiency was determined by automated microscopy 
detecting particle numbers associated with host cells at 1 or 10 h (n = 2, ~8000 cells per experiment and condition). 
Inclusion and progeny formation were determined by counting the number of inclusions per 40x field at 24 h p.i. and after 
transfer of end-cycle bacteria to fresh HeLa monolayers (n = 2, 10 fields per experiment and condition). SHC1 knockdown 
did not result in significant regulation of C. trachomatis invasion, inclusion formation, and progeny (error bars indicate SE). 
These results show that SHC1 phosphorylation during early infection is Tarp-dependent. 
Furthermore, SHC1 is recruited immediately after infection where it is not directly needed for 
adhesion, invasion, inclusion formation, or bacterial propagation. Rather, SHC1 plays a prominent 
role in early Chlamydia-induced activation of the MAPK pathway. 
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3.2.9 SHC1 activation and its transcriptional regulation during infection 
SHC1 activation is known to modulate survival, proliferation, and migration by transcriptional 
regulation, depending on the stimulus (Guo and Giancotti, 2004). Thus, the influence of SHC1 
activation on transcription upon C. trachomatis cell entry was further investigated. Because of the 
expected delay between MEK/ERK activation and its transcriptional response, experiments were 
performed at 4 h p.i. (Figure 3-19), a time point at which the host cell exhibits a strong 
transcriptional response, but bacteria are still largely metabolically inactive (EB to RB conversion 
takes place at 8-10 h p.i.) (Mathews et al., 1999). 
 
Figure 3-19. Workflow scheme of DNA microarray, qRT-PCR, and apoptosis experiments. Experimental time-scale of DNA 
microarray, qRT-PCR, and apoptosis experiments in this study. Blue bar shows time course of infection up to 10 h p.i. 
Arrows indicate treatment of cells (blue) and sample collection (black). 
Using human DNA microarrays, genes that were differentially expressed during infection of either 
control cells (without knockdown) or SHC1 knockdown cells were determined. Data from two 
biological replicates were combined and only correlated genes were used for further analysis 
(Figure 3-20, green spots). 
 
Figure 3-20. Correlation analysis of DNA microarrays. Comparison plots showing regulated genes from two independent 
biological experiments during infection (A) or SHC1 knockdown and infection (B). Correlated genes are highlighted in green, 
anti-correlated genes in red. 
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First, infected and uninfected HeLa cells at 4 h p.i. were compared, revealing 182 differentially 
regulated genes: 76 genes were down-regulated (Figure 3-21, upper left green circle, and Table 6-2) 
and 106 genes were up-regulated (Figure 3-21, lower right red circle, and Table 6-2) in response to 
infection. Second, infected SHC1 knockdown and infected luciferase (control) knockdown HeLa cells 
were compared, indicating regulation of 449 SHC1-dependent genes: 332 genes were down-
regulated (Figure 3-21, upper right green circle, and Table 6-3), whereas 117 genes were up-
regulated (Figure 3-21, lower left red circle, and Table 6-3) following SHC1 knockdown in infected 
cells. 
 
Figure 3-21. SHC1- and infection-dependent genes. Venn diagram showing differentially regulated genes during either 
infection alone or SHC1 knockdown and infection and genes regulated in both conditions. HeLa cells were infected for 4 h 
(C. trachomatis L2, MOI 20) before RNA isolation and array hybridization. Gene expression profiles of infected versus 
uninfected cells (Inf (vs. NI)) were compared to infected SHC1 knockdown versus infected luciferase knockdown cells (SHC1 
KD + Inf (vs. Luci KD + Inf)) to determine infection- and SHC1-dependently regulated genes (n = 2, each with dye-reversal). 
In total, 21 genes are regulated in a both SHC1- and infection-dependent manner (up-regulated genes are marked in red, 
down-regulated genes in green). 
The observed approximately threefold increase of down-regulated genes as compared with up-
regulated genes upon infection of SHC1 knockdown cells indicates a strong activating potential of 
SHC1 on gene expression during infection (Figure 3-21, lower left red circle and upper right green 
circle). Interestingly, infection of SHC1 knockdown cells down-regulated approximately fourfold 
more genes than infection of control (no knockdown) cells alone (Figure 3-21, green circles), most 
likely due to more genes being SHC1- rather than infection-dependently regulated. A comparison of 
genes regulated between all conditions identified a total of 21 SHC1- and infection-dependent genes 
(Figure 3-21, gray overlapping areas, and Table 3-3). 
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Table 3-3. SHC1- and infection-dependently regulated genes. List of 21 genes regulated in an infection- and SHC1-
dependent manner. Genes are grouped according to regulation pattern and functional sorting by IPA software. Full gene 
names and a short functional description including references are additionally provided. 
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1 NM_000459 TEK tyrosine kinase, 
endothelial 
receptor signaling, 
angiogenesis 
Jones and 
Dumont, 
2000 
-1.90 3.00E-05 1.87 9.24E-07 - + - 
1 BU729607 HMGB2 high mobility 
group box 2 
DNA binding, formation of 
nucleoprotein complexes, 
V(D)J recombination, trans-
cription initiation, DNA repair 
Thomas and 
Travers, 2001 
-1.73 1.64E-03 2.21 5.58E-08 - - + 
1 NM_001964 EGR1 early growth 
response 1 
transcription factor, 
suppression of trans-
formation, up-regulation of 
proapoptotic genes 
Arora et al., 
2008 
-1.89 1.79E-07 2.32 7.84E-42 + + + 
1 NM_153032 FLJ32065 hypothetical 
protein 
-. - -1.97 2.13E-07 2.41 2.94E-16 - - - 
1 NM_033503 BMF Bcl2 modifying 
factor 
BH3 only protein, inhibits pro-
survival proteins 
Willis and 
Adams, 2005 
-2.44 2.01E-09 3.15 6.73E-14 + + - 
2 AF086541 DAPL1 death associated 
protein-like 1 
apoptosis and cell 
differentiation 
Ashburner 
et al., 2000 
-1.61 9.43E-03 -1.72 5.50E-04 - - - 
2 NM_024859 MAGIX MAGI family 
member, X-
linked 
tight junction PDZ protein, 
caspase substrate 
Gregorc et al., 
2007 
-1.87 7.03E-03 -1.61 2.55E-03 - - - 
2 NM_139241 FGD4 F+VE, RhoGEF 
and PH domain 
containing 4 
guanine nucleotide exchange 
factor specific for Cdc42 
Chen et al., 
2004 
-2.00 1.59E-08 -1.82 5.34E-10 - - - 
2 NM_001956 EDN2 endothelin 2 21 AA peptide, activates 
endothelin receptors, raises 
blood pressure, induces 
vascular and myocardial 
hypertrophy 
Goraca, 2002 -2.94 0.00E+00 -2.05 1.76E-02 - - - 
2 AL833897 AL833897 cDNA clone - - -1.65 8.03E-07 -1.68 9.47E-03 - - - 
3 NM_012242 DKK1 dickkopf 
homolog 1 
Wnt inhibitor Zhao et al., 
2009 
3.53 0.00E+00 -1.99 4.67E-11 + - + 
3 NM_002017 FLI1 Friend leukemia 
virus integ. 1 
ETS transcription factor, 
proto-oncogene 
Juban et al., 
2009 
1.81 7.00E-05 -1.95 1.57E-09 + + + 
3 BC033310 GDA guanine 
deaminase 
converts guanine to xanthine - 1.65 2.82E-11 -1.70 2.73E-03 - - + 
3 NM_005556 KRT7 cytokeratin 7 cytoskeletal component - 1.62 2.66E-08 -2.13 0.00E+00 - - - 
3 NM_145110 MAP2K3 mitogen-
activated protein 
kinase kinase 3 
stress signaling, activates 
p38MAPK, pro-apoptotic 
Dhanasekaran 
and 
Premkumar 
Reddy, 1998 
1.72 1.26E-12 -1.96 4.00E-10 + + - 
3 NM_002999 SDC4 syndecan 4 transmembrane heparan 
sulfate proteoglycan, 
regulation of cytoskeleton, 
proliferation 
Oh and 
Couchman, 
2004 
1.64 1.57E-14 -1.66 2.64E-10 + - + 
4 NM_001511 CXCL1 chemokine (C-X-
C motif) ligand 1 
(melanoma 
growth stim. 
activity, alpha) 
neutrophil attraction, 
cytoskeletal control 
Reutershan 
and Ley, 2004 
1.67 5.88E-24 1.75 1.18E-09 - + + 
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4 NM_013409 FST follistatin Activin binding protein, 
proliferation, differentiation 
and apoptosis 
McDowall 
et al., 2008 
2.32 1.38E-33 1.98 1.04E-09 + + - 
4 NM_005114 HS3ST1 heparan sulfate 
(glucosamine) 
3-O-sulfo-
transferase 1 
Heparin sulfate biogenesis, 
sulfotransferase 
Munoz et al., 
2006 
2.29 2.75E-19 1.75 1.77E-28 - - + 
4 BC037430 PHLDA1 pleckstrin 
homology-like 
domain, family A, 
member 1 
expression increases basal 
apoptosis, regulation of cell 
growth and apoptosis 
Neef et al., 
2002 
2.23 6.38E-10 1.67 6.92E-14 + + + 
4 NM_203349 SHC4 SHC (Src 
homology 2 
domain cont.) 
family, member 4 
cell migration and growth 
regulation 
Fagiani et al., 
2007 
1.65 4.50E-02 1.91 1.22E-17 - - - 
 
a groups according to Figure 3-21 
b array 1 (Inf. vs. NI) 
c array 2 (SHC1 KD + Inf. vs. Luci KD + Inf.) 
d functional sorting according to IPA 
Functional analysis of these 21 differentially regulated genes using the IPA software revealed genes 
associated with apoptosis and cell growth regulation, with eight genes assigned to each category 
(Figure 3-22 and Table 3-3). 
 
Figure 3-22. SHC1-dependent regulation of apoptosis and cell growth genes. Venn diagram showing color coded circles 
from Figure 3-21 with more detailed information on the 21 differentially regulated genes. The genes correlating with both 
infection and SHC1 signaling were further analyzed using the IPA software. Of these, eight genes are grouped into the 
functional category “apoptosis” and another eight genes are assigned to the category “cell growth”. 
Indeed, these functional gene types were significantly enriched (p < 0.01) in this gene subset in 
comparison with the extended gene set, i.e., ~10 % of the 610 genes versus ~40 % of the 21 genes 
were apoptosis related (Figure 3-23). 
  Results and discussion: part I 
 
  60 
 
Figure 3-23. Gene enrichment analysis. Gene enrichment analysis of the overlapping genes (21) compared with all 
regulated genes (610). Both functional categories “apoptosis” and “cell growth” are significantly enriched in the 21 
overlapping genes (as determined by Fisher’s exact test). 
Surprisingly, IPA analysis also indicated that, among these 21 genes, nine genes are associated with 
MEK/ERK signaling, whereas 12 genes are controlled by other pathways (Figure 3-22, magenta 
colored genes, Figure 3-24, and Table 3-3). 
 
Figure 3-24. Putative SHC1 signaling. Model showing different pathways of SHC1 signaling in connection with the 21 SHC1-
dependently regulated apoptosis and cell growth genes. Genes are grouped into the three categories “MEK/ERK-
dependent regulation”, “MEK/ERK-independent regulation” and “not assigned”. Among the 21 genes (depicted in green), 
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only nine genes were MEK/ERK-dependently regulated, whereas 12 genes are controlled by other pathways. Relationships 
were analyzed using IPA software (straight line, direct relationship; dashed line, indirect relationship; A, activation; E, 
expression; LO, localization; MB, group/complex membership; P, phosphorylation/dephosphorylation; PD, protein-DNA 
binding; PP, protein-protein binding; RB, regulation of binding; T, transcription; TR, translocation). Color coding is as follow: 
yellow, potential Tarp interactions; blue, intermediate signaling molecules; red, terminal transcriptional regulators; and 
green, 21 infection- and SHC1-dependently regulated genes. 
The regulation of the majority of the 21 infection- and SHC1-dependent genes was confirmed using 
qRT-PCR (Figure 3-25 and Table 6-4). 
 
Figure 3-25. qRT-PCR confirmation of SHC1-dependent gene regulation. Bar diagrams showing gene expression of 
infected versus uninfected cells (black vs. dark blue bars) and infected SHC1 knockdown versus infected luciferase 
knockdown cells (white vs. light blue bars) (n = 2, error bars indicate SE, * denotes p < 0.05, ** denotes p < 0.01). HeLa cells 
were infected for 4 h (C. trachomatis L2, MOI 20). 10 genes identified in the array experiments and classified into apoptosis 
or growth regulation were selected for experimental verification by qRT-PCR. Figure shows comparison of qRT-PCR results 
with the Venn diagram (bottom); Table 6-4 confirms regulatory tendency of all genes tested. 
Thus, the transcriptional data suggest that Tarp-mediated SHC1 activation after C. trachomatis 
infection is involved in the regulation of apoptosis and cell growth related genes. 
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Further analysis of the 21 gene subset revealed four distinct groups (Figure 3-22 and Table 3-3). 
Group 1 comprises transcripts less abundant upon infection and more abundant in infected SHC1 
knockdown cells (Figure 3-26). Therefore, expression of the genes in group 1 is likely inhibited by 
SHC1 activation. In contrast, group 3 comprises transcripts more abundant upon infection and less 
abundant in infected SHC1 knockdown cells (Figure 3-26). Consequently, expression of genes in 
group 3 is likely enhanced by SHC1 activation.  
 
Figure 3-26. Model of the role of SHC1 during early infection-mediated gene regulation. C. trachomatis activates SHC1 
leading to four groups of regulated genes. Expression of group 1 genes is likely inhibited by SHC1 activation, explaining 
their up-regulation after SHC1 knockdown in infected cells. In contrast, gene expression in group 3 is likely enhanced by 
SHC1 activation, causing a down-regulation of group 3 genes after SHC1 knockdown in infected cells. Genes of group 2 and 
4 show an additional regulation by infection-independent of SHC1, remaining after SHC1 knockdown in infected cells. 
Groups 2 and 4 include transcripts either less abundant (group 2) or more abundant (group 4) after 
both infection and SHC1 knockdown in infected cells (Figure 3-26). This can be explained by 
infection-dependent regulation of these genes in an SHC1-independent manner, counteracted by an 
SHC1-dependent regulation. Consequently, knockdown of SHC1 in infected cells leads to an enforced 
regulation due to the remaining SHC1-independent effects. Thus, the data have identified opposing 
gene regulatory circuits during Chlamydia infection – being dependent or independent of SHC1. 
3.2.10 SHC1 activation and its role as a survival stimulus 
To further examine the role of SHC1 in early Chlamydia-induced cell survival, the effect of SHC1 
knockdown on host cell apoptosis after Chlamydia entry was investigated. For this purpose, TNFα 
was added to SHC1 or luciferase (control) knockdown cells at 6 h p.i. for a duration of 4 h, i.e., 2 h 
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after the observed transcriptional regulation changes (Figure 3-19). Apoptosis induction levels in a 
combination of SHC1 or luciferase knockdown cells infected with either C. trachomatis or 
C. pneumoniae were determined using three different readouts: PARP cleavage (Figure 3-27), CK18 
cleavage (Figure 3-28, A-C), and terminal deoxynucleotidyl transferase activity using the TUNEL assay 
(Figure 3-28, D-F). 
 
Figure 3-27. Apoptosis in early infected SHC1 knockdown cells (PARP cleavage). Western blots showing TNFα-induced 
PARP cleavage (black arrowheads) in HeLa cells with luciferase or SHC1 knockdown after C. trachomatis L2 infection 
(MOI 50) (A) or C. pneumoniae infection (MOI 50) (B) for 6 h and an additional induction of apoptosis for 4 h (25 ng/ml 
TNFα and 10 µg/ml cycloheximide). Actin and Hsp60 were used as loading control (white arrowheads). Infection with 
C. trachomatis L2 blocks PARP cleavage in infected luciferase transfected HeLa cells, whereas SHC1 knockdown sensitizes 
infected cells to apoptosis as indicated by PARP cleavage. (C) Quantification of PARP cleavage in C. trachomatis L2 and 
C. pneumoniae infection from chemiluminescence imager recorded blots (data from A and B, n = 3, error bars indicate SE). 
Band signals from PARP and cleaved PARP were measured using the AIDA software, and the ratio was calculated. The ratio 
of apoptosis inhibition in uninfected TNFα-stimulated versus infected TNFα-stimulated cells is depicted. C. trachomatis L2 
infected control cells show a high degree of apoptosis resistance, which is significantly reduced upon SHC1 knockdown. In 
contrast, C. pneumoniae infected cells exhibit a diminished apoptosis resistance, independent of SHC1. 
C. trachomatis-infected cells displayed the highest degree of apoptosis resistance under luciferase 
(control) knockdown conditions. This inhibitory phenotype was significantly reduced under SHC1 
knockdown conditions using all three assays (Figure 3-27 C and Figure 3-28, C and F). Although SHC1 
dependency was apparent for C. trachomatis at the early stages of infection, evidence was lacking 
for C. pneumoniae, which exhibited a comparably diminished degree of apoptosis resistance 
(Figure 3-27 C and Figure 3-28, C and F) and, notably, expresses a Tarp protein devoid of SHC1 
phospho-binding sites (Clifton et al., 2005). 
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Figure 3-28. Apoptosis in early infected SHC1 knockdown cells (CK 18 cleavage, TUNEL assay). Immunofluorescence 
staining showing TNFα-induced apoptosis in HeLa cells with luciferase or SHC1 knockdown after infection with 
C. trachomatis L2 (A and D) or C. pneumoniae (B and E) and apoptosis induction (identical conditions to Figure 3-27). SHC1 
knockdown sensitizes infected cells to apoptosis, whereas apoptosis is blocked in infected control cells. Apoptosis 
induction was assessed by CK18 cleavage (red) and TUNEL assay (green). Nuclei are stained blue with Hoechst 33342. 
Image area: 450 µm x 450 µm. Quantification of cells positive for (C) CK18 cleavage (data from A and B; n = 2, error bars 
indicate SE) and (F) TUNEL (data from D and E; n = 2, error bars indicate SE). An average of 10000 cells per condition was 
analyzed. Apoptosis inhibition is depicted as in Figure 3-27 C. C. trachomatis L2 infection leads to apoptosis inhibition in 
control cells, but not in SHC1 knockdown cells. In contrast, C. pneumoniae fails to block apoptosis in both control and SHC1 
knockdown cells. 
Thus, these data demonstrate that C. trachomatis, but not C. pneumoniae, is able to confer early 
apoptosis resistance to infected host cells in an SHC1-dependent manner.  
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3.2.11 Discussion 
Here, protein microarrays comprising nearly every human SH2, PTB, and SH3 domain were used to 
quantitatively assess Tarp-mediated interactions with host cellular proteins. Tarp was found to have 
the capacity to interact with many different SH2 and SH3 domain-containing proteins, which 
suggests that Tarp contributes substantially to phosphorylation-dependent and -independent 
signaling. In total, 23 novel SH2 binding partners and 34 novel SH3 binding partners of Tarp were 
discovered in vitro, while two interactions (Tarp/VAV2 and Tarp/PI3K) were confirmed that had 
previously been identified. High-affinity SH2 interactions with two proteins, the serovariant L2 
specific protein NCK2 and the serovariant D and L2 common interaction partner SHC1, were 
experimentally validated and the interaction of Tarp with SHC1 was studied in greater detail. The 
Tarp/SHC1 interaction was found to play a direct role in conferring resistance to apoptosis in 
infected cells. Together, these data extend our understanding of how Tarp modulates host cell 
functions. 
In the nonphosphorylated state, the Tarp N-terminus showed serovariant-dependent affinity for 
host SH2 domain-containing proteins. ABL2 (ARG) was found to be the strongest interaction partner 
shared by both serovariants (D and L2). Furthermore, ABL2 and other SRC family kinases (HCK and 
YES1) were among the strongest interaction partners of the Tarp C-terminal SH3 binding site. ABL 
kinases can be activated through interaction of their SH2 domains with cellular substrates (Lewis and 
Schwartz, 1998; Barila et al., 2000). Additionally, kinase activity is regulated via the interaction of 
their SH3 domain with a substrate SH3 binding site, as reported for ABL kinases and SRC kinases 
(Lerner and Smithgall, 2002; Smith et al., 2003). While an intramolecular SH3 interaction inhibits ABL 
kinase activity (Barila and Superti-Furga, 1998), mutation or deletion of the SH3 domain leads to 
increased ABL kinase activity in vivo (Franz et al., 1989; Jackson and Baltimore, 1989). The HIV-1 Nef 
protein, which is a high-affinity ligand for the SH3 domain of the SRC family kinase HCK (Saksela 
et al., 1995), has been demonstrated to activate HCK by competing with and disrupting the 
intramolecular SH3 interaction of HCK, a mechanism described as SH3 domain displacement 
(Moarefi et al., 1997). 
ABL1 and ABL2 have been shown to be among the human kinases that phosphorylate Tarp (Elwell 
et al., 2008; Jewett et al., 2008; Mehlitz et al., 2008). Consequently, the SH2 and the SH3 interaction 
between nonphosphorylated Tarp and ABL, leading to subsequent activation of ABL, may constitute 
an initial trigger for Tarp phosphorylation (Hantschel et al., 2003; Nagar et al., 2003) (Figure 3-29, (1) 
and (2)). It has previously been reported that infection of ABL/ARG-/- knockout mouse fibroblasts 
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leads to a ~50 % reduction of Tarp phosphorylation, which suggests that ABL could be the initial Tarp 
kinase (Elwell et al., 2008). Interestingly, phosphorylation of the H. pylori protein CagA and the EPEC 
effector Tir was also shown to involve ABL (Swimm et al., 2004; Poppe et al., 2007). Furthermore, 
CagA, ABL, and CRKII have been shown to physically interact (Tammer et al., 2007). 
 
Figure 3-29. The role of Tarp in host cell signaling. (1) Chlamydia injects Tarp via its type III secretion system into the host 
cell. (2) Tarp becomes phosphorylated by an initiator kinase, e.g., ABL/ARG kinases, probably through SH2- and SH3-
dependent interaction of the kinase to nonphosphorylated Tarp. Subsequently, phosphorylated Tarp is able to bind to a 
plethora of host SH2 and SH3 domain-containing proteins, which indicates that it functions as a signaling hub. SHC1 was 
validated as a serovariant D and L2 common interaction partner. (3) SHC1 binds Tarp through its C-terminal SH2 domain 
and becomes tyrosine phosphorylated on residues Tyr239/240. Other effectors are likely able to bind Tarp either in a 
timely or spatially regulated manner. NCK2 was validated as a serovariant L2 specific interaction partner and protein arrays 
indicate further interaction partners like VAV2 (which has previously been shown to interact with Tarp via 
immunoprecipitation) (Lane et al., 2008), RASA1, CRKL, and LCK. (4) SHC1 was found to be an important regulator of anti-
apoptotic and growth related genes and knockdown of SHC1 sensitized host cells for apoptosis induction via TNFα. 
Activation of MEK/ERK was not solely dependent on SHC1. The exact role of the MEK/ERK regulators RASA1 and CRKL in 
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gene regulation and Chlamydia growth and the redundancy with SHC1 in MEK/ERK activation needs further investigation. 
Additionally, Tarp-independent effects such as TLR signaling might influence the activation state of MEK/ERK. 
The nonphosphorylated state of the Tarp C-terminus is short-lived as Tarp is phosphorylated 
immediately after translocation into the host cell (Clifton et al., 2004). This phosphorylation leads to 
a dramatic increase of SH2 domain-mediated interactions, as demonstrated in this thesis. 
Accordingly, the Tarp phospho-interactome has a degree of complexity similar to that of the ERBB 
family of RTKs (Jones et al., 2006). For example, Tarp D and L2 show similar numbers of interaction 
partners as ERBB4 and ERBB3, respectively. Previously, only VAV2 and the regulatory subunit of PI3K 
have been identified as interaction partners of phosphorylated Tarp (Lane et al., 2008). Here, these 
interactions were confirmed using the SH2/PTB domain microarrays, approving the biological validity 
of the approach. Moreover, it was found that Tarp L2 interacts with several host cell kinases 
previously implicated in Tarp phosphorylation, corroborating Tarp L2 as a promiscuous 
phosphorylation substrate (Elwell et al., 2008; Jewett et al., 2008; Mehlitz et al., 2008). 
In addition to Tarp’s C-terminal interactions mediated by its SH2 binding motifs, the N-terminal SH3 
binding site expands and probably fine-tunes the capacity of Tarp to interact with host cellular 
proteins. This interaction site has so far not been described. Previous studies have focussed on a 
proline-rich domain in the N-terminal region of Tarp (Ser625 to Asn650), suggesting it promotes Tarp 
oligomerization and is required for Tarp-dependent nucleation of new actin filaments (Jewett et al., 
2006; Jewett et al., 2010). However, this domain is distinct from the SH3 binding site investigated in 
the study presented here, which is located between Ser818 and Tyr837. Protein microarrays 
revealed a large set of Tarp interactions with cellular SH3 domain-containing proteins, mainly 
involved in processes like phagocytosis, cytoskeletal rearrangement, and proliferation. Furthermore, 
as stated above, SH3-mediated interactions with host cell kinases like ABL2, HCK, and YES1 were 
detected. These interactions might contribute to kinase activation (Moarefi et al., 1997), thereby 
triggering initial phosphorylation of the Tarp N-terminus. 
To validate the functionality of the putative SH3 binding site, the interaction with NCK2, an 
interaction partner with a high interaction signal, was chosen for further investigation. Both Tarp 
and NCK2 were structurally modeled and docking experiments were performed, demonstrating the 
previously detected interaction of Tarp and NCK2 in silico. Moreover, the calculated dissociation 
constant KD for the Tarp/NCK interaction is within the lower range of values expected for SH3 
interactions (Li, 2005). This further supports the observation of a Tarp/NCK2 interaction via the 
C-terminal SH3 binding site and approves the functionality of this newly described SH3 binding site. 
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Taken together, the detected interactions with host cellular SH2 and SH3 domain-containing 
proteins suggest that Tarp operates as a phosphorylation-dependent and -independent signaling hub 
comparable to receptor-mediated signaling. Furthermore, Tarp interactions are likely to occur in a 
timely or spatially regulated manner. 
Comparison of the SH2 interactions of Tarp D and L2 revealed SHC1 as one of the strongest partners 
for both serovariants, which suggests a general role for SHC1 in C. trachomatis infections. SHC1, 
which has not previously been shown to interact with Tarp, is also involved in EGFR signaling, leading 
to MEK/ERK activation upon stimulation with EGF or TNFα. MEK/ERK activation, an emerging theme 
in the chlamydial infection process, was first shown to be involved in glycerophospholipid acquisition 
by Chlamydia (Su et al., 2004) and more recently as an important anti-apoptotic mechanism (Paland 
et al., 2008). Here, pronounced activation of MEK and ERK was found shortly after infection 
coincident with phosphorylation of Tarp and SHC1. Previous work suggested that rapid 
phosphorylation of ERK during chlamydial infection is linked to up-regulation of the anti-apoptotic 
protein MCL-1 (Rajalingam et al., 2008), which was demonstrated to be independent of SHC1 in the 
study presented here (data not shown). Moreover, activation of both MEK and ERK was previously 
shown to be necessary for C. trachomatis at an advanced stage of infection, however, this activation 
was uncoupled from upstream signaling by RAS and RAF (Gurumurthy et al., 2010). MEK activation is 
thought to be crucial during infections with H. pylori (Hatakeyama, 2008) and has been shown to be 
initiated through interaction of CagA with SHP-2 (Higashi et al., 2002), CRK (Suzuki et al., 2005), 
GRB2 (Mimuro et al., 2002) and c-MET (Churin et al., 2003). 
Here, the direct recruitment of SHC1 and the subsequent activation of RAS and the MAP kinase 
family members MEK and ERK in the early stages of a C. trachomatis infection is described 
(Figure 3-29, (3)). However, Chlamydia Tarp may very well trigger additional pathways causing 
MEK/ERK activation (see Figure 3-24). Candidate molecules are the adaptor protein CRKL, which is 
capable of activating ERK through b-RAF upon integrin signaling (Guo and Giancotti, 2004); the 
GTPase RASA1, directly activating b-RAF (Schubbert et al., 2007); and p56LCK, which bypasses 
RAS/RAF/MEK and activates ERK in a PKCε-dependent manner during Mycobacterium leprae 
infection (Tapinos and Rambukkana, 2005). All three factors were found to recognize phospho-Tarp 
in this thesis (Figure 3-1, Figure 3-29, and Table 6-1). Still, the exact role of CRKL, RASA1, and LCK on 
gene regulation and Chlamydia growth and the redundancy with SHC1 in MEK/ERK activation need 
to be further investigated. Additionally, Tarp-independent effects such as TLR signaling might 
influence the activation state of MEK/ERK. 
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SHC1 knockdown led to significant changes in the expression of anti-apoptotic and growth related 
genes in the context of C. trachomatis infection (Figure 3-29, (4)). As deduced from knowledge-
based pathway analysis, SHC1 signaling depends only partially on the MEK/ERK cascade, whereas the 
remaining genes are regulated by additional signaling pathways (Figure 3-24 and Figure 3-29, (4)). 
This is consistent with the observation of a significant reduction in C. trachomatis-induced cell 
survival upon SHC1 knockdown despite a residual activation of MEK and ERK. It is tempting to argue 
that this SHC1-mediated gene regulation is a MEK/ERK-independent branch of the EGFR-mediated 
signaling cascade. In H. pylori infection, a major outcome of CagA translocation appears to be 
regulation of growth-dependent genes (Keates et al., 1999; Mimuro et al., 2002). Thus, induction of 
growth signaling seems to be an important function of tyrosine phosphorylated effectors. Future 
investigations are required to clarify whether this also holds true for other effectors like EPEC Tir, 
Anaplasma phagocytophilum AnkA or Vaccinia virus A36R (Backert et al., 2008). Collectively, these 
observations support a model in which activation of both MEK/ERK-dependent and -independent 
growth signaling cascades plays a central role in C. trachomatis-induced cell survival. This assigns an 
important anti-apoptotic function to the interaction between phospho-Tarp and SHC1 during the 
early stage of infection. 
An alternative approach to assess protein interactions with tyrosine-phosphorylated peptides from 
CagA, Tir, Tarp, and BepD-F used differential mass-spectroscopy (SILAC) (Selbach et al., 2009). This 
study revealed only a few of the Tarp SH2 interaction partners reported here, notably the previously 
reported interaction with PI3K. Differences in methodological approach are most likely responsible 
for this small degree of overlap. The protein array analysis provides a list of all possible direct 
interaction partners. In contrast, immunoprecipitation coupled with mass spectrometry does not 
discriminate between direct and indirect interactions, owing to secondary protein contacts in 
signaling complexes. In addition, the approach used in this thesis provides a global view of 
biophysical interactions, whereas the approach of Selbach and colleagues focussed on a specific cell 
type and hence was dependent on the proteins being expressed in their cell of interest (Selbach 
et al., 2009). Nonetheless, both approaches provide important and complementary information on 
the complexity of host-pathogen interactomes. 
This thesis has shown that global interactome studies provide a powerful approach to uncover host 
cell counterparts of bacterial effector proteins, helping to increase our understanding of the 
mechanisms of host-microbe interactions. This work presents a comprehensive interactome study of 
a phosphorylated bacterial effector protein using SH2/PTB and SH3 domain microarrays. The study 
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not only confirmed several known interactions but also revealed an extensive repertoire of novel 
high- and low-affinity interactions with phosphorylated and nonphosphorylated versions of 
C. trachomatis Tarp. In addition, these interactions varied substantially between serovars. The focus 
of this thesis was on just one of the many possible Tarp-cellular protein interactions to substantiate 
the hypothesis of early Tarp-mediated host cell signaling. The remaining data reported here provide 
a wealth of additional hypotheses to test regarding Tarp-mediated signaling induced by chlamydial 
infection.
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3.3 Part II: Changes in lipid composition induced by Chlamydia 
3.3.1 Analysis of lipids using MALDI-TOF mass spectrometry 
The acquisition of host cell lipids plays a crucial role for the successful establishment and growth of 
Chlamydia (Saka and Valdivia, 2010). By subverting host cellular trafficking pathways, Chlamydia 
actively interferes with the host cell lipid composition (Wylie et al., 1997; Hatch and McClarty, 
1998a). To globally investigate changes in lipid composition induced by C. trachomatis infection, lipid 
extracts obtained from uninfected and infected (24 h p.i.) HeLa cells were analyzed by MALDI-TOF 
mass spectrometry. For this purpose, two approaches were applied: 1. the direct measurement of 
lipids in the crude lipid extract without further intermediate experimental steps, and 2. the 
separation of lipid extracts by normal phase TLC based on the properties of their head groups 
followed by lipid measurement directly on the TLC plate (Figure 3-30). While the first method 
reduces experimental procedures to a minimum and thereby avoids degradation of lipids, the 
second approach allows for a higher sensitivity to detect less abundant lipid species within the lipid 
extracts (Schiller et al., 2004). 
 
Figure 3-30. Workflow scheme of MALDI-TOF lipid analysis. Lipids were extracted from uninfected and infected HeLa cells 
(C. trachomatis L2, MOI 2.5, 24 h p.i.) according to Folch et al., 1957 and subsequently analyzed by MALDI-TOF mass 
spectrometry. Two methods were applied: 1. the direct MALDI-TOF measurement of crude lipid extracts, and 2. the 
separation of lipid classes by normal phase TLC prior to MALDI-TOF measurement. 
Normal phase TLC provided a separation of different lipid classes, such as PG, PE, PA, PI, PS, PC, SM, 
and LPC (Figure 3-31). A standard solution comprising these major lipid classes was spotted on the 
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TLC plate and separated in parallel to the lipid extracts of uninfected and infected HeLa cells. This 
allowed for the identification of lipid class spots within the extracts. After spots were marked, matrix 
solution was added to the spots and lipids were measured by MALDI-TOF mass spectrometry directly 
on the TLC plate. 
 
Figure 3-31. TLC of lipid extracts from uninfected and infected HeLa cells. Lipid extracts of uninfected and infected HeLa 
cells was subjected to normal phase TLC, providing a separation of different lipid classes. A standard solution comprising 
major lipid classes was additionally subjected to the TLC plate, allowing for correct identification of the detected spots in 
the lipid extracts. 
Both approaches – the direct and TLC coupled measurement of lipids – were combined to obtain a 
comprehensive overview of changes in lipid composition upon infection with C. trachomatis. A 
complete list of detected and assigned peaks is given in Table 3-4. 
Table 3-4. Peak assignment of MALDI-TOF mass spectrometry analysis. Assignments of ion signals detected in the MALDI-
TOF mass spectra of lipid extracts from uninfected and infected HeLa cells. Unassigned mass peaks are marked in red. 
Results are from two independent biological experiments. 
Mass (m/z) (Da) Assignment Condition (uninfected / infected) MALDI-TOF ion mode (positive / negative) 
369.4 Cholesterol + H+ / - H2O Uninfected / infected Positive 
706.0 DHSM (16:0) + H+ Uninfected / infected Positive 
728.0 DHSM (16:0) + Na+ Uninfected / infected Positive 
703.6 SM (16:0) + H+ Uninfected / infected Positive 
725.6 SM (16:0) + Na+ Uninfected / infected Positive 
813.6 SM (24:1) + H+ Infected Positive 
835.6 SM (24:1) + Na+ Infected Positive 
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706.9 PC (14:0/16:0) + H+ Uninfected / infected Positive 
728.6 PC (14:0/16:0) + Na+ Uninfected / infected Positive 
732.6 PC (16:0/16:1) + H+ Uninfected / infected Positive 
734.6 PC (16:0/16:0) + H+ Uninfected / infected Positive 
754.6 PC (16:0/16:1) + Na+ Uninfected / infected Positive 
756.6 PC (16:0/16:0) + Na+ Uninfected / infected Positive 
760.6 PC (16:0/18:1) + H+ Uninfected / infected Positive 
782.6 PC (16:0/18:1) + Na+ Uninfected / infected Positive 
808.6 PC (18:0/18:2) + Na+ Uninfected / infected Positive 
740.5 Unassigned Infected Positive 
742.5 Unassigned Infected Positive 
794.7 Unassigned Infected Positive 
816.7 Unassigned Infected Positive 
454.1 LPC (14:0) + H+ Infected Positive 
476.1 LPC (14:0) + Na+ Infected Positive 
740.6 PE (16:0/18:1) + Na+ Uninfected / infected Positive 
746.6 PE (18:0/18:1) + H+ Uninfected / infected Positive 
762.6 PE (16:0/18:1) +2 Na+ Uninfected / infected Positive 
768.6 PE (18:0/18:1) + Na+ Uninfected / infected Positive 
790.6 PE (18:0/20:4) + Na+ Uninfected / infected Positive 
813.1 PE (18:0/20:4) +2 Na+ Uninfected / infected Positive 
700.6 Unassigned Infected Positive 
722.6 Unassigned Infected Positive 
771.6 PG (16:0/18:1) + H+ Uninfected / infected Positive 
793.6 PG (16:0/18:1) + Na+ Uninfected / infected Positive 
703.6 Unassigned Infected Positive 
725.6 Unassigned Infected Positive 
731.6 Unassigned Infected Positive 
753.6 Unassigned Infected Positive 
859.6 PI (16:0/18:1) + H+ Uninfected / infected Positive 
881.7 PI (16:0/18:1) + Na+ Uninfected / infected Positive 
909.6 PI (18:0/20:4) + H+ Uninfected / infected Positive 
931.6 PI (18:0/20:4) + Na+ Uninfected / infected Positive 
784.6 PS (16:0/18:1) + H+ Uninfected / infected Positive 
812.6 PS (18:0/18:1) + H+ Uninfected / infected Positive 
834.9 PS (18:0/18:1) + Na+ Uninfected / infected Positive 
716.5 PE (16:0/18:1) Uninfected / infected Negative 
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742.5 PE (18:0/18:2) Uninfected / infected Negative 
744.5 PE (18:0/18:1) Uninfected / infected Negative 
766.5 PE (18:0/20:4) Uninfected / infected Negative 
662.5 PE (14:0/16:0) Infected Negative 
690.5 PE (16:0/16:0) Infected Negative 
747.5 PG (16:0/18:1) Uninfected / infected Negative 
773.5 PG (18:0/18:2) Uninfected / infected Negative 
693.5 PG (14:0/16:0) Infected Negative 
721.6 PG (16:0/16:0) Infected Negative 
833.6 PI (16:0/18:2) Uninfected / infected Negative 
835.6 PI (16:0/18:1) Uninfected / infected Negative 
861.6 PI (18:0/18:2) Uninfected / infected Negative 
863.6 PI (18:0/18:1) Uninfected / infected Negative 
885.6 PI (18:0/20:4) Uninfected / infected Negative 
887.6 PI (18:0/20:3) Uninfected / infected Negative 
807.6 PI (16:0/16:1) Infected Negative 
760.6 PS (16:0/18:1) Uninfected / infected Negative 
788.6 PS (18:0/18:1) Uninfected / infected Negative 
1394.0 CL (14:0/16:0/18:2/18:2) Uninfected / infected Negative 
1422.0 CL (16:0/16:0/18:2/18:2) Uninfected / infected Negative 
1448.0 CL (16:0/18:1/18:2/18:2) Uninfected / infected Negative 
1450.0 CL (16:0/18:1/18:1/18:2) Uninfected / infected Negative 
1474.1 CL (18:1/18:1/18:2/18:2) Uninfected / infected Negative 
1476.0 CL (18:1/18:1/18:1/18:2) Uninfected / infected Negative 
1373.9 CL (16:0/16:0/16:0/16:0) Infected Negative 
 
Based on both MALDI-TOF mass spectrometry approaches, the direct and the TLC coupled 
measurement of lipids, all major naturally occuring lipid classes were detected, including cholesterol, 
SM, dihydrosphingomyelin (DHSM), PC, PE, PG, PI, PS, and CL. In infected cells, PE, PG, PI, and CL 
species with shorter fatty acid chains were predominantly present compared to uninfected cells 
(Table 3-4). The lyso-form of PC (LPC) was exclusively found in infected cells. Furthermore, several 
species of PG were only found in lipid extracts from infected cells. Interestingly, additional peaks at 
m/z = 700.6, m/z = 703.6, m/z = 722.6, m/z = 725.6, m/z = 731.6, m/z = 740.5, m/z = 742.5, 
m/z = 753.6, m/z = 794.7, and m/z = 816.7 were observed in infected cells (Table 3-4, red labeling), 
showing a distinct 14 Da difference compared to their corresponding lipid species, namely 
PE (16:0/16:0) + H+, PG (14:0/16:0) + H+, PE (16:0/16:0) + Na+, PG (14:0/16:0) + Na+, PG (16:0/16:0) + 
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H+, PC (16:0/16:1) + Na+, PC (16:0/16:0) + Na+, PG (16:0/16:0) + Na+, PC (18:0/20:4) + H+, and 
PC (18:0/20:4) + Na+, respectively. These peaks could not be assigned to any lipid species typically 
occurring in eukaryotic cells. 
3.3.2 Temporal changes in lipid composition during the chlamydial infection cycle 
Analysis of lipids at a single time point in the developmental cycle of C. trachomatis (24 h p.i.) can 
not sufficiently reveal temporal variations of the lipid composition and does not cover changes 
occuring at later stages. Therefore, time course experiments were performed to cover the complete 
chlamydial developmental cycle. Lipid extracts from four different time points of infection and two 
uninfected samples were analyzed (Figure 3-32). 
 
Figure 3-32. Workflow scheme of time course lipid analysis. Lipids were extracted from uninfected and infected HeLa cells 
(C. trachomatis L2, MOI 2.5) according to Folch et al., 1957 and subsequently analyzed by MALDI-TOF mass spectrometry. 
Cells were infected for 12 h, 24 h, 36 h, and 44 h to cover the complete chlamydial developmental cycle. Lipids from 
uninfected cells (start) and uninfected cells (end) reflect the lipid composition at the beginning and at the end of the 
experiment, respectively.  
Cells were infected at different time points; lipids were extracted at the same time point (Figure 
3-32). To differentiate between cell type specific and cell type independent effects on the lipid 
composition, two different cell lines, HeLa cells and HEp-2 cells, were used for the time course 
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experiments (Figure 3-33 A). Extracted lipids amounts were normalized based on cell numbers, 
which were microscopically determined prior to MALDI-TOF mass spectrometry measurement 
(Figure 3-33 B). 
 
Figure 3-33. Cell numbers during infection time course. (A) Microscopy pictures of cells infected with C. trachomatis. HeLa 
cells and HEp-2 cells were infected for 12 h, 24 h, 36 h, and 44 h. White arrows mark inclusions. (B) Quantification of cell 
numbers from Figure 3-33 A. Cell numbers were normalized to the 24 h time point. Results are from two independent 
biological experiments. 
Negative ion mode MALDI-TOF measurement of all time points revealed major changes in PI and CL 
lipid composition during the chlamydial developmental cycle in HeLa cells. Focussing on lipids with 
lower masses (m/z < 900), PI species with comparably long fatty acid residues (PI (18:0/20:4), 
PI (18:0/20:3)) decreased during the progression of the cycle, while PI species with shorter fatty acid 
residues (PI (16:0/16:1), PI (16:0/18:2), PI (16:0/18:1), PI (18:0/18:2), PI (18:0/186:1)) increased over 
time (Figure 3-34 A). These changes are also reflected in the quantification of Figure 3-34 A (Figure 
3-34 B). 
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Figure 3-34. Lipid profile of infection time course in HeLa cells (intermediate masses). (A) Negative ion mode mass spectra 
of lipid extracts from C. trachomatis infection time course in HeLa cells. HeLa cells were infected for 12 h, 24 h, 36 h, and 
44 h. PI species with long fatty acid residues decrease over time, while PI species with short fatty acid residues increase. 
Figure shows representative mass spectra of two independent biological experiments. (B) Bar diagram quantifying changes 
in PI composition during infection of HeLa cells with C. trachomatis (Figure 3-34 A). Values are normalized to PI (18:0/20:3). 
Results are from two independent biological experiments. Error bars indicate SE. 
Negative ion mode MALDI-TOF measurement of HEp-2 cells infected with C. trachomatis resulted in 
the detection of the same lipid species with lower masses (m/z < 900) as in infected HeLa cells. 
Furthermore, the same tendency of changes in the lipid profile was observed (Figure 3-35). 
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Figure 3-35. Lipid profile of infection time course in HEp-2 cells (intermediate masses). (A) Negative ion mode mass 
spectra of lipid extracts from C. trachomatis infection time course in HEp-2 cells. HEp-2 cells were infected for 12 h, 24 h, 
36 h, and 44 h. PI species with long fatty acid residues decrease over time, while PI species with short fatty acid residues 
increase. Figure shows representative mass spectra of two independent biological experiments. (B) Bar diagram 
quantifying changes in PI composition during infection of HEp-2 cells with C. trachomatis (Figure 3-35 A). Values are 
normalized to PI (18:0/20:3). Results are from two independent biological experiments. Error bars indicate SE. 
Among the lipids with higher masses (m/z > 1300), CL levels were found to be affected during 
progression of the infection in HeLa cells. While a core set of CL species (CL (2x16:0/2x18:2), 
CL (16:0/18:1/2x18:2), CL (16:0/2x18:1/18:2), CL (2x18:1/2x18:2), CL (3x18:1/18:2)) remained 
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unchanged during infection, CL species with shorter fatty acid residues (CL (4x16:0), 
CL (14:0/16:0/2x18:2)) increased over time (Figure 3-36). Furthermore, additional unassigned peaks 
(m/z = 1331.9, m/z = 1345.9, m/z = 1359.9) increased during the infectious cycle. Interestingly, these 
peaks differ from the mass of CL (4x16:0) by a multitude of 14 Da (Figure 3-36 A). 
 
Figure 3-36. Lipid profile of infection time course in HeLa cells (high masses). (A) Negative ion mode mass spectra of lipid 
extracts from C. trachomatis infection time course in HeLa cells. HeLa cells were infected for 12 h, 24 h, 36 h, and 44 h. CL 
species with short fatty acid residues increase over time. Red marks indicate unassigned mass peaks increasing during the 
developmental cycle. Figure shows representative mass spectra of two independent biological experiments. (B) Bar 
diagram quantifying changes in CL composition during infection of HeLa cells with C. trachomatis (Figure 3-36 A). Values 
are normalized to CL (3x18:1/18:2). Results are from two independent biological experiments. Error bars indicate SE. 
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Similar changes were detected during C. trachomatis infection of HEp-2 cells. CL species with shorter 
fatty acid residues (CL (4x16:0), CL (14:0/16:0/2x18:2)) were found to increase during the infection 
cycle (Figure 3-37). Again, peaks at m/z = 1331.9, m/z = 1345.9, and m/z = 1359.9 were found to 
increase during the infectious cycle (Figure 3-37 A). 
 
Figure 3-37. Lipid profile of infection time course in HEp-2 cells (high masses). (A) Negative ion mode mass spectra of lipid 
extracts from C. trachomatis infection time course in HEp-2 cells. HEp-2 cells were infected for 12 h, 24 h, 36 h, and 44 h. 
CL species with short fatty acid residues increase over time. Red marks indicate unassigned mass peaks increasing during 
the developmental cycle. Figure shows representative mass spectra of two independent biological experiments. (B) Bar 
diagram quantifying changes in CL composition during infection of HEp-2 cells with C. trachomatis (Figure 3-37 A). Values 
are normalized to CL (3x18:1/18:2). Results are from two independent biological experiments. Error bars indicate SE. 
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Among lipid species with m/z < 800, PE species (PE (14:0/16:0), PE (2x16:0), PE (16:0/18:1), 
PE (18:0/18:2), PE (18:0/18:1), PE (18:0/20:4)), and PG species (PG (14:0/16:0), PG (2x16:0), 
PG (16:0/18:1), PE (18:0/18:2)) were detected, while short fatty acid lipids (PE (14:0/16:0), 
PE (2x16:0), PG (14:0/16:0), PG (2x16:0)) were found mainly at later infection time points (Figure 
3-38). Interestingly, peaks at m/z = 676.5, m/z = 702.5, and m/z = 707.5 were observed, with a 
distinct 14 Da difference compared to PE (2x16:0), PE (16:0/18:1), and PG (2x16:0), respectively. 
 
Figure 3-38. Lipid profile of infection time course in HeLa and HEp-2 cells (low masses) (part I). Negative ion mode mass 
spectra of lipid extracts from C. trachomatis infection time course in HeLa and HEp-2 cells. Cells were infected for 12 h, 
24 h, 36 h, and 44 h. Red marks indicate unassigned mass peaks increasing during the developmental cycle. Figure shows 
representative mass spectra of two independent biological experiments. 
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Positive ion mode MALDI-TOF spectra of all time points of the developmental cycle revealed 
SM (16:0) and several PC species with nearly no changes during progression of the infection (Figure 
3-39). Remarkably, additional peaks at m/z = 740.5, m/z = 742.5, and m/z = 768.6 were detected, 
with a distinct 14 Da difference compared to PC (16:0/16:1) + Na+, PC (16:0/16:0) + Na+, and PC 
(16:0/18:1) + Na+, respectively. 
 
Figure 3-39. Lipid profile of infection time course in HeLa and HEp-2 cells (low masses) (part II). Positive ion mode mass 
spectra of lipid extracts from C. trachomatis infection time course in HeLa and HEp-2 cells. Cells were infected for 12 h, 
24 h, 36 h, and 44 h. Red marks indicate unassigned mass peaks increasing during the developmental cycle. Figure shows 
representative mass spectra of two independent biological experiments. 
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Taken together, these data show that C. trachomatis changes the overall lipid composition of 
infected cells. During the infectious cycle, PI species with long fatty acid residues decreased, while 
short chain PI and CL species increased. Interestingly, LPC species are only detected in infected cells. 
Furthermore, peaks with a characteristic 14 Da shift compared to their related lipids were observed 
exclusively in infected cells. 
3.3.3 Impact of cPLA2 and CRLS1 on chlamydial growth and progeny formation 
To further elucidate the relevance of the detected changes in lipid composition for the successful 
progression of C. trachomatis infection, two host cell enzymes implicated in processing and 
biosynthesis of phospholipids were studied. cPLA2 is involved in modifying glycerophospholipids, 
preparing them for the translocation to the chlamydial inclusion. cPLA2 is activated during 
C. trachomatis infection (Su et al., 2004; Vignola et al., 2010). Active cPLA2 can hydrolyze 
glycerophospholipids, cleaving the fatty acid residue at the sn-2 position of the glycerol backbone. 
The remaining lysophospholipid is then translocated to the chlamydial inclusion and taken up by the 
bacteria. Subsequently, a Chlamydia-derived branched chain fatty acid is added to the sn-2 position 
(Wylie et al., 1997; Su et al., 2004). These branched chain fatty acids are found in prokaryotic, but 
not in eukaryotic cells. Due to this branch within the fatty acid, a mass difference of 14 Da 
(CH2 group) is observed in comparison to the corresponding straight chain fatty acid (Kaneda, 1991). 
CRLS1 catalyzes the formation of CL from phosphatidylglycerol and CDP-diacylglycerol (Figure 3-40). 
The enzyme is localized to the inner membrane of mitochondria and is expressed in HeLa cells (Chen 
et al., 2006; Lu et al., 2006), while no homolog can be found in C. trachomatis. 
 
Figure 3-40. Enzymatic reaction of CRLS1. CRLS1 catalyzes the formation of CL from phosphatidylglycerol and CDP-
diacylglycerol. CRLS1 is present in human cells, but not in C. trachomatis. 
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To investigate the influence of cPLA2 and CRLS1 on the lipid composition of host cells during 
infection, both the development of C. trachomatis in cPLA2 and CRLS1 knockdown cells and the 
formation of infectious progeny were analyzed. For this purpose, cells were transfected with the 
respective siRNA and infected with C. trachomatis. After 48 h, cells were lysed to release infectious 
particles and untreated cells were reinfected with infectious particles to monitor progeny formation 
(infectivity) (Figure 3-41). 
 
Figure 3-41. Workflow scheme of infectivity assay. Cells were transfected with respective siRNA at day 1 and left for 72 h 
to achieve a maximum knockdown of cPLA2 or CRLS1. At day 4, cells were infected with C. trachomatis for 24 h, fixed, and 
stained for inclusions and nuclei. Additionally, cells were infected for 48 h, lysed, and titrated on untreated cells to monitor 
progeny formation (infectivity) after another 24 h. 
Knockdown efficiency for cPLA2 was measured by Western blot analysis, CRLS1 knockdown was 
monitored by qRT-PCR (Figure 3-42). Neither cPLA2 knockdown nor CRLS1 knockdown did affect cell 
viability (data not shown). Furthermore, C. trachomatis infection (24 h p.i.) did not change mRNA 
levels of cPLA2 and CRLS1 as detected by DNA microarray analysis (data not shown). 
 
Figure 3-42. Confirmation of cPLA2 and CRLS1 knockdown. (A) Western blot showing nearly complete knockdown of 
cPLA2 after siRNA-mediated gene silencing of luciferase (Luci) or cPLA2. Cortactin represents loading control. (B) Bar 
diagram showing knockdown of CRLS1 after siRNA-mediated gene silencing of luciferase (Luci) or CRLS1. Knockdown was 
detected by qRT-PCR and normalized to GAPDH. 
  Results and discussion: part II 
 
  85 
Fixed cells were stained for C. trachomatis OMP1, analyzed by automated microscopy, and a relative 
value for inclusions per nuclei was calculated. Knockdown of cPLA2 or CRLS1 did not affect primary 
infection (Figure 3-43 A). In contrast, formation of infectious particles was significantly decreased by 
cPLA2 and CRLS1 knockdown to approximately 60 % (Figure 3-43, A and B). 
 
Figure 3-43. Infectivity assay after cPLA2 or CRLS1 knockdown. (A) Immunofluorescence staining of C. trachomatis OMP1 
(green) and nuclei (blue). (B) Quantification of inclusions per nucleus during secondary infection (progeny formation). 
Neither cPLA2 nor CRLS1 knockdown reduced primary infection. However, formation of infectious particles was 
significantly decreased by cPLA2 and CRLS1 knockdown. 
Taken together, these results demonstrate that knockdown of cPLA2 and CRLS1 leads to a reduced 
reinfection rate. Although C. trachomatis invasion and establishment of infection is not influenced 
by knockdown of cPLA2 and CRLS1, both enzymes play a crucial role in the process of infectious 
particle formation.  
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3.3.4 Discussion 
In this approach, MALDI-TOF mass spectrometry analysis of lipids was performed to globally study 
changes in the lipid composition of C. trachomatis infected host cells. This revealed a prominent shift 
of the PI and CL composition towards lipid species with short fatty acids during the progression of 
the infectious cycle. Moreover, peaks with a distinct mass difference of 14 Da in comparison to the 
respective PI, PE, PG, and CL lipid species were detected in infected cells, suggesting the presence of 
lipids with Chlamydia-derived branched chain fatty acids and, thus, the involvement of remodeling 
enzymes in this process. Hence, both CRLS1 and cPLA2 were shown to be involved in successful 
replication of Chlamydia, since knockdown of these enzymes resulted in a decreased formation of 
infectious particles. Collectively, these results demonstrate a crucial role of CL during Chlamydia 
infection, highlight the impact of cPLA2 in lipid remodeling, and illustrate the importance of host cell 
trafficking pathways for the successful replication of Chlamydia. 
CL is a major membrane protein found exclusively in mitochondria and plays an important role for 
mitochondrial structure and function (Hatch, 1998; Nie et al., 2010). It is connected with 
mitochondrial energy production (Eble et al., 1990; Hatch, 1998; Gomez and Robinson, 1999) and 
apoptosis (Lutter et al., 2000). CL deficiency is associated with X-linked cardioskeletal myopathy and 
neutropenia (Barth syndrome), caused by mutations in tafazzin, a transacylase involved in fatty acid 
remodeling of CL (Bione et al., 1996; Houtkooper et al., 2009). Albeit its functional and clinical 
importance, it has been reported that CL deficiency due to CRLS1 knockdown does not impact cell 
viability, mitochondrial membrane potential, numbers of mitochondria, or ATP levels (Choi et al., 
2007; Huang et al., 2008). However, knockdown of CRLS1 resulted in significantly decreased CL levels 
and an altered ultrastructure of mitochondria with disorganized cristae (Choi et al., 2007; Huang 
et al., 2008). Interestingly, CRLS1 knockdown cells exhibited a decreased susceptibility to apoptotic 
stimuli like actinomycin D or rotenone (Huang et al., 2008). Here, the reduction of chlamydial 
progeny formation after CRLS1 knockdown shows for the first time the importance of CRLS1 activity 
and, thus CL, for chlamydial growth. This observation might be explained by a critical structural and 
functional role of CL for the late developmental stages of C. trachomatis, as the observed alterations 
in CL lipid composition are mainly detected beginning at 24 h p.i. Despite this, it is tempting to 
suggest a connection of C. trachomatis-induced alteration of CL composition and Chlamydia-
mediated inhibition of apoptosis. Thus, stimulating mitochondrial metabolism, modifying the 
molecular fatty acid composition of CL, and re-routing CL species to the chlamydial inclusion could 
be an mechanism of actively decreasing the susceptibility of the host cell to apoptosis. 
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Using a mutant CHO cell line unable to synthesize CTP, which is generally necessary for 
glycerophospholipid synthesis, it has been shown that C. trachomatis does not depend on the 
de novo host cell glycerophospholipid synthesis (Wylie et al., 1997; Hatch and McClarty, 1998a). Due 
to a mutation in its CTP synthetase, this cell line is dependent on exogenous cytidine or lipids in the 
cell culture medium. Contrary to this, the results presented here indicate for the first time a 
dependency of Chlamydia on host cell CL synthesis, as knockdown of CRLS1, the enzyme catalyzing 
the final step of CL synthesis, led to a reduction of infectious particles. This discrepancy might be 
explained by residual glycerophospholipid pools in the CTP synthase deficient cell line after being 
cultured under restrictive conditions, sufficiently promoting intracellular growth of C. trachomatis. In 
contrast, CRLS1 knockdown cells used in the work presented here only show remaining CL levels 
insufficient for chlamydial development. It will be interesting to analyze CRLS1 knockdown cells for 
their lipid composition and to test for the relevance of other glycerophospholipid synthesis 
pathways to chlamydial growth via siRNA-mediated gene silencing. 
Remodeling of CL during C. trachomatis infection has been investigated before, showing the 
alteration of the molecular fatty acid composition of CL (Hatch and McClarty, 1998b). McClarty and 
colleagues analyzed the uptake and incorporation of radioactively labeled myrisate, palmitate, or 
oleate into de novo synthesized mitochondrial lipids (PG, CL) upon infection, suggesting a link to 
elevated mitochondrial metabolism (Hatch and McClarty, 1998b). The results presented here extend 
these observations, demonstrating both the chlamydial influence on the overall CL composition and 
the remodeling of the molecular CL fatty acid composition with Chlamydia-derived fatty acids. Since 
the latter requires the transport of CL to the chlamydial inclusion, a close association of 
mitochondria and the inclusion is of importance. This association has been shown for C. psittaci by 
electron microscopy (Matsumoto, 1981; Matsumoto et al., 1991). 
The host cell enzyme cPLA2 gets activated upon C. trachomatis infection and is involved in the 
deacylation of glycerophospholipids at the sn-2 position (Su et al., 2004). Pharmacological inhibition 
of cPLA2 reduces glycerophospholipid uptake and bacterial replication (Su et al., 2004; Vignola et al., 
2010). Here, the knockdown of cPLA2 leads to a significant reduction in infectious particle formation, 
indicating an central role of cPLA2 in the processing of glycerophospholipids for the uptake by 
Chlamydia (Wylie et al., 1997). Valdivia and colleagues were unable to detect a decreased progeny 
formation of C. trachomatis after cPLA2 knockdown (Vignola et al., 2010). However, this observation 
could be due to a low knockdown efficiency (< 10 % residual cPLA2 levels), while the efficiency of 
cPLA2 knockdown in the study presented here is considerably higher (< 1 % residual cPLA2 levels). 
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Another explanation for the inhibitory phenotype of cPLA2 knockdown could be the role of 
lysophospholipids in modulating membrane curvature and membrane tubules formation, thereby 
assisting membrane transport (Brown et al., 2003, San Pietro et al., 2009). These transport events 
have been shown to be necessary for C. trachomatis replication (Carabeo et al., 2003; Robertson 
et al., 2009). Furthermore, the production of lysophospholipids by cPLA2 is a prerequisite for the 
generation of glycerophospholipids with Chlamydia-derived branched chain fatty acids (Su et al., 
2004; Vignola et al., 2010) (Figure 3-44).  
 
Figure 3-44. Model of CL biosynthesis and phospholipid acquisition by Chlamydia. During C. trachomatis infection, host 
phospholipids are hydrolyzed at the sn-2 position by activated cPLA2, resulting in lysophospholipids and straight chain fatty 
acids. The lysophospholipids are then transported to the chlamydial inclusion and taken up by the bacteria. Subsequently, 
lysophospholipids are modified by the addition of a prokaryotic branched chain fatty acid to the sn-2 position. 
To synthesize branched chain fatty acids, Chlamydia and other prokaryotes use isoleucine as 
precursor of the α-keto acid primer during fatty acid biosynthesis (Kaneda, 1991; Wylie et al., 1997). 
A branch within the fatty acid results in a mass difference of 14 Da – equal to the mass of a CH2 
group – in comparison to the corresponding straight chain fatty acid (Kaneda, 1991), for example 
between CL (4x16:0) and CL (15:0/3x16:0). In this study, both the intermediate product of the 
modification process, the lysophospholipid (LPC) and the final product of the remodeling process, 
the branched chain lipid, have been detected in infected cells. These branched chain fatty acids 
could be detected in PC, PE, PG, and CL species. Branched chain fatty acids in C. trachomatis infected 
cells have been described previously (Wylie et al., 1997). Nonetheless, this study is the first to show 
remodeling of CL with branched chain fatty acids. 
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cPLA2 has been demonstrated to process CL despite its rather uncommon structure compared to 
other glycerophospholipids (Schlame and Rüstow, 1990; Schlame, 2008). However, cPLA2 is not the 
only host cell enzyme involved in modifying glycerophospholipids. The group of PLA2 enzymes 
consists of 20 enzymes classified in mammals (Ghosh et al., 2006). Moreover, enzymes belonging to 
the group of phospholipase A1 (PLA1) can deacylate glycerophospholipids at the sn-1 position and 
are also present in mammalian cells (Ghosh et al., 2006). Additionally, tafazzin, a CL-specific 
transacylase, might also be involved in the process of CL modification during infection (Bione et al., 
1996; Houtkooper et al., 2009). It will be interesting to investigate the influence of these lipid-
modifying enzymes on the molecular lipid composition and, subsequently, on the successful 
replication of C. trachomatis. 
Another product of cPLA2 activity is arachidonic acid, which serves as a precursor of eicosanoid-
derived metabolites. Cellular lipoxygenases and cyclooxygenases catalyze the formation of 
leukotrienes and prostanoids, respectively. It has been shown that C. trachomatis infection induces 
the expression of cyclooxygenase 2 (COX2) in epithelial cells (Fukuda et al., 2005) (see also Table 6-2) 
and promotes production and release of prostaglandin E2, which in turn stimulates IL8 release in 
epithelial cells (Krausse-Opatz et al., 2004; Fukuda et al., 2005). Furthermore, COX2 inhibition was 
demonstrated to reduce C. pneumoniae growth (Rupp et al., 2004; Yan et al., 2008). These results 
underline the importance of cPLA2 function during Chlamydia infection and create an additional 
explanation for the inhibitory effect of cPLA2 knockdown on chlamydial infection observed in the 
work presented here. 
Previous studies have analyzed lipid changes during C. trachomatis infection by means of TLC, 
indicating both trafficking and modification of lipids by Chlamydia (Wylie et al., 1997; Hatch and 
McClarty, 1998a). Lipid composition of infected cells was either described by composition of fatty 
acids or composition of lipid classes. In contrast, the study presented here shows a comprehensive 
and detailed description of the lipid composition in infected cells, specifically detecting single lipid 
species. McClarty and colleagues have described the increase of short chain and branched chain 
fatty acids over time and a decrease of other straight chain fatty acids, suggesting the modification 
of host lipids by Chlamydia (Wylie et al., 1997). Here, detection of LPC contributes to this finding, as 
LPC constitutes an intermediate step of the modification process. Furthermore, a shift towards lipids 
with short and branched chain fatty acids upon infection implicates an increased fluidity of 
membranes (Hazel and Williams, 1990). This modulation of bacterial or inclusion membrane stability 
might be favored by Chlamydia towards the end of the developmental cycle. However, further 
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studies have to be performed to distinguish between lipid changes of the host cell and in the 
bacteria. 
For the detection of lipids by mass spectrometry, other soft-ionization techniques like electrospray 
ionization (ESI) have been used more frequently compared with MALDI-TOF mass spectrometry 
(Pulfer and Murphy, 2003; Schiller et al., 2004). The major advantage of ESI mass spectrometry is the 
possibility of coupling the prior separation of lipid classes directly with their detection, namely the 
combination of HPLC and ESI mass spectrometry online (Pulfer and Murphy, 2003). Further, MALDI-
TOF mass spectrometry bears the risk of detecting interferences from ions derived from the matrix 
(Pulfer and Murphy, 2003). However, MALDI-TOF mass spectrometry has also several advantages: 
the method is fast and convenient, requires only low amounts of lipid extract, and has both a high 
reproducibility and sensitivity (Schiller et al., 2004). Moreover, the approach used in the study 
presented here combines TLC with MALDI-TOF mass spectrometry offline, thereby matching the 
advantages of HPLC/ESI online methods. 
In summary, these data show an example of how Chlamydia subverts host cellular trafficking 
pathways to ensure its intracellular replication. Further work will focus on the specific mechanisms 
of lipid trafficking to the chlamydial inclusion in general and on the processes involved in CL 
transport and remodeling in more detail. 
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4 Conclusions and outlook 
Following the investigation of Chlamydia’s repertoire to exploit the host cell, several additional 
questions remain to be answered. 
Tarp has been shown to interact with a multitude of cellular SH2 and SH3 domains. Further studies 
will have to focus on validating these additional interactions, especially ABL2 and NCK2, and 
dissecting their spatiotemporal profile during the progression of the developmental cycle. This could 
be performed by blue native gel electrophoresis, a common approach for the identification and 
analysis of multiprotein complexes (Swamy et al., 2006). Also, the detailed phosphorylation status of 
Tarp’s phospho-sites at different time points of invasion might be investigated by mass 
spectrometry. Moreover, solving the three-dimensional structure of Tarp would greatly add to the 
understanding of how Tarp interacts with host cell proteins, especially via SH2 and SH3 interactions. 
The outcome of Tarp-mediated signaling induced by other interaction partners than SHC1 is best 
explored by analyzing the transcriptional impact of these interactors using DNA microarray analysis, 
as described in this study. The development of a heterologous Tarp expression system could be a 
major advantage in this regard – the infection-independent setting of such a system would facilitate 
the detailed investigation of Tarp interactions by both siRNA-mediated knockdown of interaction 
partners and mutational analysis of the Tarp sequence and its interaction interfaces. This would also 
allow studying the role of RASA1, CRKL, and LCK for SHC1-independent MEK/ERK activation. 
Moreover, it will be interesting to dissect the role of all SHC1 isoforms in early Chlamydia-induced 
cell survival by isoform-specific knockdown and to further investigate the MEK/ERK-independent 
branch of SHC1 signaling. 
Future investigation the Chlamydia’s impact on the host cell lipid composition includes the lipid 
analysis after knockdown of cPLA2 or CRLS1. Also, ultrastructural analysis of infected cPLA2 and 
CRLS1 knockdown cells, e.g., by electron microscopy, could give additional insight into the 
association of mitochondria and the chlamydial inclusion. Using fluorescently labeled lipids and lipid 
tracers, trafficking of lipids during infection could be investigated. Moreover, the purification of 
bacteria from infected host cells at various time points of infection would allow to distinguish 
between lipid changes of the host cell and the bacteria. This study showed the relevance of enzymes 
involved in biosynthesis and modification of lipids. It will be interesting to further study the impact 
of other lipid synthesis pathways, phospholipid-modifying enzymes, and lipid transporters on the 
replication of C. trachomatis via siRNA-mediated gene silencing. 
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6 Appendix 
6.1 Supplemental material 
Table 6-1. Dissociation constants of Tarp SH2 interactions. Peptides were synthesized as nonphosphorylated, singly, or 
doubly phosphorylated variants. Amino acid sequence of peptides is given in the footnotes. Phosphorylation is indicated by 
an X. Dissociation constants KD (nM) of peptide/domain interactions are shown in the table. Each peptide was incubated 
twice with an array (KD1, KD2). Only domains giving an interaction value in both experiments were included in the 
interaction map, as a mean of the two values. Blank cells indicate that the KD was below the 2 µM threshold. 
    Peptide 1a Peptide 2b Peptide 3c Peptide 4d Peptide 5e Peptide 6f Peptide 7g Peptide 8h 
Number Name KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
KD1 
(nM) 
KD2 
(nM) 
SH2#1 PIK3R1-N       1563 360 310     745   
SH2#2 PIK3R1-C         922    542    
SH2#3 PIK3R1-NC      59  988 1264 532    990   
SH2#97 PIK3R3-N  1827   715 847  798 867 409  913  1225   
SH2#106 PIK3R3-NC 1919    206 804 1054 1048 417 459 765  860 1424   
SH2#99 PIK3R2-N     394 494 428 495 247 202   886 841   
SH2#107 PIK3R2-NC  19     647 1089         
SH2#102 ABL2 82 627 624 521 5 48 12 22 14 16 126 115 8 6 873 777 
SH2#46 ABL1 1724 657   796 531  1055 758 330 1586 1917  295   
SH2#10 FGR     327 409 622 333 360 292 1049  930 663   
SH2#15 SRC              713   
SH2#120 SYK-NC 1541    152 304 175 235 297 225 1996  672 597   
SH2#19 LYN       1402          
SH2#69 FER      354    847    524   
SH2#88 HCK     903 778 1101 1675 183 245   917 893   
SH2#109 LCK         1623 1523    1847   
SH2#95 FES     1429            
SH2#37 YES1  1954   1800 518 787 524 567 570    21   
SH2#5 PLCG1-C              1872   
SH2#115 PLCG2-C          1548       
SH2#116 PLCG2-NC      942 1748 458    269     
SH2#11 GRB2     815 179 12  1125 357       
SH2#63 GRB7        1946         
SH2#94 GRB10       1284      433    
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SH2#13 CRK  206   1029  1487  1569 1262       
SH2#45 CRKL 1037 454   364 505 1119 1853  105    1707   
SH2#14 NCK1     494    1893     954   
SH2#26 NCK2  1819   344 219 110  159 282   365 156   
SH2#9 PTPN11-NC       1867          
SH2#72 APS        1945         
SH2#84 SH3BP2     4  907 1949 988 926       
SH2#61 LNK  969   1835  1127  1653 1524       
SH2#112 SH2B  843               
SH2#51 SHC1 163 117 1396 1708 8 35  518 216 115  1672 21 39   
SH2#65 SHC3 880 652    163 1234 1675 466 935    286   
SH2#91 JAK3         1804 1485       
SH2#39 BRDG1              1655   
SH2#49 RIN1  1437               
SH2#50 SH2D3A         1140        
SH2#113 RASA1-N 1029 1669   71 73 77 56 30 88 933 626 77 133   
SH2#114 RASA1-NC     1766            
SH2#110 SH2D2A         1253        
SH2#111 SH2D3C    1242     1223  622   2   
SH2#20 VAV1        1600 1416 1632       
SH2#28 VAV2     167  84 505 32 28  1417 141 212   
SH2#67 PTPN6-C          1069  1397     
SH2#96 CTEN     323  1997  523 1053       
SH2#59 E138606   1954 1913       1246 1373     
SH2#83 E105251          1397       
SH2#125 SHB   1426  1052  789 954   943      
SH2#25 TNS     1793            
SH2#66 TENC1 697    476 915   675 1029       
SH2#21 TENS1          1799       
SH2#A CBL     1824      1688      
STAT2 STAT2          949       
PTB#22 DOK4     1538      1386      
PTB#24 IRS1         809 953       
PTB#32 GULP1     1887            
PTB#44 DOK5L         519        
 
a Peptide 1, amino acid sequence EPIRTTENIXESIGGSRT, C. trachomatis serovar D  
b Peptide 2, amino acid sequence EPIRTTENIYESIGGSRT, C. trachomatis serovar D 
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c Peptide 3, amino acid sequence EPISTTENIXENIYESID, C. trachomatis serovar L2 
d Peptide 4, amino acid sequence EPISTTENIYENIXESID, C. trachomatis serovar L2 
e Peptide 5, amino acid sequence EPISTTENIXENIXESID, C. trachomatis serovar L2 
f Peptide 6, amino acid sequence EPISTTENIYENIYESID, C. trachomatis serovar L2 
g Peptide 7, amino acid sequence EPISTTENIXESIDDSST, C. trachomatis serovar L2 
h Peptide 8, amino acid sequence EPISTTENIYESIDDSST, C. trachomatis serovar L2 
X = phosphotyrosine 
Table 6-2. Infection-dependently regulated genes. List of genes regulated in an infection-dependent manner. Genes are 
sorted according to their fold regulation. A 1.6-fold expression cutoff was taken as selection criterion. 
Gene identifier Gene name Full name Fold change p-value 
NM_004267 CHST2 CHST2,C6ST 4.16 3.95E-13 
NM_001657 AREG AREG,amphiregulin (schwannoma-derived growth factor) 3.79 0.00E+00 
NM_012242 DKK1 DKK1,SK,DKK-1 3.53 0.00E+00 
NM_001946 DUSP6 DUSP6,dual specificity phosphatase 6 3.11 1.16E-13 
THC1837102 THC1837102 THC1837102 2.78 1.20E-04 
NM_004419 DUSP5 DUSP5,dual specificity phosphatase 5 2.75 6.15E-36 
XM_379108 LOC400969 LOC400969 2.74 6.33E-21 
M57765 IL11 IL11,AGIF,IL-11 2.72 0.00E+00 
BC037430 PHLDA1 PHLDA1,PHRIP,TDAG51,DT1P1B11,MGC131738 2.71 0.00E+00 
THC1870278 THC1870278 THC1870278 2.59 3.71E-08 
BC018929 PHLDA1 PHLDA1,PHRIP,TDAG51,DT1P1B11,MGC131738 2.42 0.00E+00 
U17077 MALL MALL,BENE,MGC4419 2.37 1.44E-12 
NM_001432 EREG EREG,ER 2.33 3.48E-11 
NM_013409 FST FST,FS 2.32 1.38E-33 
NM_005114 HS3ST1 HS3ST1,heparan sulfate (glucosamine) 3-O-sulfotransferase 1 2.29 2.75E-19 
NM_001993 F3 F3,coagulation factor III (thromboplastin, tissue factor) 2.27 0.00E+00 
NM_007350 PHLDA1 PHLDA1,PHRIP,TDAG51,DT1P1B11,MGC131738 2.26 7.99E-40 
NM_005686 SOX13 SOX13,ICA12,Sox-13,MGC117216,SRY-box 13 2.25 3.42E-25 
NM_003633 ENC1 ENC1,NRPB,CCL28,ENC-1,PIG10,TP53I10,FLJ39259 2.24 1.33E-14 
AF220656 PHLDA1 PHLDA1,pleckstrin homology-like domain, family A, member 1 2.23 6.38E-10 
NM_005490 SH2D3A SH2D3A,NSP1 2.22 8.74E-03 
NM_032270 LRRC8C LRRC8C,AD158,FAD158,MGC138551,DKFZp586J1119 2.20 5.49E-40 
NM_139314 ANGPTL4 ANGPTL4,NL2,ARP4,FIAF,PGAR,HFARP,pp1158,ANGPTL2 2.13 1.14E-02 
XM_370948 SBK1 SBK1 2.11 5.75E-03 
BC042545 RAB22A RAB22A,MGC16770 2.06 3.38E-06 
AY049781 ENC1 ENC1,NRPB,CCL28,ENC-1,PIG10,TP53I10,FLJ39259 2.05 3.56E-19 
A_32_P4882 A_32_P4882 A_32_P4882 2.04 2.09E-16 
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NM_013940 OR10H1 OR10H1 2.03 3.33E-11 
NM_006504 PTPRE PTPRE,protein tyrosine phosphatase, receptor type, E 2.03 1.22E-26 
NM_000584 IL8 IL8,interleukin 8 2.03 3.00E-05 
AK074235 B3GNT5 B3GNT5,B3GN-T5,beta3Gn-T5 1.99 9.98E-32 
BX325074 VASP VASP 1.99 3.00E-05 
NM_018948 ERRFI1 ERRFI1,MIG6,RALT,MIG-6,GENE-33 1.98 2.81E-41 
NM_000080 CHRNE CHRNE,ACHRE,CMS1D,CMS1E,CMS2A,FCCMS,SCCMS 1.97 3.46E-03 
NM_023016 C2orf26 C2orf26 1.97 3.36E-18 
NM_001671 ASGR1 ASGR1,asialoglycoprotein receptor 1 1.93 1.22E-02 
D86519 NPY6R NPY6R,neuropeptide Y receptor Y6 (pseudogene) 1.93 4.84E-02 
NM_005952 MT1X MT1X,MT1,MT-1l 1.90 4.43E-31 
NM_139172 MDAC1 MDAC1 1.89 5.59E-20 
NM_003266 TLR4 TLR4,TOLL,CD284,hToll 1.89 7.80E-04 
ENST00000322282 ENST00000322282 ENST00000322282 1.89 4.77E-19 
AK123439 AK123439 AK123439 1.89 1.11E-02 
NM_130901 OTUD7A OTUD7A,OTUD7,C15orf16,CEZANNE2 1.89 8.90E-03 
THC1862126 THC1862126 THC1862126 1.89 1.32E-02 
THC1847096 THC1847096 THC1847096 1.87 1.94E-17 
NM_004431 EPHA2 EPHA2,EphA2 1.86 4.89E-21 
THC1935995 THC1935995 THC1935995 1.85 6.15E-03 
AK024943 USH1C USH1C,PDZ73,AIE-75,DFNB18,PDZ-45,PDZ-73,NY-CO-37,NY-CO-38,ush1cpst,PDZ-73/NY-CO-38 1.83 3.67E-02 
NM_003631 PARG PARG,poly (ADP-ribose) glycohydrolase 1.83 2.94E-03 
A_24_P797366 A_24_P797366 A_24_P797366 1.83 7.11E-06 
BC035496 CITED4 CITED4 1.83 2.74E-08 
NM_002923 RGS2 RGS2,regulator of G-protein signalling 2, 24 kDa 1.82 1.05E-07 
NM_002017 FLI1 FLI1,Friend leukemia virus integration 1 1.81 7.00E-05 
THC1993781 THC1993781 THC1993781 1.80 1.89E-02 
BC016648 FOSL1 FOSL1,FRA1,fra-1 1.79 8.12E-25 
NM_144652 LETM2 LETM2,FLJ25409 1.79 8.14E-09 
NM_000170 GLDC GLDC,glycine dehydrogenase (decarboxylating, glycine decarboxylase, glycine cleavage system protein P) 1.79 4.00E-04 
NM_152594 SPRED1 SPRED1,FLJ33903 1.79 4.90E-04 
THC1833111 THC1833111 THC1833111 1.77 7.28E-08 
BC063316 FBXL17 FBXL17,Fbl17,Fbx13,FBXO13,DKFZp434C1715 1.76 5.34E-09 
AL136788 C3orf31 C3orf31,MGC16471,DKFZp434E0519 1.76 7.10E-06 
A_23_P208579 A_23_P208579 A_23_P208579 1.76 1.63E-03 
NM_001945 DTR DTR,diphtheria toxin receptor (heparin-binding epidermal growth factor-like growth factor) 1.76 4.53E-13 
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NM_000963 PTGS2 PTGS2,prostaglandin-endoperoxide synthase 2 (prostaglandin G/H synthase and cyclooxygenase) 1.76 6.27E-19 
AF333388 LOC645745 LOC645745 1.75 2.11E-06 
A_32_P101073 A_32_P101073 A_32_P101073 1.75 2.84E-08 
NM_014992 DAAM1 DAAM1,KIAA0666 1.75 2.32E-42 
AK002195 ARHGAP18 ARHGAP18,MacGAP,FLJ25728,MGC126757,MGC138145,bA307O14.2 1.75 8.90E-10 
NM_002185 IL7R IL7R,interleukin 7 receptor 1.74 8.17E-20 
THC1892644 THC1892644 THC1892644 1.73 3.76E-15 
NM_024827 HDAC11 HDAC11,histone deacetylase 11 1.73 1.69E-02 
NM_174945 ZNF575 ZNF575,FLJ32567 1.72 4.32E-07 
NM_145110 MAP2K3 MAP2K3,MEK3,MKK3,MAPKK3,PRKMK3 1.72 1.26E-12 
AK056774 H19 H19,ASM,BWS,ASM1,MGC4485,PRO2605,D11S813E,predicted protein of HQ2605 1.72 1.50E-02 
NM_144777 SCEL SCEL,FLJ21667,MGC22531 1.71 6.75E-13 
AB058715 CDH23 CDH23,USH1D,DFNB12,FLJ00233,FLJ36499,KIAA1774,KIAA1812,MGC102761,DKFZp434P2350 1.71 4.89E-02 
A_32_P104469 A_32_P104469 A_32_P104469 1.71 5.09E-08 
BC015940 NT5E NT5E,NT,eN,NT5,NTE,eNT,CD73,E5NT 1.70 5.14E-24 
NM_006465 ARID3B ARID3B,BDP,DRIL2 1.70 4.40E-16 
NM_004864 PLAB PLAB,prostate differentiation factor 1.69 1.08E-12 
NM_032933 C18orf45 C18orf45,FLJ44259,MGC11386,MGC138577 1.68 2.30E-04 
NM_032181 FLJ13391 FLJ13391,hypothetical protein FLJ13391 1.68 2.28E-15 
NM_003311 PHLDA2 PHLDA2,IPL,BRW1C,BWR1C,HLDA2,TSSC3 1.68 1.42E-15 
NM_001511 CXCL1 CXCL1,chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 1.67 5.88E-24 
NM_002480 PPP1R12A PPP1R12A,protein phosphatase 1, regulatory (inhibitor) subunit 12A 1.67 1.39E-06 
X97261 MT1L MT1L,MT1,MTF,MT1R,metallothionein 1R 1.67 5.88E-25 
THC1950983 THC1950983 THC1950983 1.66 4.00E-05 
NM_016643 LOC51333 LOC51333 1.66 4.66E-03 
AF406557 PTPRE PTPRE,PTPE,HPTPE,DKFZp313F1310,R-PTP-EPSILON 1.66 1.97E-18 
NM_001394 DUSP4 DUSP4,TYP,HVH2,MKP2,MKP-2 1.66 1.03E-09 
NM_005950 MT1G MT1G,MT1,MT1K,MGC12386 1.66 4.65E-34 
AL832345 PRKCE PRKCE,PKCE,MGC125656,MGC125657,nPKC-epsilon 1.66 1.16E-12 
NM_018413 CHST11 CHST11,C4ST,C4ST1,C4ST-1,HSA269537 1.66 1.14E-20 
BC017197 MCL1 MCL1,myeloid cell leukemia sequence 1 (BCL2-related) 1.65 1.57E-08 
NM_203349 SHC4 SHC4,RaLP,MGC34023 1.65 4.50E-02 
BC033310 GDA GDA,CYPIN,GUANASE,MGC9982,NEDASIN,KIAA1258 1.65 2.82E-11 
AK058031 TGM2 TGM2,TG2,TGC 1.65 1.08E-11 
NM_020803 KLHL8 KLHL8,FLJ46304,KIAA1378 1.65 2.07E-03 
A_32_P192044 A_32_P192044 A_32_P192044 1.65 9.65E-03 
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AY358798 PHGDHL1 PHGDHL1,FLJ26351,FLJ30001,FLJ30548,FLJ42413,MGC90487 1.65 3.52E-02 
NM_002999 SDC4 SDC4,syndecan 4 (amphiglycan, ryudocan) 1.64 1.57E-14 
AK093501 RC3H1 RC3H1,RNF198,KIAA2025,RP5-1198E17.5 1.64 1.79E-06 
NM_005946 MT1A MT1A,MT1,MTC,MT1S,MGC32848 1.63 3.80E-08 
ENST00000316643 ENST00000316643 ENST00000316643 1.63 4.02E-03 
NM_015472 WWTR1 WWTR1,TAZ,DKFZP586I1419 1.63 1.57E-06 
THC1946380 THC1946380 THC1946380 1.62 5.00E-05 
A_24_P187626 A_24_P187626 A_24_P187626 1.62 1.95E-17 
BC007034 MT2A MT2A,MT2 1.62 7.25E-19 
NM_005556 KRT7 KRT7,keratin 7 1.62 2.66E-08 
NM_174953 ATP2A3 ATP2A3,SERCA3 1.62 1.07E-06 
NM_001986 ETV4 ETV4,E1AF,PEA3,E1A-F,PEAS3 1.61 1.06E-03 
NM_000490 AVP AVP,arginine vasopressin (neurophysin II, antidiuretic hormone, diabetes insipidus, neurohypophyseal) 1.61 8.08E-03 
NM_033306 CASP4 CASP4,caspase 4, apoptosis-related cysteine protease 1.61 8.08E-15 
NM_005285 NPBWR1 NPBWR1,GPR7,MGC129755 1.61 1.40E-04 
NM_153344 C6orf141 C6orf141,MGC46457 1.61 2.04E-15 
BC007242 ETV4 ETV4,E1AF,PEA3,E1A-F,PEAS3 1.61 1.40E-02 
NM_003028 SHB SHB,RP11-3J10.8 1.61 2.42E-12 
NM_032407 PCDHGC5 PCDHGC5,MGC138286,MGC138288,PCDH-GAMMA-C5 1.60 9.57E-06 
BC024020 TMEM49 TMEM49,VMP1,DKFZP566I133 1.60 5.31E-03 
BM701491 LOC145853 LOC145853 1.60 2.86E-02 
NM_014331 SLC7A11 SLC7A11,xCT,CCBR1 1.60 1.41E-02 
NM_005953 MT2A MT2A,MT2 1.60 2.99E-37 
AJ243670 UBAP2L UBAP2L,NICE-4,FLJ42300,KIAA0144 1.60 4.35E-06 
NM_053056 CCND1 CCND1,cyclin D1 (PRAD1: parathyroid adenomatosis 1) 1.60 1.84E-11 
THC2004644 THC2004644 THC2004644 -1.60 1.80E-04 
AW901958 PRKCB1 PRKCB1,PKCB,PRKCB,PRKCB2,MGC41878,PKC-beta -1.61 1.01E-03 
A_32_P231250 A_32_P231250 A_32_P231250 -1.61 2.45E-02 
AK123333 AK123333 AK123333 -1.61 4.51E-06 
THC1910570 THC1910570 THC1910570 -1.61 8.01E-06 
AF086541 LOC92196 LOC92196 -1.61 9.43E-03 
AK097640 TPRX1 TPRX1,TPRX,FLJ40321 -1.62 1.08E-03 
THC2000697 THC2000697 THC2000697 -1.62 3.00E-04 
NM_020970 KIAA1641 KIAA1641,FLJ21281 -1.62 1.20E-04 
BF592593 GRIN2D GRIN2D,EB11,NMDAR2D -1.62 2.00E-05 
A_32_P233049 A_32_P233049 A_32_P233049 -1.62 3.90E-02 
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NM_007034 DNAJB4 DNAJB4,DnaJ (Hsp40) homolog, subfamily B, member 4 -1.62 4.39E-17 
AK024270 KLHL24 KLHL24,DRE1,FLJ25796 -1.62 1.30E-04 
BC013024 LOC154822 LOC154822 -1.62 8.10E-14 
A_24_P230100 A_24_P230100 A_24_P230100 -1.62 4.82E-06 
BI517435 BI517435 BI517435 -1.63 6.58E-03 
NM_058168 GDEP GDEP -1.63 1.72E-02 
AF086297 NBR2 NBR2,MGC104305,DKFZp686F081 -1.64 3.55E-08 
NM_153008 FLJ30277 FLJ30277,FLJ30278 -1.64 1.71E-02 
NM_016188 ACTL6B ACTL6B,ACTL6,BAF53B -1.64 2.50E-04 
A_32_P133464 A_32_P133464 A_32_P133464 -1.64 3.60E-15 
A_24_P178475 A_24_P178475 A_24_P178475 -1.64 2.03E-06 
AK056190 DFNB31 DFNB31,WHRN,CIP98,KIAA1526,RP11-9M16.1,DKFZP434N014 -1.64 2.08E-07 
BF897263 BF897263 BF897263 -1.65 1.10E-04 
AL833897 AL833897 AL833897 -1.65 8.03E-07 
AK058070 MDH1B MDH1B,FLJ25341,RP11-95H11 -1.66 2.93E-03 
NM_153768 CABYR CABYR,CBP86,FSP-2,MGC9117 -1.67 7.06E-03 
AB037793 USP35 USP35 -1.67 3.08E-21 
NM_024584 FLJ13646 FLJ13646 -1.67 1.21E-07 
NM_004821 HAND1 HAND1,Hxt,eHand,Thing1 -1.67 4.10E-02 
AL137350 FAM44A FAM44A,FLJ33215,KIAA1327 -1.68 2.10E-04 
THC1848900 THC1848900 THC1848900 -1.68 7.80E-04 
NM_033427 CTTNBP2 CTTNBP2,Orf4,C7orf8,CORTBP2,FLJ34229,KIAA1758,MGC104579 -1.68 4.63E-06 
AK124638 PLCXD3 PLCXD3 -1.69 1.23E-17 
A_24_P110521 A_24_P110521 A_24_P110521 -1.69 5.00E-05 
A_32_P215003 A_32_P215003 A_32_P215003 -1.70 3.76E-03 
BE904671 EPHA5 EPHA5,CEK7,EHK1,HEK7,TYRO4 -1.71 6.77E-16 
ENST00000334819 ENST00000334819 ENST00000334819 -1.71 4.25E-06 
AK074353 HBP1 HBP1,FLJ16340 -1.71 2.05E-19 
THC1933749 THC1933749 THC1933749 -1.71 8.03E-03 
NM_006813 PROL2 PROL2,proline rich 2 -1.72 3.90E-04 
NM_002133 HMOX1 HMOX1,heme oxygenase (decycling) 1 -1.72 6.51E-10 
BU729607 HMGB2 HMGB2,HMG2 -1.73 1.64E-03 
NM_005279 GPR1 GPR1 -1.73 3.00E-05 
AF080397 FZR1 FZR1,FZR,CDH1,FZR2,HCDH,HCDH1,CDC20C,KIAA1242 -1.73 3.04E-10 
A_32_P117453 A_32_P117453 A_32_P117453 -1.73 2.00E-05 
ENST00000328259 ENST00000328259 ENST00000328259 -1.75 2.83E-06 
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NM_152405 JMY JMY,FLJ37870 -1.76 3.47E-07 
M76744 CEACAM1 CEACAM1,BGP,BGP1,BGPI -1.77 4.49E-08 
THC1859333 THC1859333 THC1859333 -1.77 1.00E-04 
A_32_P110042 A_32_P110042 A_32_P110042 -1.77 6.00E-05 
THC1827959 THC1827959 THC1827959 -1.78 3.04E-03 
NM_006238 PPARD PPARD,FAAR,NUC1,NUCI,NR1C2,NUCII,PPARB,MGC3931,PPAR-beta -1.78 1.17E-03 
A_32_P61538 A_32_P61538 A_32_P61538 -1.79 2.90E-04 
BC040628 GTF2A1 GTF2A1,TF2A1,TFIIA,MGC129969,MGC129970 -1.82 9.50E-04 
A_32_P213543 A_32_P213543 A_32_P213543 -1.83 1.41E-02 
A_32_P97536 A_32_P97536 A_32_P97536 -1.84 4.74E-08 
A_23_P108534 A_23_P108534 A_23_P108534 -1.85 2.62E-03 
NM_024859 FLJ21687 FLJ21687,JM10,MGC138889 -1.87 7.03E-03 
M96843 ID2B ID2B -1.88 2.15E-10 
THC1826185 THC1826185 THC1826185 -1.88 6.30E-04 
NM_153032 FLJ32065 FLJ32065,MGC90301 -1.89 1.79E-07 
NM_000459 TEK TEK,TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal) -1.90 3.00E-05 
NM_014848 SV2B SV2B,synaptic vesicle glycoprotein 2B -1.91 3.57E-37 
A_32_P73707 A_32_P73707 A_32_P73707 -1.91 9.40E-04 
NM_182522 FAM19A4 FAM19A4,TAFA4,TAFA-4,FLJ25161 -1.91 2.44E-02 
AF251079 DACT1 DACT1,DPR1,FRODO,HDPR1,DAPPER,THYEX3,DAPPER1 -1.92 3.00E-05 
NM_001710 BF BF,B-factor, properdin -1.96 1.43E-17 
AK091057 LOC285535 LOC285535 -1.96 1.17E-06 
NM_001964 EGR1 EGR1,early growth response 1 -1.97 2.13E-07 
AB002297 DOCK3 DOCK3,PBP,MOCA,KIAA0299 -1.98 1.12E-03 
BX091616 BX091616 BX091616 -2.00 1.82E-03 
NM_139241 FGD4 FGD4,FRABP,FRABIN,ZFYVE6,MGC57222,DKFZp313E1818 -2.00 1.59E-08 
AK057247 NEK10 NEK10,FLJ32685 -2.00 2.22E-15 
AK123235 CCDC108 CCDC108,MGC35338,DKFZp434O0527 -2.02 2.47E-11 
ENST00000309333 ENST00000309333 ENST00000309333 -2.02 1.03E-06 
AF152502 PCDHB9 PCDHB9,PCDH3H,MGC119555,MGC119556,PCDH-BETA9 -2.05 1.43E-07 
AK023134 ECAT8 ECAT8,FLJ13072 -2.07 2.45E-08 
NM_006308 HSPB3 HSPB3,heat shock 27 kDa protein 3 -2.07 0.00E+00 
AF086511 AF086511 AF086511 -2.28 1.79E-10 
NM_033503 BMF BMF,FLJ00065 -2.44 2.01E-09 
NM_001956 EDN2 EDN2,endothelin 2 -2.94 0.00E+00 
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Table 6-3. SHC1-dependently regulated genes. List of genes regulated in an SHC1-dependent manner. Genes are sorted 
according to their fold regulation. A 1.6-fold expression cutoff was taken as selection criterion. 
Gene identifier Gene name Full name Fold change p-value 
NM_033503 BMF BMF,FLJ00065 3.15 6.73E-14 
NM_031418 C11orf25 C11orf25,chromosome 11 open reading frame 25 2.74 7.00E-05 
NM_006919 SERPINB3 SERPINB3,serine (or cysteine) proteinase inhibitor, clade B (ovalbumin), member 3 2.63 3.21E-13 
NM_005994 TBX2 TBX2,T-box 2 2.51 0.00E+00 
NM_153032 FLJ32065 FLJ32065,MGC90301 2.41 2.94E-16 
NM_025212 CXXC4 CXXC4,IDAX 2.37 2.79E-03 
THC1819187 THC1819187 THC1819187 2.34 2.30E-04 
NM_001964 EGR1 EGR1,early growth response 1 2.32 7.84E-42 
NM_021995 UTS2 UTS2,UII,U-II,UCN2,PRO1068 2.28 1.20E-04 
NM_002974 SERPINB4 SERPINB4,PI11,SCCA1,SCCA2,LEUPIN,SCCA-2 2.28 2.17E-22 
BU729607 HMGB2 HMGB2,HMG2 2.21 5.58E-08 
NM_000550 TYRP1 TYRP1,tyrosinase-related protein 1 2.18 3.60E-04 
NM_139284 LGI4 LGI4,LGIL3 2.16 7.70E-11 
BX094364 BX094364 BX094364 2.07 5.37E-03 
ENST00000333984 ENST00000333984 ENST00000333984 2.03 1.00E-05 
AF220656 PHLDA1 PHLDA1,pleckstrin homology-like domain, family A, member 1 2.02 1.79E-10 
BC018929 PHLDA1 PHLDA1,PHRIP,TDAG51,DT1P1B11,MGC131738 2.00 1.57E-23 
A_23_P211468 A_23_P211468 A_23_P211468 2.00 3.00E-05 
AK023629 AK023629 AK023629 1.98 1.78E-08 
NM_013409 FST FST,FS 1.98 1.04E-09 
AK001987 FLJ11125 FLJ11125 1.98 9.49E-08 
AB007870 NUPL1 NUPL1,PRO2463,KIAA0410 1.98 5.13E-11 
NM_002546 TNFRSF11B TNFRSF11B,tumor necrosis factor receptor superfamily, member 11b (osteoprotegerin) 1.97 1.66E-20 
A_32_P180538 A_32_P180538 A_32_P180538 1.95 7.67E-03 
NM_000029 AGT 
AGT,angiotensinogen (serine (or cysteine) proteinase inhibitor, clade A (alpha-1 antiproteinase, 
antitrypsin), member 8) 1.92 9.91E-21 
NM_012258 HEY1 HEY1,CHF2,OAF1,HERP2,HESR1,HRT-1,MGC1274 1.92 4.25E-41 
NM_203349 SHC4 SHC4,RaLP,MGC34023 1.91 1.22E-17 
NM_000104 CYP1B1 CYP1B1,cytochrome P450, family 1, subfamily B, polypeptide 1 1.90 6.00E-05 
NM_016040 TMED5 TMED5,CGI-100,RP5-976O13.2 1.88 0.00E+00 
THC1910374 THC1910374 THC1910374 1.88 4.67E-19 
NM_003897 IER3 IER3,DIF2,IEX1,PRG1,DIF-2,GLY96,IEX-1,IEX-1L 1.87 7.31E-09 
NM_000459 TEK TEK,TEK tyrosine kinase, endothelial (venous malformations, multiple cutaneous and mucosal) 1.87 9.24E-07 
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NM_001242 TNFRSF7 TNFRSF7,tumor necrosis factor receptor superfamily, member 7 1.85 2.40E-04 
AB028957 SATB2 SATB2,FLJ21474,FLJ32076,KIAA1034,MGC119474,MGC119477 1.84 5.50E-07 
NM_024680 E2F8 E2F8,FLJ23311 1.84 2.99E-13 
THC1877698 THC1877698 THC1877698 1.84 1.44E-13 
BC023566 RASEF RASEF,RAB45,FLJ31614 1.83 2.00E-05 
NM_006216 SERPINE2 SERPINE2,GDN,PI7,PN1,PNI 1.82 2.05E-20 
NM_002314 LIMK1 LIMK1,LIM domain kinase 1 1.82 0.00E+00 
NM_012080 FAM16AX FAM16AX,family with sequence similarity 16, member A, X-linked 1.81 6.37E-36 
THC2005782 THC2005782 THC2005782 1.81 3.48E-08 
AK024362 LOC147650 LOC147650,MGC125919,MGC125920 1.81 0.00E+00 
ENST00000332248 ENST00000332248 ENST00000332248 1.79 2.26E-02 
NM_145056 MGC15476 MGC15476 1.79 6.00E-05 
NM_001047 SRD5A1 
SRD5A1,steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase 
alpha 1) 1.78 2.76E-24 
NM_017933 FLJ20701 FLJ20701,HMFN2073 1.78 3.95E-28 
AL832448 SLC2A14 SLC2A14,GLUT14 1.77 1.23E-02 
NM_004350 RUNX3 RUNX3,AML2,CBFA3,PEBP2aC,FLJ34510 1.77 4.72E-13 
NM_015115 DCUN1D4 DCUN1D4,KIAA0276 1.77 5.94E-17 
NM_006469 IVNS1ABP 
IVNS1ABP,ND1,NS-1,NS1BP,FLARA3,NS1-BP,HSPC068,FLJ10069,FLJ10411,FLJ10962,FLJ35593,KIAA0850, 
DKFZp686K06216 1.77 7.50E-22 
A_32_P129689 A_32_P129689 A_32_P129689 1.77 4.00E-05 
NM_005114 HS3ST1 HS3ST1,heparan sulfate (glucosamine) 3-O-sulfotransferase 1 1.75 1.77E-28 
NM_005931 MICB MICB,MHC class I polypeptide-related sequence B 1.75 7.73E-08 
NM_001511 CXCL1 CXCL1,chemokine (C-X-C motif) ligand 1 (melanoma growth stimulating activity, alpha) 1.75 1.18E-09 
A_24_P384029 A_24_P384029 A_24_P384029 1.75 6.72E-23 
BC005178 HES1 HES1,HHL,HRY,HES-1,FLJ20408 1.75 1.68E-09 
A_32_P146169 A_32_P146169 A_32_P146169 1.75 2.15E-02 
NM_007329 DMBT1 DMBT1,GP340,muclin 1.74 3.16E-07 
THC1881984 THC1881984 THC1881984 1.73 5.52E-12 
A_32_P27991 A_32_P27991 A_32_P27991 1.73 3.20E-03 
AL832945 LOC284262 LOC284262 1.72 5.59E-09 
BC018658 REEP3 REEP3,C10orf74 1.72 0.00E+00 
AF085962 AF085962 AF085962 1.72 2.50E-03 
A_24_P1873 A_24_P1873 A_24_P1873 1.71 1.85E-02 
BC044246 KIAA1913 KIAA1913,TTMC 1.71 2.08E-06 
AB037855 KIAA1434 KIAA1434,FLJ11085,MGC26147,RP5-1022P6.2 1.71 1.00E-05 
NM_080593 HIST1H2BK HIST1H2BK,H2B/S,H2BFT,H2BFAiii,MGC131989 1.70 6.21E-11 
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BC039118 STX6 STX6 1.70 6.62E-13 
NM_002280 KRTHA5 KRTHA5,HA5,Ha-5,hHa5 1.70 2.10E-04 
AK095176 C10orf39 C10orf39,FLJ37857 1.70 1.87E-22 
BC007329 TLE6 TLE6,GRG6,FLJ14009,MGC14966 1.70 1.42E-03 
A_32_P85360 A_32_P85360 A_32_P85360 1.70 1.39E-02 
NM_018653 GPRC5C GPRC5C,RAIG3,RAIG-3,MGC131820 1.69 1.80E-04 
AL359062 COL8A1 COL8A1,MGC9568 1.69 3.41E-16 
AK093577 MKL2 MKL2,MRTF-B,NPD001,FLJ31823,DKFZp686J1745 1.69 1.88E-16 
NM_032995 ARHGEF4 ARHGEF4,ASEF,GEF4,STM6 1.68 3.23E-11 
NM_000067 CA2 CA2,CAII,Car2,CA II,CA-II 1.68 1.88E-06 
NM_152336 FLJ32310 FLJ32310 1.68 1.50E-04 
THC1982550 THC1982550 THC1982550 1.68 3.00E-05 
A_32_P71768 A_32_P71768 A_32_P71768 1.68 1.00E-05 
A_32_P75141 A_32_P75141 A_32_P75141 1.68 1.85E-27 
NM_003483 HMGA2 HMGA2,BABL,LIPO,HMGIC,HMGI-C 1.68 5.86E-03 
A_32_P225328 A_32_P225328 A_32_P225328 1.68 4.65E-15 
NM_021205 RHOU RHOU,ARHU,WRCH1,hG28K,CDC42L1,FLJ10616,DJ646B12.2,fJ646B12.2 1.68 9.65E-09 
NM_004460 FAP FAP,fibroblast activation protein, alpha 1.68 3.59E-37 
U83115 AIM1 AIM1,absent in melanoma 1 1.67 3.89E-08 
NM_006202 PDE4A PDE4A,phosphodiesterase 4A, cAMP-specific (phosphodiesterase E2 dunce homolog, Drosophila) 1.67 7.14E-13 
AV756170 RPS11 RPS11 1.67 3.95E-03 
AK055368 ETV1 ETV1,ER81,MGC104699,MGC120533,MGC120534,DKFZp781L0674 1.67 7.28E-03 
NM_012285 KCNH4 KCNH4,potassium voltage-gated channel, subfamily H (eag-related), member 4 1.67 2.70E-03 
BC037430 PHLDA1 PHLDA1,PHRIP,TDAG51,DT1P1B11,MGC131738 1.67 6.92E-14 
NM_002026 FN1 FN1,fibronectin 1 1.67 8.86E-21 
A_24_P490704 A_24_P490704 A_24_P490704 1.66 1.83E-06 
NM_006186 NR4A2 NR4A2,nuclear receptor subfamily 4, group A, member 2 1.66 4.57E-06 
NM_016122 NY-REN-58 NY-REN-58,NY-REN-58 antigen 1.66 3.54E-13 
THC1949165 THC1949165 THC1949165 1.66 3.03E-10 
THC1816039 THC1816039 THC1816039 1.65 3.00E-05 
AK094718 FLJ22536 FLJ22536,FLJ12803 1.65 1.01E-25 
NM_005269 GLI GLI,glioma-associated oncogene homolog (zinc finger protein) 1.65 2.08E-02 
A_32_P36412 A_32_P36412 A_32_P36412 1.64 9.33E-06 
NM_003020 SGNE1 SGNE1,secretory granule, neuroendocrine protein 1 (7B2 protein) 1.64 3.00E-05 
NM_001146 ANGPT1 ANGPT1,AGP1,AGPT,ANG1 1.64 3.15E-14 
THC1868308 THC1868308 THC1868308 1.64 1.76E-11 
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NM_144707 PROM2 PROM2,PROM-2,MGC138714 1.63 6.35E-03 
A_32_P155588 A_32_P155588 A_32_P155588 1.63 3.66E-02 
AK094629 AK094629 AK094629 1.63 5.80E-04 
NM_020432 PHTF2 PHTF2,FLJ33324,MGC86999,DKFZP564F013 1.63 1.19E-11 
NM_175061 JAZF1 JAZF1,TIP27,DKFZp761K2222 1.63 2.27E-06 
NM_024760 TLE6 TLE6,GRG6,FLJ14009,MGC14966 1.63 1.58E-06 
AF273047 GOLGA4 GOLGA4,GCP2,GOLG,p230,MU-RMS-40.18 1.63 6.98E-06 
NM_005252 FOS FOS,v-fos FBJ murine osteosarcoma viral oncogene homolog 1.63 3.00E-05 
NM_004117 FKBP5 FKBP5,FK506 binding protein 5 1.62 3.38E-03 
NM_015192 PLCB1 PLCB1,PLC-I,PI-PLC,PLC-154,FLJ45792 1.62 2.55E-12 
NM_006380 APPBP2 APPBP2,amyloid beta precursor protein (cytoplasmic tail) binding protein 2 1.62 2.15E-08 
NM_014454 PA26 PA26,p53 regulated PA26 nuclear protein 1.62 2.03E-34 
THC1808272 THC1808272 THC1808272 1.62 3.94E-15 
AF220047 C3orf10 C3orf10,MDS027,hHBrk1,HSPC300 1.62 1.87E-02 
AK093435 FLJ36116 FLJ36116 1.61 4.05E-03 
THC1924019 THC1924019 THC1924019 1.61 6.47E-09 
BU729734 MATR3 MATR3,MGC9105,KIAA0723,DKFZp686K0542,DKFZp686K23100 1.61 1.00E-04 
BM664049 NCF1 NCF1,NCF1A,NOXO2,p47phox,SH3PXD1A 1.61 5.20E-04 
THC1849267 THC1849267 THC1849267 1.61 4.50E-06 
NM_020200 PRTFDC1 PRTFDC1,HHGP,FLJ11888 1.61 5.47E-16 
NM_003272 GPR137B GPR137B,TM7SF1 1.61 2.60E-04 
BC016285 PRKACB PRKACB,PKACB,MGC9320,MGC41879,DKFZp781I2452 1.61 1.10E-02 
BC007436 FAM44B FAM44B 1.60 1.23E-06 
AB007950 TMCC2 TMCC2,HUCEP11,FLJ38497,KIAA0481 1.60 3.37E-10 
NM_080741 NEU4 NEU4,MGC18222,MGC102757 1.60 3.34E-07 
NM_005388 PDCL PDCL,phosducin-like -1.60 2.46E-06 
NM_138432 SDSL SDSL,SDS-RS1 -1.60 1.25E-12 
NM_000224 KRT18 KRT18,keratin 18 -1.60 4.56E-14 
NM_018999 KIAA1128 KIAA1128,Gcap14,FLJ14262,FLJ25809,bA486O22.1 -1.60 6.61E-31 
AK024475 PLEKHG4 PLEKHG4,DKFZP434I216,puratrophin1 -1.60 1.59E-07 
NM_022445 TPK1 TPK1,PP20,HTPK1 -1.60 3.73E-02 
BG178211 BG178211 BG178211 -1.61 2.39E-09 
NM_001769 CD9 CD9,CD9 antigen (p24) -1.61 1.93E-13 
NM_024859 FLJ21687 FLJ21687,JM10,MGC138889 -1.61 2.55E-03 
NM_144722 FLJ23577 FLJ23577,FLJ23164,FLJ25395,KIAA1770,MGC102842 -1.61 5.42E-11 
NM_144603 NOXO1 NOXO1,P41NOX,P41NOXA,P41NOXB,P41NOXC,SH3PXD5,MGC20258 -1.61 2.48E-08 
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NM_018964 SLC37A1 SLC37A1,G3PP,FLJ22340 -1.61 1.86E-15 
ENST00000328614 ENST00000328614 ENST00000328614 -1.61 1.00E-05 
NM_022469 GREM2 GREM2,PRDC,DAND3,CKTSF1B2 -1.62 1.68E-02 
NM_017590 ZC3H7B ZC3H7B,RoXaN,FLJ13787,KIAA1031,DKFZp434K0920 -1.62 3.50E-04 
NM_181526 MYL9 MYL9,LC20,MLC2,MRLC1,MYRL2,MGC3505 -1.62 1.66E-08 
NM_003725 RODH RODH,3-hydroxysteroid epimerase -1.62 3.04E-08 
THC1893261 THC1893261 THC1893261 -1.62 1.54E-02 
NM_025149 FLJ20920 FLJ20920 -1.62 6.08E-06 
A_24_P686014 A_24_P686014 A_24_P686014 -1.62 7.00E-06 
NM_002646 PIK3C2B PIK3C2B,phosphoinositide-3-kinase, class 2, beta polypeptide -1.62 1.00E-05 
ENST00000329590 ENST00000329590 ENST00000329590 -1.62 1.70E-04 
NM_013404 MSLN MSLN,mesothelin -1.62 5.00E-05 
NM_000475 NR0B1 NR0B1,AHC,AHX,DSS,GTD,HHG,AHCH,DAX1,DAX-1,NROB1 -1.62 6.00E-05 
NM_000228 LAMB3 LAMB3,laminin, beta 3 -1.62 4.84E-16 
AL713754 DKFZp667M2411 DKFZp667M2411 -1.62 1.78E-18 
NM_005100 AKAP12 AKAP12,A kinase (PRKA) anchor protein (gravin) 12 -1.62 1.24E-06 
ENST00000327707 ENST00000327707 ENST00000327707 -1.62 6.12E-18 
A_24_P229911 A_24_P229911 A_24_P229911 -1.62 1.21E-12 
BC030956 GNGT1 GNGT1,GNG1 -1.62 6.00E-05 
A_24_P471242 A_24_P471242 A_24_P471242 -1.62 1.13E-13 
NM_004096 EIF4EBP2 EIF4EBP2,4EBP2 -1.62 1.01E-03 
NM_000248 MITF MITF,microphthalmia-associated transcription factor -1.63 7.46E-18 
AK095472 TMEM64 TMEM64,DKFZp762C1112 -1.63 1.01E-15 
A_23_P254384 A_23_P254384 A_23_P254384 -1.63 1.44E-16 
AB033040 RNF150 RNF150,MGC125502 -1.63 6.80E-08 
AK095098 COL25A1 COL25A1,CLAC -1.63 3.44E-06 
NM_014051 TMEM14A TMEM14A,PTD011,C6orf73 -1.63 2.05E-19 
ENST00000332794 ENST00000332794 ENST00000332794 -1.63 8.81E-06 
NM_018242 FLJ10847 FLJ10847,MATE1,MATE2,MGC64822 -1.63 1.05E-11 
NM_000447 PSEN2 PSEN2,presenilin 2 (Alzheimer disease 4) -1.63 5.86E-09 
NM_003368 USP1 USP1,ubiquitin specific protease 1 -1.63 4.24E-13 
A_24_P247233 A_24_P247233 A_24_P247233 -1.63 2.87E-09 
THC1843344 THC1843344 THC1843344 -1.63 2.00E-05 
THC1991717 THC1991717 THC1991717 -1.63 3.05E-06 
A_24_P230466 A_24_P230466 A_24_P230466 -1.63 2.95E-12 
NM_006827 TMP21 TMP21,transmembrane trafficking protein -1.63 0.00E+00 
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NM_007271 STK38 STK38,serine/threonine kinase 38 -1.64 0.00E+00 
THC1924184 THC1924184 THC1924184 -1.64 9.25E-03 
NM_003356 UCP3 UCP3,uncoupling protein 3 (mitochondrial, proton carrier) -1.64 1.44E-03 
NM_004473 FOXE1 FOXE1,TTF2,FOXE2,HFKH4,HFKL5,TITF2,TTF-2,FKHL15 -1.64 7.97E-09 
AK091178 LOC285401 LOC285401 -1.64 3.57E-10 
NM_003979 GPRC5A GPRC5A,RAI3,RAIG1,GPCR5A -1.64 3.25E-30 
NM_006992 LRRC23 LRRC23,B7,LRPB7,B7 isoform -1.64 1.04E-09 
AB007952 FBXO28 FBXO28,Fbx28,FLJ10766,KIAA0483 -1.64 4.70E-04 
S73202 
argininosuccinate 
synthetase argininosuccinate synthetase -1.64 8.90E-22 
A_24_P418687 A_24_P418687 A_24_P418687 -1.64 2.63E-06 
AL832465 NPNT NPNT,POEM,EGFL6L -1.65 4.10E-06 
A_24_P792988 A_24_P792988 A_24_P792988 -1.65 3.95E-23 
A_24_P230486 A_24_P230486 A_24_P230486 -1.65 1.26E-07 
NM_007075 WDR45 WDR45,JM5,WDRX1,WIPI4,WIPI-4 -1.65 5.21E-17 
A_24_P264644 A_24_P264644 A_24_P264644 -1.65 1.37E-12 
NM_014521 SH3BP4 SH3BP4,TTP,BOG25 -1.65 1.23E-10 
A_24_P118391 A_24_P118391 A_24_P118391 -1.65 0.00E+00 
AJ001827 UBPH UBPH,FLJ38870 -1.65 2.00E-05 
A_32_P211494 A_32_P211494 A_32_P211494 -1.65 6.30E-04 
NM_020987 ANK3 ANK3,ankyrin 3, node of Ranvier (ankyrin G) -1.65 2.10E-04 
AB014511 ATP9A ATP9A,ATPIIA,KIAA0611 -1.66 1.26E-09 
NM_023076 FLJ23360 FLJ23360,hypothetical protein FLJ23360 -1.66 1.14E-08 
NM_002999 SDC4 SDC4,syndecan 4 (amphiglycan, ryudocan) -1.66 2.64E-10 
A_24_P213336 A_24_P213336 A_24_P213336 -1.66 1.27E-25 
NM_005542 INSIG1 INSIG1,CL-6,MGC1405 -1.66 8.63E-28 
BC045163 BC045163 BC045163 -1.66 6.00E-05 
ENST00000332105 ENST00000332105 ENST00000332105 -1.66 1.52E-11 
THC1983708 THC1983708 THC1983708 -1.66 5.97E-13 
NM_144492 CLDN14 CLDN14,DFNB29 -1.66 3.00E-02 
NM_024110 CARD14 CARD14,BIMP2,CARMA2 -1.66 1.45E-03 
THC1881484 THC1881484 THC1881484 -1.66 1.78E-06 
ENST00000332292 ENST00000332292 ENST00000332292 -1.66 4.36E-06 
NM_016230 CYB5R4 CYB5R4,NCB5OR,dJ676J13.1,RP4-676J13.1 -1.66 9.00E-05 
NM_153291 FAM10A5 FAM10A5 -1.67 8.04E-20 
A_24_P358857 A_24_P358857 A_24_P358857 -1.67 4.07E-10 
NM_013411 AK2 AK2,ADK2 -1.67 1.68E-12 
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NM_001159 AOX1 AOX1,AO,AOH1 -1.67 5.84E-03 
A_32_P157671 A_32_P157671 A_32_P157671 -1.67 1.61E-17 
NM_016533 NINJ2 NINJ2 -1.67 3.54E-08 
A_24_P281605 A_24_P281605 A_24_P281605 -1.67 3.43E-14 
THC1953252 THC1953252 THC1953252 -1.67 2.60E-04 
A_24_P812018 A_24_P812018 A_24_P812018 -1.67 2.46E-30 
A_24_P255954 A_24_P255954 A_24_P255954 -1.67 2.25E-20 
A_24_P186746 A_24_P186746 A_24_P186746 -1.67 2.97E-26 
THC1901913 THC1901913 THC1901913 -1.67 5.80E-04 
NM_152748 KIAA1324L KIAA1324L,FLJ31340 -1.67 2.04E-09 
A_24_P127362 A_24_P127362 A_24_P127362 -1.67 5.33E-09 
NM_144765 EVA1 EVA1,EVA,MPZL2 -1.67 1.26E-06 
NM_017540 GALNT10 GALNT10,FLJ00205,FLJ11715,GalNAcT10,DKFZp586H0623,pp-GalNAc-T10 -1.68 7.98E-09 
NM_020179 C11orf75 C11orf75,FN5 -1.68 2.57E-06 
NM_018194 FLJ10724 FLJ10724,melanoma antigen recognized by T cells 2 -1.68 3.00E-05 
A_24_P332595 A_24_P332595 A_24_P332595 -1.68 9.98E-13 
NM_007283 MGLL MGLL,MGL,HU-K5 -1.68 9.94E-21 
NM_001753 CAV1 CAV1,caveolin 1, caveolae protein, 22 kDa -1.68 1.27E-06 
NM_173624 FLJ40504 FLJ40504,MGC138231,MGC138233 -1.68 4.83E-08 
NM_172229 KREMEN2 KREMEN2,KRM2,MGC10791,MGC16709 -1.68 7.79E-12 
NM_006366 CAP2 CAP2,adenylyl cyclase-associated protein 2 -1.68 5.18E-09 
NM_001831 CLU 
CLU,clusterin (complement lysis inhibitor, SP-40,40, sulfated glycoprotein 2, testosterone-repressed 
prostate message 2, apolipoprotein J) -1.68 1.99E-32 
ENST00000330515 ENST00000330515 ENST00000330515 -1.68 7.23E-03 
A_24_P153003 A_24_P153003 A_24_P153003 -1.68 1.91E-11 
NM_015996 SIDT2 SIDT2,CGI-40,FLJ90656,DKFZp686L17253 -1.68 5.53E-08 
AL833897 AL833897 AL833897 -1.68 9.47E-03 
BC046196 TGOLN2 TGOLN2,TGN38,TGN46,TGN48,TGN51,TTGN2,MGC14722 -1.69 5.37E-06 
ENST00000316797 ENST00000316797 ENST00000316797 -1.69 6.08E-16 
NM_018421 TBC1D2 TBC1D2,TBC1 domain family, member 2 -1.69 1.55E-33 
AF277193 LSM12 LSM12,FLJ30656,MGC104211 -1.69 2.32E-39 
AB007935 IGSF3 IGSF3,immunoglobulin superfamily, member 3 -1.69 9.59E-20 
AK074645 APOL6 APOL6,APOL-VI,FLJ90164,MGC57495,DKFZp667M075 -1.69 2.00E-05 
A_24_P281443 A_24_P281443 A_24_P281443 -1.69 1.40E-08 
NM_018393 TCP11L1 TCP11L1,FLJ11336,FLJ11386,dJ85M6.3 -1.69 6.98E-17 
ENST00000330088 ENST00000330088 ENST00000330088 -1.69 0.00E+00 
A_24_P187355 A_24_P187355 A_24_P187355 -1.70 1.32E-11 
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ENST00000330461 ENST00000330461 ENST00000330461 -1.70 4.77E-15 
A_24_P409420 A_24_P409420 A_24_P409420 -1.70 5.03E-17 
NM_032208 ANTXR1 ANTXR1,ATR,TEM8,FLJ10601,FLJ11298,FLJ21776 -1.70 3.08E-07 
NM_174887 IFT20 IFT20 -1.70 5.58E-20 
NM_002284 KRTHB6 KRTHB6,HB6,Hb1,MNX,hHb6,KRTHB1 -1.70 1.16E-02 
A_24_P401124 A_24_P401124 A_24_P401124 -1.70 2.40E-23 
U28918 ST13 ST13,HIP,HOP,P48,AAG2,SNC6,HSPABP,FAM10A1,HSPABP1,PRO0786,FLJ27260,MGC129952 -1.70 8.33E-13 
A_24_P247454 A_24_P247454 A_24_P247454 -1.70 1.44E-08 
NM_182487 OLFML2A OLFML2A,FLJ00237,PRO34319 -1.70 4.49E-07 
A_24_P247303 A_24_P247303 A_24_P247303 -1.70 2.43E-21 
A_24_P161733 A_24_P161733 A_24_P161733 -1.70 3.18E-07 
ENST00000331037 ENST00000331037 ENST00000331037 -1.70 2.93E-17 
ENST00000302335 ENST00000302335 ENST00000302335 -1.70 2.97E-12 
A_24_P418216 A_24_P418216 A_24_P418216 -1.70 1.41E-17 
ENST00000330116 ENST00000330116 ENST00000330116 -1.70 3.88E-19 
BC033310 GDA GDA,CYPIN,GUANASE,MGC9982,NEDASIN,KIAA1258 -1.70 2.73E-03 
NM_001312 CRIP2 CRIP2,CRIP,CRP2,ESP1 -1.70 7.00E-05 
NM_018375 SLC39A9 SLC39A9,FLJ11274,MGC74989 -1.70 3.02E-06 
NM_153251 ZDHHC20 ZDHHC20,FLJ25952,MGC126005 -1.71 8.37E-11 
A_24_P93321 A_24_P93321 A_24_P93321 -1.71 0.00E+00 
NM_018685 ANLN ANLN,Scraps,ANILLIN,DKFZp779A055 -1.71 5.55E-26 
A_24_P383660 A_24_P383660 A_24_P383660 -1.71 9.09E-10 
Y00706 COL4A1 COL4A1,arresten -1.71 3.28E-06 
NM_014290 TDRD7 TDRD7,KIAA1529,PCTAIRE2BP,RP11-508D10.1 -1.71 2.00E-05 
NM_173473 C10orf104 C10orf104,FLJ33728,bA570G20.3 -1.71 5.73E-14 
A_24_P584463 A_24_P584463 A_24_P584463 -1.71 9.40E-14 
A_24_P6850 A_24_P6850 A_24_P6850 -1.71 2.45E-19 
BC028735 LOC401431 LOC401431 -1.71 1.55E-10 
AL109708 AL109708 AL109708 -1.72 9.00E-05 
ENST00000305049 ENST00000305049 ENST00000305049 -1.72 1.05E-08 
ENST00000333197 ENST00000333197 ENST00000333197 -1.72 6.91E-12 
A_24_P264293 A_24_P264293 A_24_P264293 -1.72 5.23E-18 
AF117819 BDKRB1 BDKRB1,B1R,BKR1,B1BKR,BKB1R,BRADYB1 -1.72 4.00E-05 
NM_001151 SLC25A4 SLC25A4,T1,ANT,ANT1,PEO2,PEO3 -1.72 1.63E-19 
NM_007173 PRSS23 PRSS23,SIG13,SPUVE,ZSIG13,MGC5107 -1.72 1.83E-17 
NM_021197 WFDC1 WFDC1,PS20 -1.72 1.73E-07 
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NM_007085 FSTL1 FSTL1,follistatin-like 1 -1.72 1.77E-10 
NM_002534 OAS1 OAS1,OIAS,IFI-4,OIASI -1.72 8.00E-05 
ENST00000320079 ENST00000320079 ENST00000320079 -1.72 1.39E-12 
AK024926 DDAH1 DDAH1,dimethylarginine dimethylaminohydrolase 1 -1.72 7.09E-03 
AF086541 LOC92196 LOC92196 -1.72 5.50E-04 
NM_006106 YAP1 YAP1,YAP,YAP2,YAP65 -1.73 2.20E-04 
A_32_P140501 A_32_P140501 A_32_P140501 -1.73 2.64E-09 
Z97068 CYR61 CYR61,CCN1,GIG1,IGFBP10 -1.73 0.00E+00 
A_24_P7021 A_24_P7021 A_24_P7021 -1.73 1.42E-13 
NM_020826 SYT13 SYT13,KIAA1427 -1.73 2.11E-09 
AK001616 FNBP1 FNBP1,FBP17,KIAA0554,MGC126804 -1.73 2.07E-10 
NM_016571 GLULD1 GLULD1,LGS -1.73 9.08E-03 
AL831830 RAB11FIP4 RAB11FIP4,FLJ00131,KIAA1821,MGC11316,MGC126566,RAB11-FIP4 -1.73 1.36E-06 
A_32_P193166 A_32_P193166 A_32_P193166 -1.73 2.07E-03 
NM_001554 CYR61 CYR61,cysteine-rich, angiogenic inducer, 61 -1.73 1.20E-28 
AK057293 TMEM76 TMEM76,FLJ22242,FLJ32731,DKFZp686G24175 -1.74 1.65E-08 
NM_018475 TPARL TPARL,TMPT27 -1.74 1.72E-43 
BC042853 LOC645923 LOC645923 -1.74 6.56E-03 
THC1852481 THC1852481 THC1852481 -1.74 9.34E-15 
A_24_P306704 A_24_P306704 A_24_P306704 -1.74 5.75E-31 
A_24_P341546 A_24_P341546 A_24_P341546 -1.74 2.02E-14 
AF010447 MR1 MR1,HLALS -1.74 1.28E-17 
ENST00000333983 ENST00000333983 ENST00000333983 -1.74 1.63E-12 
NM_012155 EML2 EML2,ELP70,EMAP2,EMAP-2 -1.74 1.16E-08 
NM_057089 AP1S1 AP1S1,AP19,CLAPS1,SIGMA1A -1.74 5.69E-20 
NM_153012 TNFSF12 TNFSF12,APO3L,DR3LG,TWEAK,MGC20669,MGC129581 -1.74 9.46E-11 
A_24_P358406 A_24_P358406 A_24_P358406 -1.75 1.93E-28 
AK026668 UHMK1 UHMK1,KIS,Kist -1.75 3.42E-24 
NM_004318 ASPH ASPH,BAH,HAAH,JCTN,junctin,CASQ2BP1 -1.75 1.13E-27 
NM_002451 MTAP MTAP,methylthioadenosine phosphorylase -1.75 2.82E-26 
NM_002006 FGF2 FGF2,fibroblast growth factor 2 (basic) -1.75 8.93E-13 
AK092522 ACOT4 ACOT4,PTE1B,PTE2B,PTE-Ib -1.75 4.16E-06 
A_24_P169843 A_24_P169843 A_24_P169843 -1.76 3.38E-19 
AF131814 NPAL3 NPAL3,DJ462O23.2,RP3-462O23.3,DKFZp686E22155 -1.76 4.18E-03 
ENST00000327852 ENST00000327852 ENST00000327852 -1.76 4.36E-11 
XM_015334 XM_015334 XM_015334 -1.76 1.50E-22 
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NM_198473 NM_198473 NM_198473 -1.76 1.72E-26 
A_24_P161827 A_24_P161827 A_24_P161827 -1.76 4.35E-06 
NM_004481 GALNT2 
GALNT2,UDP-N-acetyl-alpha-D-galactosamine:polypeptide N-acetylgalactosaminyltransferase 2 (GalNAc-
T2) -1.76 1.12E-26 
NM_014506 TOR1B TOR1B,DQ1,MGC4386 -1.76 1.53E-12 
A_24_P7750 A_24_P7750 A_24_P7750 -1.76 1.34E-14 
NM_004815 ARHGAP29 ARHGAP29,PARG1,RP11-255E17.1 -1.76 1.29E-13 
THC1855826 THC1855826 THC1855826 -1.76 2.00E-06 
NM_004293 GDA GDA,CYPIN,GUANASE,MGC9982,NEDASIN,KIAA1258 -1.76 6.77E-12 
A_24_P843309 A_24_P843309 A_24_P843309 -1.76 2.87E-22 
AF003114 CYR61 CYR61,CCN1,GIG1,IGFBP10 -1.76 3.73E-39 
NM_024956 TMEM62 TMEM62,FLJ23375 -1.76 2.71E-10 
BC030949 PTPN11 PTPN11,CFC,NS1,SHP2,BPTP3,PTP2C,PTP-1D,SH-PTP2,SH-PTP3,MGC14433 -1.77 0.00E+00 
AK095896 LOC340061 LOC340061 -1.77 1.54E-21 
AF161372 HSPC254 HSPC254 -1.77 2.34E-06 
A_24_P195974 A_24_P195974 A_24_P195974 -1.77 3.92E-14 
THC1869247 THC1869247 THC1869247 -1.77 8.55E-03 
NM_006402 HBXIP HBXIP,XIP,MGC71071 -1.77 1.21E-22 
THC1958020 THC1958020 THC1958020 -1.78 8.92E-16 
AL834493 TMEM135 TMEM135,FLJ22104 -1.78 2.41E-13 
NM_145306 C10orf35 C10orf35 -1.78 2.15E-08 
NM_017855 ODAM ODAM,APIN,FLJ20513 -1.78 4.63E-03 
NM_175834 KRT6L KRT6L,FLJ26646 -1.78 1.51E-17 
NM_006793 PRDX3 PRDX3,peroxiredoxin 3 -1.78 2.10E-15 
NM_003544 HIST1H4B HIST1H4B,H4/I,H4FI -1.78 1.94E-10 
A_24_P890995 A_24_P890995 A_24_P890995 -1.78 9.68E-10 
THC1953344 THC1953344 THC1953344 -1.79 2.97E-11 
BC040993 KIAA1458 KIAA1458,FLJ21611 -1.79 5.21E-10 
A_24_P15973 A_24_P15973 A_24_P15973 -1.79 2.15E-19 
AK075319 FAM63B FAM63B,KIAA1164 -1.79 2.67E-09 
A_24_P358474 A_24_P358474 A_24_P358474 -1.79 9.45E-23 
A_24_P247074 A_24_P247074 A_24_P247074 -1.80 2.92E-13 
BM926140 BM926140 BM926140 -1.81 1.40E-04 
THC1901760 THC1901760 THC1901760 -1.81 3.87E-06 
NM_020373 TMEM16B TMEM16B,C12orf3,DKFZp434P102 -1.81 2.00E-05 
A_24_P306644 A_24_P306644 A_24_P306644 -1.81 3.20E-24 
NM_004925 AQP3 AQP3,GIL -1.82 0.00E+00 
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NM_139241 FGD4 FGD4,FRABP,FRABIN,ZFYVE6,MGC57222,DKFZp313E1818 -1.82 5.34E-10 
NM_002195 INSL4 INSL4,EPIL,PLACENTIN -1.82 2.28E-06 
NM_004074 COX8 COX8,cytochrome c oxidase subunit VIII -1.83 1.05E-20 
NM_020216 RNPEP RNPEP,DKFZP547H084 -1.83 8.10E-19 
THC1972202 THC1972202 THC1972202 -1.83 5.70E-03 
NM_012137 DDAH1 DDAH1,DDAH,FLJ21264,FLJ25539 -1.83 9.34E-07 
X07109 PRKCB1 PRKCB1,PKCB,PRKCB,PRKCB2,MGC41878,PKC-beta -1.83 2.47E-02 
NM_012342 NMA NMA,putative transmembrane protein -1.84 1.01E-12 
BC032478 MAP2K3 MAP2K3,MEK3,MKK3,MAPKK3,PRKMK3 -1.84 7.51E-12 
BC052560 LOC387763 LOC387763 -1.84 1.04E-06 
NM_006120 HLA-DMA HLA-DMA,major histocompatibility complex, class II, DM alpha -1.84 1.15E-10 
NM_014583 LMCD1 LMCD1 -1.84 2.20E-12 
NM_153290 FAM10A4 FAM10A4 -1.85 1.91E-15 
NM_032578 MYOP MYOP,sarcomeric protein myopalladin, 145 kDa -1.85 4.66E-03 
NM_005576 LOXL1 LOXL1,LOL,LOXL -1.85 8.40E-04 
NM_016203 PRKAG2 PRKAG2,AAKG,WPWS,AAKG2,H91620p -1.86 0.00E+00 
A_24_P375076 A_24_P375076 A_24_P375076 -1.86 8.86E-19 
BC038556 BC038556 BC038556 -1.86 3.87E-21 
A_24_P315594 A_24_P315594 A_24_P315594 -1.86 7.70E-10 
NM_020151 STARD7 STARD7,GTT1 -1.87 2.12E-25 
ENST00000301446 ENST00000301446 ENST00000301446 -1.87 2.96E-18 
D13540 PTPN11 PTPN11,CFC,NS1,SHP2,BPTP3,PTP2C,PTP-1D,SH-PTP2,SH-PTP3,MGC14433 -1.87 2.98E-11 
NM_138453 RAB3C RAB3C -1.87 2.03E-06 
NM_152420 C9orf41 C9orf41,FLJ25795 -1.87 2.39E-10 
NM_138444 KCTD12 KCTD12,PFET1,C13orf2,KIAA1778 -1.87 2.92E-30 
NM_003480 MAGP2 MAGP2,Microfibril-associated glycoprotein-2 -1.87 7.76E-11 
THC1914617 THC1914617 THC1914617 -1.88 1.00E-05 
NM_033664 CDH11 CDH11,OB,CAD11,CDHOB,OSF-4 -1.88 3.68E-07 
NM_015176 FBXO28 FBXO28,Fbx28,FLJ10766,KIAA0483 -1.89 4.07E-03 
NM_152330 FRMD6 FRMD6,EX1,Willin,C14orf31,MGC17921,c14_5320 -1.89 1.12E-21 
NM_000218 KCNQ1 KCNQ1,LQT,RWS,WRS,LQT1,SQT2,ATFB1,JLNS1,KCNA8,KCNA9,Kv1.9,Kv7.1,KVLQT1,FLJ26167 -1.89 1.71E-10 
NM_016619 PLAC8 PLAC8,C15,onzin -1.89 7.97E-16 
NM_005590 MRE11A MRE11A,ATLD,HNGS1,MRE11,MRE11B -1.89 3.38E-09 
AL117511 C14orf125 C14orf125,MGC72028,DKFZp781E083 -1.89 1.53E-03 
AK092716 PRKAG2 PRKAG2,AAKG,WPWS,AAKG2,H91620p -1.89 2.21E-25 
ENST00000324460 ENST00000324460 ENST00000324460 -1.90 2.39E-11 
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BC029662 C20orf142 C20orf142,MGC30135,dJ881L22.2 -1.91 4.83E-22 
XM_372991 LOC391540 LOC391540 -1.91 6.36E-30 
NM_152344 LSM12 LSM12,FLJ30656,MGC104211 -1.91 0.00E+00 
M86492 GMFB GMFB,GMF -1.92 2.17E-09 
NM_004105 EFEMP1 EFEMP1,EGF-containing fibulin-like extracellular matrix protein 1 -1.92 1.84E-17 
BC010946 TAGLN TAGLN,SM22,SMCC,TAGLN1,WS3-10,DKFZp686P11128 -1.92 1.42E-07 
AF188611 HSPA5 HSPA5,BIP,MIF2,GRP78,FLJ26106 -1.92 9.98E-13 
BC015977 BC015977 BC015977 -1.93 1.35E-06 
THC1808546 THC1808546 THC1808546 -1.93 6.16E-24 
XM_208058 LOC283247 LOC283247 -1.93 2.82E-02 
NM_021101 CLDN1 CLDN1,CLD1,SEMP1,ILVASC -1.93 4.68E-16 
NM_024636 STEAP4 STEAP4,TIARP,STAMP2,TNFAIP9,FLJ23153,DKFZp666D049 -1.95 7.50E-08 
NM_199324 OTUD4 OTUD4,HIN1,HSHIN1,KIAA1046,DKFZp434I0721 -1.95 3.20E-04 
NM_002017 FLI1 FLI1,Friend leukemia virus integration 1 -1.95 1.57E-09 
AK057075 TPD52 TPD52,D52,N8L,PC-1,PrLZ,hD52 -1.95 4.12E-08 
NM_024628 SLC12A8 SLC12A8,CCC9,FLJ23188,DKFZp686L18248 -1.96 9.95E-15 
NM_145110 MAP2K3 MAP2K3,MEK3,MKK3,MAPKK3,PRKMK3 -1.96 4.00E-10 
AK057669 PURB PURB,PURBETA,MGC126784,MGC126786 -1.96 1.34E-31 
NM_003330 TXNRD1 TXNRD1,thioredoxin reductase 1 -1.96 0.00E+00 
A_32_P149416 A_32_P149416 A_32_P149416 -1.97 2.31E-27 
NM_003186 TAGLN TAGLN,transgelin -1.97 6.21E-03 
AK024669 WDR26 WDR26,MIP2,FLJ21016 -1.97 2.12E-18 
AK000311 CRKL CRKL -1.98 5.53E-28 
AB028952 SYNPO SYNPO,KIAA1029 -1.98 2.83E-07 
NM_152780 FLJ14503 FLJ14503,MGC104944,RP11-393H10.2 -1.98 2.63E-06 
NM_017977 AIM1L AIM1L,FLJ10040 -1.98 1.00E-05 
ENST00000332472 ENST00000332472 ENST00000332472 -1.99 5.18E-37 
AK026351 PRKAR2A PRKAR2A,PKR2,PRKAR2,MGC3606 -1.99 4.83E-30 
NM_012242 DKK1 DKK1,SK,DKK-1 -1.99 4.67E-11 
NM_021213 PCTP PCTP,STARD2 -2.02 3.86E-08 
BC018117 TPD52 TPD52,D52,N8L,PC-1,PrLZ,hD52 -2.02 1.59E-17 
NM_014452 TNFRSF21 TNFRSF21,DR6,BM-018,MGC31965 -2.02 4.37E-10 
AF228738 PFN2 PFN2,PFL,D3S1319E -2.02 2.36E-09 
NM_005610 RBBP4 RBBP4,NURF55,RBAP48 -2.02 1.74E-09 
M12996 G6PD G6PD,G6PD1 -2.02 1.10E-13 
NM_001299 CNN1 CNN1,SMCC,Sm-Calp -2.03 2.90E-02 
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NM_001956 EDN2 EDN2,endothelin 2 -2.05 1.76E-02 
NM_002543 OLR1 OLR1,oxidised low density lipoprotein (lectin-like) receptor 1 -2.06 7.00E-05 
NM_021102 SPINT2 SPINT2,serine protease inhibitor, Kunitz type, 2 -2.07 3.58E-03 
BC018548 FBXL17 FBXL17,Fbl17,Fbx13,FBXO13,DKFZp434C1715 -2.07 3.12E-09 
NM_021955 GNGT1 GNGT1,GNG1 -2.08 2.80E-45 
AB002445 DCP2 DCP2,NUDT20,FLJ33245 -2.08 2.24E-07 
NM_014766 SCRN1 SCRN1,SES1,KIAA0193 -2.08 1.56E-11 
NM_012095 AP3M1 AP3M1,MGC22164 -2.09 4.49E-16 
AF088076 AF088076 AF088076 -2.10 1.28E-06 
AK025336 MYO5B MYO5B,myosin,KIAA1119 -2.12 1.48E-18 
X92098 TMED2 TMED2,P24A,RNP24,FLJ21323 -2.12 7.79E-20 
NM_005556 KRT7 KRT7,keratin 7 -2.13 0.00E+00 
NM_007236 CHP CHP,SLC9A1BP -2.15 1.35E-09 
NM_018662 DISC1 DISC1,SCZD9,KIAA0457 -2.15 3.89E-07 
NM_032837 FAM104A FAM104A,FLJ14775 -2.15 3.21E-31 
NM_001979 EPHX2 EPHX2,epoxide hydrolase 2, cytoplasmic -2.15 2.15E-16 
NM_006148 LASP1 LASP1,MLN50,Lasp-1 -2.15 3.43E-36 
AF068868 TNFRSF21 TNFRSF21,DR6,BM-018,MGC31965 -2.16 2.87E-23 
NM_152331 ACOT4 ACOT4,PTE1B,PTE2B,PTE-Ib -2.16 1.65E-34 
NM_004661 CDC23 CDC23,CDC23 (cell division cycle 23, yeast, homolog) -2.17 0.00E+00 
THC1900459 THC1900459 THC1900459 -2.17 1.04E-03 
NM_002354 TACSTD1 TACSTD1,tumor-associated calcium signal transducer 1 -2.17 5.88E-03 
NM_018050 MANSC1 MANSC1,FLJ10298,LOH12CR3,9130403P13Rik -2.18 2.48E-36 
NM_006815 TMED2 TMED2,P24A,RNP24,FLJ21323 -2.20 1.36E-12 
AK022936 CNIH CNIH,CNIL,CNIH1,TGAM77,MGC117156 -2.20 4.94E-13 
NM_012106 BART1 BART1,binder of Arl Two -2.20 3.09E-28 
THC1820486 THC1820486 THC1820486 -2.21 4.18E-17 
NM_003280 TNNC1 TNNC1,TNC,TNNC -2.21 1.90E-04 
M13975 PRKCB1 PRKCB1,PKCB,PRKCB,PRKCB2,MGC41878,PKC-beta -2.22 2.27E-03 
NM_022917 NOL6 NOL6,NRAP,UTP22,FLJ21959,MGC14896,MGC14921,MGC20838,bA311H10.1 -2.23 1.10E-33 
AI970688 TAGLN TAGLN,SM22,SMCC,TAGLN1,WS3-10,DKFZp686P11128 -2.23 5.33E-22 
NM_016399 TRIAP1 TRIAP1,WF-1,P53CSV,HSPC132 -2.25 6.90E-36 
NM_001613 ACTA2 ACTA2,actin, alpha 2, smooth muscle, aorta -2.25 3.40E-02 
NM_012219 MRAS MRAS,M-RAs,RRAS3,R-RAS3 -2.25 1.59E-40 
AF077199 LYPLA1 LYPLA1,LPL1,APT-1,LYSOPLA -2.26 0.00E+00 
AK057223 LOC647589 LOC647589 -2.27 4.69E-02 
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X89674 OR1C1 OR1C1,OR1-42,TPCR27,HSTPCR27 -2.31 4.64E-02 
NM_173216 ST6GAL1 ST6GAL1,CD75,SIAT1,ST6GalI,MGC48859,ST6Gal I -2.32 4.73E-20 
THC1851133 THC1851133 THC1851133 -2.32 5.40E-04 
NM_199511 CCDC80 CCDC80,URB,DRO1,SSG1,MGC131805,MGC134851 -2.32 2.60E-21 
AL080111 NEK7 NEK7 -2.36 1.71E-29 
NM_004124 GMFB GMFB,GMF -2.36 4.73E-24 
NM_000359 TGM1 TGM1,LI,LI1,TGK,ICR2,TGASE -2.39 6.58E-14 
BC011813 SHC1 SHC1,SHC,p66,SHCA,p52SHC,p66SHC,FLJ26504 -2.40 4.27E-06 
AK074567 FLJ90086 FLJ90086 -2.41 3.55E-17 
NM_004433 ELF3 ELF3,ERT,ESX,EPR-1,ESE-1 -2.42 1.89E-22 
NM_053025 MYLK MYLK,myosin, light polypeptide kinase -2.44 9.37E-13 
NM_152588 TMTC2 TMTC2,DKFZp762A217 -2.51 2.84E-26 
NM_153687 IKIP IKIP,FLJ31051 -2.58 0.00E+00 
A_32_P199736 A_32_P199736 A_32_P199736 -2.62 9.45E-06 
NM_019556 MOSPD1 MOSPD1,DJ473B4 -2.65 1.22E-32 
NM_001562 IL18 IL18,interleukin 18 (interferon-gamma-inducing factor) -2.69 4.26E-32 
NM_003881 WISP2 WISP2,WNT1 inducible signaling pathway protein 2 -2.70 3.98E-11 
A_24_P853366 A_24_P853366 A_24_P853366 -2.71 2.94E-13 
NM_032405 TMPRSS3 TMPRSS3,DFNB8,DFNB10,ECHOS1,TADG12 -3.02 1.68E-15 
AK098698 EID3 EID3 -3.13 2.56E-16 
NM_005130 HBP17 HBP17,heparin-binding growth factor binding protein -3.23 1.19E-11 
NM_019000 FLJ20152 FLJ20152,hypothetical protein FLJ20152 -3.49 2.92E-28 
NM_003029 SHC1 SHC1,SHC (Src homology 2 domain containing) transforming protein 1 -3.63 6.34E-03 
NM_005025 SERPINI1 SERPINI1,serine (or cysteine) proteinase inhibitor, clade I (neuroserpin), member 1 -4.02 1.27E-31 
 
Table 6-4. qRT-PCR results table. List showing the real-time quantitative values (RQ) and significance analysis of 10 genes 
selected for further experimental verification. Values are graphically represented in Figure 3-25. 
Sample name Gene RQ 1 RQ 2  RQ 1 Min RQ 1 Max RQ 2 Min RQ 2 Max Mean RQ SE p-valuea 
HeLa + C. trachomatis TEK 1.000 1.000 0.588 1.702 0.542 1.844 1.000 0.000 n.d. 
HeLa + C. trachomatis BMF 1.000 1.000 0.506 1.975 0.654 1.530 1.000 0.000 0.028 
HeLa + C. trachomatis EGR1 1.000 1.000 0.581 1.721 0.528 1.895 1.000 0.000 0.877 
HeLa + C. trachomatis FST 1.000 1.000 0.620 1.613 0.697 1.435 1.000 0.000 0.346 
HeLa + C. trachomatis PHLDA 1.000 1.000 0.422 2.371 0.534 1.873 1.000 0.000 0.015 
HeLa + C. trachomatis CXCL1 1.000 1.000 0.562 1.781 0.632 1.583 1.000 0.000 0.183 
HeLa + C. trachomatis DKK1 1.000 1.000 0.725 1.379 0.771 1.297 1.000 0.000 0.003 
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HeLa + C. trachomatis SDC4 1.000 1.000 0.813 1.231 0.759 1.318 1.000 0.000 0.976 
HeLa + C. trachomatis MAP2K3 n.d. 1.000 n.d. n.d. 0.615 1.627 n.d. n.d. n.d. 
HeLa + C. trachomatis FLI1 1.000 1.000 1.000 1.000 0.506 1.976 1.000 0.000 0.003 
HeLa - C. trachomatis TEK 0.329 n.d.  0.220 0.493 n.d. n.d. n.d. n.d. n.d. 
HeLa - C. trachomatis BMF 2.853 2.308 2.084 3.906 0.994 5.361 2.581 0.273 0.028 
HeLa - C. trachomatis EGR1 0.496 1.354 0.365 0.674 0.412 4.453 0.925 0.429 0.877 
HeLa - C. trachomatis FST 0.288 0.928 0.216 0.384 0.390 2.207 0.608 0.320 0.346 
HeLa - C. trachomatis PHLDA 0.729 0.651 0.534 0.994 0.229 1.848 0.690 0.039 0.015 
HeLa - C. trachomatis CXCL1 0.753 0.917 0.510 1.113 0.567 1.486 0.835 0.082 0.183 
HeLa - C. trachomatis DKK1 0.168 0.252 0.109 0.257 0.116 0.548 0.210 0.042 0.003 
HeLa - C. trachomatis SDC4 1.465 0.502 1.262 1.702 0.298 0.844 0.984 0.482 0.976 
HeLa - C. trachomatis MAP2K3 n.d. n.d.  n.d. n.d.  n.d. n.d.  n.d. n.d. n.d. 
HeLa - C. trachomatis FLI1 0.293 0.214 0.213 0.402 0.122 0.376 0.253 0.039 0.003 
HeLa SHC1KD + C. trachomatis TEK 1.000 1.000 0.550 1.819 0.201 0.664 1.000 0.000 0.152 
HeLa SHC1KD + C. trachomatis BMF 1.000 1.000 0.545 1.834 0.787 2.647 1.000 0.000 0.021 
HeLa SHC1KD + C. trachomatis EGR1 1.000 1.000 0.542 1.844 2.299 7.815 1.000 0.000 0.003 
HeLa SHC1KD + C. trachomatis FST 1.000 1.000 0.545 1.834 0.773 2.600 1.000 0.000 0.674 
HeLa SHC1KD + C. trachomatis PHLDA 1.000 1.000 0.530 1.887 1.319 4.697 1.000 0.000 0.038 
HeLa SHC1KD + C. trachomatis CXCL1 1.000 1.000 0.388 2.577 0.650 4.319 1.000 0.000 0.372 
HeLa SHC1KD + C. trachomatis DKK1 1.000 1.000 0.831 1.203 0.788 1.141 1.000 0.000 0.008 
HeLa SHC1KD + C. trachomatis SDC4 1.000 1.000 0.869 1.151 0.588 0.779 1.000 0.000 0.277 
HeLa SHC1KD + C. trachomatis MAP2K3 1.000 1.000 0.583 1.715 0.717 2.108 1.000 0.000 0.213 
HeLa SHC1KD + C. trachomatis FLI1 1.000 1.000 0.612 1.634 0.246 0.656 1.000 0.000 0.398 
HeLa Luci KD + C. trachomatis  TEK 0.890 0.715 0.404 1.265 0.147 0.462 0.802 0.087 0.152 
HeLa Luci KD + C. trachomatis  BMF 0.402 0.195 0.099 0.384 0.143 0.555 0.298 0.103 0.021 
HeLa Luci KD + C. trachomatis  EGR1 0.383 0.314 0.215 0.457 0.912 1.938 0.348 0.035 0.003 
HeLa Luci KD + C. trachomatis  FST 0.397 1.208 0.670 2.177 0.951 3.086 0.802 0.406 0.674 
HeLa Luci KD + C. trachomatis  PHLDA 0.519 0.680 0.495 0.934 1.232 2.326 0.599 0.080 0.038 
HeLa Luci KD + C. trachomatis  CXCL1 0.694 0.980 0.551 1.741 0.924 2.917 0.837 0.143 0.372 
HeLa Luci KD + C. trachomatis  DKK1 1.823 1.688 1.195 2.384 1.133 2.260 1.756 0.068 0.008 
HeLa Luci KD + C. trachomatis  SDC4 2.377 1.266 0.818 1.959 0.554 1.326 1.822 0.556 0.277 
HeLa Luci KD + C. trachomatis  MAP2K3 1.872 1.250 0.618 2.527 0.760 3.107 1.561 0.311 0.213 
HeLa Luci KD + C. trachomatis  FLI1 1.926 1.029 0.658 1.610 0.264 0.646 1.478 0.448 0.398 
 
a p-value according to Student’s t test  
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6.2 Abbreviations 
5(6)-TAMRA, 5-(and 6)-carboxytetramethylrhodamine; A, activation; AC, cytoplasmic ancillary 
proteins; ADT, AutoDockTools; AIDA, Advanced Image Data Analyzer; Aλ [nm], absorbance; APAF-1, 
apoptosis activating factor-1; ATCC, American Type Culture Collection; b-FA, Chlamydia-derived 
branched fatty acid; bp, basepair; BSA, bovine serum albumin; CagA, cytotoxicity associated gene A; 
cDNA, complementary DNA; CH1, collagen-homology domain 1; CK18, cytokeratin 18; CL, cardiolipin; 
COX2, cyclooxygenase 2; cPLA2, cytosolic phospholipase A2; CRLS1, cardiolipin synthase 1; Cy, 
cyanine; Da, Dalton; DAG, diacylglycerol; ddH2O, double-distilled H2O; ∆G, free energy of binding; 
DHSM, dihydrosphingomyelin; DMEM, Dulbecco’s modified Eagle's medium; E, biomacromolecular 
target; E, expression; EB, elementary body; EGF, epidermal growth factor; eGFP, enhanced green 
fluorescent protein; EGFR, EGF receptor; EMBL-EBI, European Bioinformatics Institute; EPEC, 
enteropathogenic Escherichia coli; ERK, extracellular signal-regulated kinase; ESI, electrospray 
ionization; F0, background fluorescence; FASL, FAS ligand; FCS, fetal calf serum; Fmax, maximum 
fluorescence at saturation; Fobs, observed fluorescence; GC, guanine-cytosine content; GRB2, growth 
factor receptor-bound protein 2; GST, glutathione S-transferase; HEPES, 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid; HM, host membrane; HPLC, high-performance liquid 
chromatography; HRP, horseradish peroxidase; Hsp60, heat shock protein 60; I, ligand; IFNγ, 
interferon gamma; IFU, inclusion forming unit; IgG, immunoglobulin G; IL-8, interleukin-8; IM, 
bacterial inner membrane; IPA, Ingenuity Pathway Analysis; KD, equilibrium dissociation constant; 
KD, knockdown; KEGG, Kyoto Encyclopedia of Genes and Genomes; Lda, lipid droplet-associated 
protein; LGV, Lymphogranuloma venereum; LO, localization; LPC, lysophosphatidylcholine; Luci, 
luciferase; MALDI-TOF, matrix-assisted laser desorption/ionization time-of-flight; MAPK, mitogen-
activated protein kinase; MB, group/complex membership; MEK, MAPK/ERK kinase; MOI, 
multiplicity of infection; mRNA, messenger RNA; MS, mass spectrometry; MTOC, microtubule-
organizing center; MVB, multivesicular body; m/z, mass-to-charge ratio; NC, needle complex; NCBI, 
National Center for Biotechnology Information; NCK, non-catalytic region of tyrosine kinase adaptor 
protein; n.d., not determined; NF-κB, nuclear factor κB; NK cell, natural killer cell; OM, bacterial 
outer membrane; OMP1, outer membrane protein 1; P, phosphorylation/dephosphorylation; PA, 
phosphatidic acid; PAGE, polyacrylamide gel electrophoresis; PARP, poly (ADP-ribose) polymerase; 
PB, persistent body; PBS, phosphate buffered saline; PC, phosphatidylcholine; PD, protein-DNA 
binding; PDB, Protein Data Bank; PE, phosphatidylethanolamine; [pep], peptide concentration; PFA, 
paraformaldehyde; PG, phosphatidylglycerol; p.i., post infectionem; PI, phosphatidylinositol; PI3K, 
phosphatidylinositol 3-kinase; PID, pelvic inflammatory disease; PKCδ, protein kinase Cδ; PL, 
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phospholipid; PLA1, phospholipase A1; PP, bacterial periplasm; PP, protein-protein binding; PS, 
phosphatidylserine; PTB, phosphotyrosine binding; qRT-PCR, quantitative real-time polymerase 
chain reaction; RB, regulation of binding; RB, reticulate body; RBD, RAS binding domain; RQ, real-
time quantitative value; RT, room temperature; RTK, receptor tyrosine kinase; SD, standard 
deviation; SDS, sodium dodecyl sulfate; SE, standard error; SH2, SRC homology 2; SH3, SRC homology 
3; SHC, SRC homology-containing; siRNA, small interfering RNA; SM, sphingomyelin; SOCS, 
suppressors of cytokine signaling; SPG buffer, sucrose phosphate glutamate buffer; SRC, sarcoma; 
STAT, signal transducers and activator of transcription; STD, sexually transmitted disease; T, 
transcription; TAG, triacylglycerol; Tarp, translocated actin-recruiting phosphoprotein; Tarp L21, 
singly phosphorylated Tarp L2; Tarp L22, doubly phosphorylated Tarp L2; TC, tip complex; Tir, 
translocated intimin receptor; TLC, thin-layer chromatography; Tm, melting temperature; TNFα, 
tumor necrosis factor alpha; TNFR1, TNF receptor 1; TR, translocation; Tr, translocator complex; 
TUNEL, terminal deoxynucleotidyl transferase dUTP nick end labeling; v/v, volume per volume; vol., 
volume; vs., versus; w/v, weight per volume.  
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